Cytochrome P-450 CYP3A4 Substrates

DrugDrug NameDrug Indication
DB00224IndinavirIndinavir is an antiretroviral drug for the treatment of HIV infection.
DB00227LovastatinFor management as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels in patients with primary hypercholesterolemia and mixed dyslipidemia. For primary prevention of coronary heart disease and to slow progression of coronary atherosclerosis in patients with coronary heart disease.
DB00238NevirapineFor use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.
DB00343DiltiazemFor the treatment of Hypertension
DB00381AmlodipineFor the treatment of hypertension and chronic stable angina.
DB00401NisoldipineFor the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.
DB00404AlprazolamFor the management of anxiety disorder or the short-term relief of symptoms of anxiety and for the treatment of panic disorder, with or without agoraphobia.
DB00468QuinineFor the treatment of malaria and leg cramps
DB00490BuspironeFor the management of anxiety disorders or the short-term relief of the symptoms of anxiety, and also as an augmention of SSRI-treatment against depression.
DB00541VincristineTreatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
DB00604CisaprideFor the symptomatic treatment of adult patients with nocturnal heartburn due to gastroesophageal reflux disease.
DB00619ImatinibFor the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).
DB00637AstemizoleAstemizole was indicated for use in the relieving allergy symptoms, particularly rhinitis and conjunctivitis. It has been withdrawn from the market however due to concerns of arrhythmias.
DB00641SimvastatinFor the treatment of hypercholesterolemia and for the reduction in the risk of cardiac heart disease mortality and cardiovascular events. It can also be used in adolescent patients for the treatment of heterozygous familial hypercholesterolemia.
DB00675TamoxifenTamoxifen is indicated for the treatment of metastatic breast cancer in women and men and ductal carcinoma in Situ.
DB00683MidazolamThe midazolam injection is indicated for preoperative sedation/anziolysis/amnesia. It is also an agent for sedation/anziolysis/amnesia prior to or during diagnostic, therapeutic, or endoscopic procedures. Midazolam can also be given intravenously for induction of general anaesthesia.
DB00802AlfentanilFor the management of postoperative pain and the maintenance of general anesthesia.
DB00820TadalafilUsed for the treatment of erectile dysfunction.
DB00829DiazepamUsed in the treatment of severe anxiety disorders, as a hypnotic in the short-term management of insomnia, as a sedative and premedicant, as an anticonvulsant, and in the management of alcohol withdrawal syndrome.
DB00862VardenafilUsed for the treatment of erectile dysfunction
DB00864TacrolimusFor use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It was first approved by the FDA in 1994 for use in liver transplantation, this has been extended to include kidney, heart, small bowel, pancreas, lung, trachea, skin, cornea, and limb transplants. It has also been used in a topical preparation in the treatment of severe atopic dermatitis.
DB00877SirolimusFor the prophylaxis of organ rejection in patients receiving renal transplants.
DB00897TriazolamFor the short-term treatment of insomnia.
DB00976TelithromycinFor the treatment of Pneumococcal infection, acute sinusitis, acute bacterial tonsillitis, acute bronchitis and bronchiolitis, lower respiratory tract infection and lobar (pneumococcal) pneumonia.
DB01023FelodipineFor the treatment of mild to moderate essential hypertension.
DB01054NitrendipineFor the treatment of mild to moderate hypertension
DB01076AtorvastatinMay be used as primary prevention in individuals with multiple risk factors for coronary heart disease (CHD) and as secondary prevention in individuals with CHD to reduce the risk of myocardial infarction (MI), stroke, angina, and revascularization procedures. May be used to reduce the risk of cardiovascular events in patients with acute coronary syndrome (ACS). May be used in the treatment of primary hypercholesterolemia and mixed dyslipidemia, homozygous familial hypercholesterolemia, primary dysbetalipoproteinemia, and/or hypertriglyeridemia as an adjunct to dietary therapy to decrease serum total and low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (apoB), and triglyceride concentrations, while increasing high-density lipoprotein cholesterol (HDL-C) levels.
DB01100PimozideUsed for the suppression of motor and phonic tics in patients with Tourette's Disorder who have failed to respond satisfactorily to standard treatment.
DB01114ChlorphenamineFor the treatment of rhinitis, urticaria, allergy, common cold, asthma and hay fever.
DB01115NifedipineFor the management of vasospastic angina, chronic stable angina, hypertension, and Raynaud's phenomenon. May be used as a first line agent for left ventricular hypertrophy and isolated systolic hypertension (long-acting agents).
DB01211ClarithromycinAn alternative medication for the treatment of acute otitis media caused by H. influenzae, M. catarrhalis, or S. pneumoniae in patients with a history of type I penicillin hypersensitivity. Also for the treatment of pharyngitis and tonsillitis caused by susceptible Streptococcus pyogenes, as well as respiratory tract infections including acute maxillary sinusitis, acute bacterial exacerbations of chronic bronchitis, mild to moderate community-acquired pneuomia, Legionnaires' disease, and pertussis. Other indications include treatment of uncomplicated skin or skin structure infections, helicobacter pylori infection, duodenal ulcer disease, bartonella infections, early Lyme disease, and encephalitis caused by Toxoplasma gondii (in HIV infected patients in conjunction with pyrimethamine). Clarithromycin may also decrease the incidence of cryptosporidiosis, prevent the occurence of α-hemolytic (viridans group) streptococcal endocarditis, as well as serve as a primary prevention for Mycobacterium avium complex (MAC) bacteremia or disseminated infections (in adults, adolescents, and children with advanced HIV infection).
DB01232SaquinavirFor the treatment of HIV-1 with advanced immunodeficiency together with antiretroviral nucleoside analogues.
DB01238AripiprazoleFor the treatment of schizophrenia and related psychotic disorders.
DB00199ErythromycinFor use in the treatment of infections caused by susceptible strains of microorganisms in the following diseases: respiratory tract infections (upper and lower) of mild to moderate degree, pertussis (whooping cough), as adjunct to antitoxin in infections due to Corynebacterium diphtheriae, in the treatment of infections due to Corynebacterium minutissimum, intestinal amebiasis caused by Entamoeba histolytica, acute pelvic inflammatory disease caused by Neisseria gonorrhoeae, skin and soft tissue infections of mild to moderate severity caused by Streptococcus pyogenes and Staphylococcus aureus, primary syphilis caused by Treponema pallidum, infections caused by Chlamydia trachomatis, nongonococcal urethritis caused by Ureaplasma urealyticum, and Legionnaires' disease caused by Legionella pneumophila.
DB00564CarbamazepineFor the treatment of epilepsy and pain associated with true trigeminal neuralgia.
DB00203SildenafilFor the treatment of erectile dysfunction and to relieve symptoms of pulmonary arterial hypertension (PAH).
DB00908QuinidineFor the treatment of ventricular pre-excitation and cardiac dysrhythmias
DB00656TrazodoneFor the treatment of depression.
DB00091CyclosporineFor treatment of transplant (kidney, liver, and heart) rejection, rheumatoid arthritis, severe psoriasis.
DB00661VerapamilFor the treatment of hypertension, angina, and cluster headache prophylaxis.
DB00502HaloperidolFor the treatment of schizophrenia [L2016] For the treatment of acute psychosis in acutely agitated schizophrenic patients with moderately severe to very severe symptoms [L2016] For the treatment of severe behavioral or psychological symptoms of dementia [L2016] For the treatment of delirium in the pediatric intensive care unit [L2016] For the treatment of agitation or delirium [L2016] For agitation† or delirium in adult patients with no underlying psychiatric illness [L2016] For use as a second-line agent for rescue treatment of chemotherapy-induced nausea/vomiting [L2016] For the treatment of irritability associated with autistic disorder [L2016] For the treatment of tics and vocal utterances associated with Tourette's syndrome [L2016] For the treatment of severe behavioral problems associated with oppositional defiant disorder or other disruptive behavioral disorders, or for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients who show excessive motor activity with accompanying conduct disorders [L2016]
DB00207AzithromycinFor the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions: H. influenzae, M. catarrhalis, S. pneumoniae, C. pneumoniae, M. pneumoniae, S. pyogenes, S. aureus, S. agal
DB01098RosuvastatinUsed as an adjunct to dietary therapy to treat primary hyperlipidemia (heterozygous familial and nonfamilial), mixed dyslipidemia and hypertriglyceridemia. Also indicated for homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering therapies or when other such therapies are not available. Furthermore, it is used to slow the progression of atherosclerosis and for primary prevention of cardiovascular disease.
DB05521TelaprevirTelaprevir, when used in combination with [DB00811], [DB00008], and [DB00022] is indicated for use in the treatment of chronic HCV genotype 1 infection in adults [FDA Label].
DB08873BoceprevirBoceprevir, when used in combination with [DB00811], [DB00008], and [DB00022] is indicated for use in the treatment of chronic HCV genotype 1 infection in adults [FDA Label].
DB00503RitonavirIndicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
DB01118AmiodaroneIntravenously, for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. Orally, for the treatment of life-threatening recurrent ventricular arrhythmias such as recurrent ventricular fibrillation and recurrent hemodynamically unstable ventricular tachycardia.
DB11633Isavuconazole- Indicated for patients 18 years of age and older for the treatment of invasive aspergillosis [FDA Label]. - Indicated for patients 18 years of age and older for the treatment of invasive mucormycosis [FDA Label], including patients where treatment amphotericin B is inappropriate [L1482].
DB01072AtazanavirUsed in combination with other antiretroviral agents for the treatment of HIV-1 infection, as well as postexposure prophylaxis of HIV infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with HIV when that exposure represents a substantial risk for HIV transmission.
DB06414EtravirineIndicated as an adjunct therapy in the treatment of adult HIV-1 infections resistant to therapy with other NNRTIs and antiretroviral agents.
DB00701AmprenavirFor the treatment of HIV-1 infection in combination with other antiretroviral agents.
DB00220NelfinavirUsed in combination with other antiviral drugs in the treatment of HIV in both adults and children.
DB01319FosamprenavirIndicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection, as well as postexposure prophylaxis of HIV infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with HIV when that exposure represents a substantial risk for HIV transmission. The use of fosamprenavir is pending revision due to a potential association between the drug and myocardial infarction and dyslipidemia in HIV infected adults.
DB01149NefazodoneFor the treatment of depression.
DB08931RiociguatRiociguat is indicated for the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), (WHO Group 4) after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class. Riociguat is indicated for the treatment of adults with pulmonary arterial hypertension (PAH), (WHO Group 1), to improve exercise capacity, WHO functional class and to delay clinical worsening. Efficacy was shown in patients on Riociguat monotherapy or in combination with endothelin receptor antagonists or prostanoids. Studies establishing effectiveness included predominately patients with WHO functional class II–III and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (25%).
DB06290SimeprevirIndicated for the treatment of adults with chronic hepatitis C virus (HCV) infection: typically in combination with sofosbuvir in patients with HCV genotype 1 without cirrhosis or with compensated cirrhosis and in combination with peginterferon alfa (Peg-IFN-alfa) and ribavirin (RBV) in patients with HCV genotype 1 or 4 without cirrhosis or with compensated cirrhosis. Resistance: Reduced susceptibility to simeprevir was most commonly associated with the viral NS3 Q80K polymorphism. Amino acid substitutions at NS3 positions S122, R155 and/or D168 are also shown to reduce susceptibility to simeprevir in genotype 1a/b patients.
DB06287TemsirolimusFor the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.
DB11586AsunaprevirAsunaprevir is indicated in combination with other agents for the treatment of chronic hepatitis C in adult patients with hepatitis C virus genotypes 1 or 4 and compensated liver cirrhosis.[L2278] Hepatitis C is a liver disease caused by the hepatitis C virus. The chronic state of this condition accounts for 60-80% of the cases from which the risk of cirrhosis of the liver within 20 years is of around 15-30%.[L2281] The genotype 1 is the most common type of hepatitis C in the United States and the most difficult to treat.[L2282]
DB00321Amitriptyline- Indicated for the treatment of major depressive disorder in adults - Indicated for the management of neuropathic pain in adults - Indicated for the prophylactic treatment of chronic tension type headache (CTTH) in adults - Indicated for the prophylactic treatment of migraine in adults - Indicated for the the treatment of nocturnal enuresis in children aged 6 years and above when organic pathology, including spina bifida and related disorders, have been excluded and no response has been achieved to all other non-drug and drug treatments, including antispasmodics and vasopressin-related products. This medicinal product should only be prescribed by a healthcare professional with expertise in the management of persistent enuresis. -Other off-label uses include irritable bowel syndrome, sleep disorders, diabetic neuropathy, agitation and insomnia
DB01242ClomipramineMay be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, Tourette’s disorder). Unlabeled indications include: depression, panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy (limited evidence), autistic disorder (limited evidence), trichotillomania (limited evidence), onchophagia (limited evidence), stuttering (limited evidence), premature ejaculation, and premenstrual syndrome.
DB00924CyclobenzaprineFor use as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions.
DB01142Doxepin**Oral: ** - Indicated for the treatment of depression and/or anxiety [FDA Label]. - Indicated for the treatment of depression and/or anxiety associated with different conditions, including alcoholism, organic disease and manic-depressive disorders [FDA Label]. - Indicated for the treatment of insomnia characterized by difficulties with sleep maintenance [L1347]. Topical: - Indicated for the short-term (up to 8 days) management of moderate pruritus in adult patients with atopic dermatitis or lichen simplex chronicus [L1344].
DB00458ImipramineFor the relief of symptoms of depression and as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older [FDA Label]. May also be used off-label to manage panic disorders with or without agoraphobia, as a second line agent for ADHD in children and adolescents, to manage bulimia nervosa, for short-term management of acute depressive episodes in bipolar disorder and schizophrenia, for the treatment of acute stress disorder and posttraumatic stress disorder, and for symptomatic treatment of postherpetic neuralgia and painful diabetic neuropathy [L1349,L1348,A31900,L1351,L1352,L1353,A31904].
DB00540NortriptylinePrimarily indicated for the relief of symptoms of depression.
DB09289TianeptineUsed primarily in the treatment of major depressive disorder and anxiety [A31969]. It is currently being studied for fibromyalgia pain treatment [L1426].
DB00726TrimipramineFor the treatment of depression and depression accompanied by anxiety, agitation or sleep disturbance
DB00783EstradiolEstradiol is indicated for the treatment of moderate to severe vasomotor symptoms and vulvar and vaginal atrophy due to menopause, for the treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure, and for the prevention of post-menopausal osteoarthritis. It is also used for the treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease, and for the treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only).
DB13954Estradiol cypionateDepo-Estradiol intramuscular depot injection is indicated for the treatment of moderate to severe vasomotor symptoms and hypoestrogenism due to hypogonadism.
DB13956Estradiol valerateEstradiol valerate is commercially available as an intramuscular injection as the product Delestrogen and is indicated for the treatment of moderate to severe vasomotor symptoms and vulvovaginal atrophy due to menopause, for the treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure, and for the treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). Estradiol valerate is also available in combination with [DB09123] as the commercially available product Natazia used for the prevention of pregnancy and for the treatment of heavy menstrual bleeding.
DB00977EthinylestradiolFor treatment of moderate to severe vasomotor symptoms associated with the menopause, female hypogonadism, prostatic carcinoma-palliative therapy of advanced disease, breast cancer, as an oral contraceptive, and as emergency contraceptive.
DB01357MestranolMestranol was used as one of the first oral contraceptives.
DB01223AminophyllineFor the treatment of bronchospasm due to asthma, emphysema and chronic bronchitis.
DB00277TheophyllineFor the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.
DB01200BromocriptineFor the treatment of galactorrhea due to hyperprolactinemia, prolactin-dependent menstrual disorders and infertility, prolactin-secreting adenomas, prolactin-dependent male hypogonadism, as adjunct therapy to surgery or radiotherapy for acromegaly or as monotherapy is special cases, as monotherapy in early Parksinsonian Syndrome or as an adjunct with levodopa in advanced cases with motor complications. Bromocriptine has also been used off-label to treat restless legs syndrome and neuroleptic malignant syndrome.
DB00248CabergolineFor the treatment of hyperprolactinemic disorders, either idiopathic or due to prolactinoma (prolactin-secreting adenomas). May also be used to manage symptoms of Parkinsonian Syndrome as monotherapy during initial symptomatic management or as an adjunct to levodopa therapy during advanced stages of disease.
DB00320DihydroergotamineFor the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes.
DB01049Ergoloid mesylateIt was labeled by the FDA for the treatment of symptoms of an idiopathic decline in the mental capacity not related to a potentially reversible condition[A32913] as well as for age-related cognitive impairment.[A32926] The prescription of this drug is conditioned to the corroboration that the patient is not suffering from a potentially reversible and treatable condition especially delirium and dementiform illness secondary to systemic disease, primary neurological disease or primary mood disturbance.[L2637] To know more about the individual components of the ergoloid mixture, please visit [DB13345] and [DB11274]
DB01253ErgonovineUsed to treat postpartum haemorrhage and postabortion haemorrhage in patients with uterine atony.
DB00696ErgotamineFor use as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants, or so called "histaminic cephalalgia".
DB00589LisurideFor the management of Parkinson's Disease
DB04829Lysergic Acid DiethylamideNot Available
DB00353MethylergometrineFor the prevention and control of excessive bleeding following vaginal childbirth
DB01186PergolideIndicated as adjunctive treatment to levodopa/carbidopa in the management of the signs and symptoms of Parkinson's disease. It was withdrawn from the US and Canadian markets in 2007 due to an increased risk of cardiac valvulopathy.
DB00620TriamcinoloneFor the treatment of perennial and seasonal allergic rhinitis.
DB00582VoriconazoleFor the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp.
DB00736EsomeprazoleFor the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
DB00338OmeprazoleOmeprazole is indicated for the treatment of duodenal ulcers, benign gastric ulcers, gastroesophageal reflux disease (GERD), heartburn and other symptoms associated with GERD, erosive esophagitis, and long-term treatment of pathological hypersecretory conditions like Zollinger-Ellison syndrome, multiple endocrine adenomas, and systemic mastocytosis.
DB01182PropafenoneUsed to prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. Also used for the treatment of life-threatening documented ventricular arrhythmias, such as sustained ventricular tachycardia.
DB08496(R)-warfarinNot Available
DB00946PhenprocoumonUsed for the prevention and treatment of thromboembolic disease including venous thrombosis, thromboembolism, and pulmonary embolism as well as for the prevention of ischemic stroke in patients with atrial fibrillation (AF).
DB00444TeniposideTeniposide is used for the treatment of refractory acute lymphoblastic leukaemia
DB00932TipranavirFor combination antiretroviral treatment of HIV-1 infected adult patients with evidence of viral replication, who are highly treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors.
DB08867UlipristalAs the product Ella (available in Canada and the US), ulipristal is indicated for use as emergency contraception after unprotected intercourse or possible contraceptive failure when administered within 120 hours (5 days) after unprotected intercourse or a known or suspected contraceptive failure. As the product Fibristal (available in Canada), ulipristal is indicated for treatment of the signs and symptoms of uterine fibroids in adult women.
DB00280DisopyramideFor the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, ventricular pre-excitation and cardiac dysrhythmias. It is a Class Ia antiarrhythmic drug.
DB00333MethadoneFor the treatment of dry cough, drug withdrawal syndrome, opioid type drug dependence, and pain.
DB00346AlfuzosinFor the reduction of urinary obstruction and relief of associated manifestations (eg. sensation of incomplete bladder emptying or straining, urgency, interrupted or weak stream) in patients with symptomatic beningn prostatic hyperplasia.
DB00921BuprenorphineFor the treatment of moderate to severe pain, peri-operative analgesia, and opioid dependence.
DB06237AvanafilTreatment of erectile dysfunction in males.
DB12010FostamatinibFostamatinib is indicated for use in the treatment of chronic immune thrombocytopenia (ITP) in patients who have had insufficient response to previous therapy [FDA Label].
DB06267UdenafilInvestigated for use/treatment in erectile dysfunction and hypertension.
DB00213PantoprazoleShort-term (up to 16 weeks) treatment of erosive esophagitis.
DB00448LansoprazoleFor the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
DB05351DexlansoprazoleIndicated for healing all grades of erosive esophagitis (EE), maintaining and healing of EE and relief of heartburn, and treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD).
DB01129RabeprazoleFor the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
DB00673AprepitantFor the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including high-dose cisplatin (in combination with other antiemetic agents).
DB09236LacidipineIndicated for the treatment of hypertension either alone or in combination with other antihypertensive agents, including β-adrenoceptor antagonists, diuretics, and ACE-inhibitors [L1126].
DB14568IvosidenibIvosidenib is approved for use in the treatment of relapsed or refractory AML with a susceptible IDH1 mutation as detected by an FDA-approved test [FDA Label].
DB126293,5-diiodothyropropionic acidNot Available
DB014565-androstenedioneNot Available
DB00240AlclometasoneFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
DB04630AldosteroneNot Available
DB01431AllylestrenolAllylestrenol was designed to be used for miscarriage prevention, prevention of premature labour and has been investigated for possible use in men for treatment for benign prostatic hyperplasia.
DB00288AmcinonideFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
DB01536AndrostenedioneNot Available
DB00394Beclomethasone dipropionateUsed in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older, and in treating symptoms for allergic rhinitis (seasonal or perennial) in patients 12 years of age and older. Also being investigated for oral treatment in mild-to-moderate Crohn's disease of ileal or ileal-right colonic localisation and for "topical" use mild-to-moderate graft versus host disease.
DB00443BetamethasoneTopical use (cream, lotion and ointment): for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Topical use (foam): relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp. Systemic use: for the treatment of edocrine disorders, rheumatic disorders, collagen diseases, dermatological diseases, allergic states, ophthalmic diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, gastrointestinal diseases, tuberculous meningitis and trichinosis.
DB01222BudesonideThe oral capsule is used for the treatment of mild to moderate active Crohn's disease. The oral tablet is used for induction of remission in patients with active, mild to moderate ulcerative colitis. The oral inhalation formulation is used for the treatment of asthma, non-infectious rhinitis (including hay fever and other allergies), and for treatment and prevention of nasal polyposis.
DB01410CiclesonideFor the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older.
DB11750ClobetasolNot Available
DB01013Clobetasol propionateFor short-term topical treatment of the inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp.
DB13158ClobetasoneIn dermatology, topical clobestasone butyrate helps to reduce the itchiness and erythema associated with eczema and dermatitis. In ophthalmology, clobetasone butyrate 0.1% eye drops have been shown to be safe and effective in the treatment of dry eyes in Sjögren's Syndrome.
DB04652CorticosteroneNot Available
DB01285CorticotropinFor use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.
DB01380Cortisone acetateFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders.
DB04839Cyproterone acetateFor the palliative treatment of patients with advanced prostatic carcinoma.
DB11921Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older
DB09123DienogestIndicated for use as the treatment of endometriosis alone and as a contraceptive in combination with ethinylestradiol.
DB11636NomegestrolNot Available
DB13981Nomegestrol acetateNot Available
DB00304DesogestrelFor the prevention of pregnancy in women who elect to use this product as a method of contraception.
DB01260DesonideFor the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatose.
DB06780Desoxycorticosterone acetateNot Available
DB01134Desoxycorticosterone PivalateExamined for treatment of adrenocortical insufficiency especially in multiple sclerosis, congenital cerebral palsy, polyarteritis nodosa, and rheumatoid arthritis. Currently only approved in treating cats and dogs for the treatment of Addison's disease.
DB01234DexamethasoneInjection: for the treatment of endocrine disorders, rheumatic D=disorders, collagen diseases, dermatologic diseases, allergic statesc, ophthalmic diseases, gastrointestinal diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, cerebral edema.
Ophthalmic ointment and solution: for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.
Ophthalmic solution only: for the treatment of steroid responsive inflammatory conditions of the external auditory meatus
Topic cream: for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses
Oral aerosol: for the treatment of bronchial asthma and related corticosteroid responsive bronchospastic states intractable to adequate trial of conventional therapy
Intranasal aerosol: for the treatment of allergic ot inflammatory nasal conditions, and nasal polyps
DB11487Dexamethasone isonicotinateNot Available
DB09095DifluocortoloneDifluocortolone is used as a topical treatment of the symptoms of inflammatory skin disorders like eczema, seborrheic eczema, lichen planus and psoriasis. All these disorders present as a common characteristic the occurrence of symptoms as itching, swelling, redness and scaling.[L1083]
DB06781DifluprednateFor the treatment of inflammation and pain associated with ocular surgery.
DB01395DrospirenoneFor the prevention of pregnancy in women who elect an oral contraceptive.
DB00378DydrogesteroneUsed to treat irregular duration of cycles and irregular occurrence and duration of periods caused by progesterone deficiency. Also used to prevent natural abortion in patients who have a history of habitual abortions.
DB03515EquileninNot Available
DB02187EquilinFor the treatment of moderate to severe vasomotor symptoms associated with the menopause, atrophic vaginitis, osteoporosis, hypoestrogenism due to hypogonadism, castration, primary ovarian failure, breast cancer (for palliation only), and Advanced androgen-dependent carcinoma of the prostate (for palliation only)
DB00655EstroneFor management of perimenopausal and postmenopausal symptoms.
DB04574Estrone sulfateEstropipate is used for the treatment of moderate to severe vasomotor symptoms associated with the monopause, and moderate to severe symptoms of vulval and vaginal atrophy associated with the menopause. It is also used to treat hypoestrogenism due to hypogonadism, castration or primary ovarian failure, and prevent postmenopausal osteoporosis.
DB13866EthynodiolNot Available
DB00823Ethynodiol diacetateFor the prevention of pregnancy in women who elect to use this product as a method of contraception.
DB00294EtonogestrelFor use as a female contraceptive (depot).
DB00687FludrocortisoneFor partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenogenital syndrome.
DB00663FlumethasoneFor the treatment of contact dermatitis, atopic dermatitis, exczema, psoriasis, diaper rash and other skin conditions
DB00180FlunisolideFor the maintenance treatment of asthma as a prophylactic therapy.
DB00591Fluocinolone acetonideFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (Retisert).
DB01047FluocinonideA topical anti-inflammatory product for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
DB08971FluocortoloneNot Available
DB00324FluorometholoneFor the ophthalmic treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe.
DB08970FluprednideneNot Available
DB09378FluprednisoloneNot Available
DB00846FlurandrenolideFor relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, particularly dry, scaling localized lesions
DB13867FluticasoneNot Available
DB08906Fluticasone furoateFluticasone furoate nasal spray is indicated for the treatment of the symptoms of seasonal and perennial allergic rhinitis in patients aged 2 years and older. Breo Ellipta, a mixture of fluticasone furoate and vilanterol is indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema. It is also indicated for once-daily maintenance treatment of asthma in patients aged 18 or older with reversible obstructive airways disease. Breo Ellipta should not be used for the relief of acute symptoms of asthma or COPD.
DB00588Fluticasone propionateFluticasone propionate, a medium-potency synthetic corticosteroid, is used topically to relieve inflammatory and pruritic symptoms of dermatoses and psoriasis, intranasally to manage symptoms of allergic and non-allergic rhinitis, and orally for the maintenance treatment of asthma as prophylactic therapy and for patients requiring oral corticosteroid therapy for asthma.
DB06730GestodeneNot Available
DB06786HalcinonideIndicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
DB05212HE3286For the treatment of rheumatoid arthritis and type 2 diabetes.
DB00741HydrocortisoneFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.
DB14538Hydrocortisone aceponateFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.
DB14539Hydrocortisone acetateFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.
DB14540Hydrocortisone butyrateFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.
DB14541Hydrocortisone cypionateFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.
DB14542Hydrocortisone phosphateFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.
DB14543Hydrocortisone probutateFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.
DB14545Hydrocortisone succinateNot Available
DB14544Hydrocortisone valerateFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.
DB14570HydroxyprogesteroneNot Available
DB06789Hydroxyprogesterone caproateHydroxyprogesterone caproate is indicated for the prevention of spontaneous preterm births in singleton pregnancies in women who have previously had a spontaneous preterm birth. (1)
DB00007LeuprolideFor treatment of prostate cancer, endometriosis, uterine fibroids and premature puberty
DB00367LevonorgestrelFor the treatment of menopausal and postmenopausal disorders and alone or in combination with other hormones as an oral contraceptive.
DB00451LevothyroxineFor use alone or in combination with antithyroid agents to treat hypothyroidism, goiter, chronic lymphocytic thyroiditis, myxedema coma, and stupor.
DB00279LiothyronineUsed as replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyrodism during the recovery phase of subacute thyroiditis.
DB01583LiotrixMay be used to treat primary, secondary or tertiary hypothyroidism. May also be used to suppress thyroid stimulating hormone (TSH) secretion in patients with simple (nontoxic) goiter, subacute or chronic lymphocytic thyroiditis multinodular goiter, and in the management of thyroid cancer. May be used in conjunction with other antithyroid agents to treat thyrotoxicosis to prevent goitrogenesis and hypothyroidism. May also be used for differential diagnosis of suspected mild hyperthyroidism or thyroid gland autonomy.
DB14596Loteprednol etabonateA number of prescription loteprednol etabonate ophthalmic products are specifically indicated for the treatment of post-operative inflammation and pain following ocular surgery [FDA Label].
DB12474LynestrenolNot Available
DB09124MedrogestoneMedrogestone is indicated as adjunct to treat endometial shedding in menopausal women, to treat secondary amenorrhea, to induce menses and to treat dysfunctional uterine bleeding in adult and adolescent women.[T76]
DB00603Medroxyprogesterone acetateUsed as a contraceptive and to treat secondary amenorrhea, abnormal uterine bleeding, pain associated with endometriosis, endometrial and renal cell carcinomas, paraphilia in males, GnRH-dependent forms of precocious puberty, as well as to prevent endometrial changes associated with estrogens.
DB00253MedrysoneFor the treatment of allergic conjunctivitis, vernal conjunctivitis, episcleritis, and epinephrine sensitivity.
DB00351Megestrol acetateFor the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS). Also used for the palliative management of recurrent, inoperable, or metastatic breast cancer, endometrial cancer, and prostate cancer in Canada and some other countries.
DB11529MelengestrolNot Available
DB09383MeprednisoneNot Available
DB00959MethylprednisoloneAdjunctive therapy for short-term administration in rheumatoid arthritis.
DB00764MometasoneThe inhaler is indicated for the maintenance treatment of asthma as prophylactic therapy. The nasal spray is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis.
DB14512Mometasone furoateThe inhaler is indicated for the maintenance treatment of asthma as prophylactic therapy. The nasal spray is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis.
DB06713NorelgestrominNorelgestromin is used for contraception and menopausal hormonal therapy. Norelgestromin may potentially be used in breast cancer treatment due to its inhibitory effect on estrone sulfatase . They convert sulfated steroid precursors to estrogen during pregnancy.
DB00717NorethisteroneFor the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer.
DB09371NorethynodrelNot Available
DB00957NorgestimateFor the prevention of pregnancy
DB09389NorgestrelNorgestrel in combination with ethinyl estradiol is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.
DB01384ParamethasoneFor the treatment of all conditions in which corticosteroid therapy is indicated except adrenal-deficiency states for which its lack of sodium-retaining properties makes it less suitable than hydrocortisone with supplementary fludrocortisone.
DB01708PrasteroneDHEA is taken as a supplement for a variety of unsubstantiated indications. The following indications have shown promise and are backed up by some scientific evidence: schizophrenia (DHEA may be more effective in women than men); improving the appearance of older people’s skin (taking DHEA by mouth seems to increase skin thickness and moisture, and decrease facial “age spots” in elderly men and women); improving ability to achieve an erection in men with sexual dysfunction. Additionally, DHEA has shown promise in improving symptoms of lupus (SLE). Taking DHEA by mouth along with conventional treatment may help reduce the number of times symptoms flare up and may allow a reduction in the dose of prescription drugs needed. DHEA may also help SLE symptoms such as muscle ache and mouth ulcers. DHEA also seems to strengthen bones in SLE patients being treated with high-dose steroids (corticosteroids). DHEA also shows promise in the treatment of osteoporosis. Taking DHEA by mouth daily seems to improve bone mineral density (BMD) in older women and men with osteoporosis or osteopenia (pre-osteoporosis). DHEA may also increase BMD in young women with the eating disorder called anorexia nervosa. DHEA is often prescribed in India for the induction of ovulation to improve chances of pregnancy.
DB01130PrednicarbateFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
DB00860PrednisoloneFor the treatment of primary or secondary adrenocortical insufficiency, such as congenital adrenal hyperplasia, thyroiditis. Also used to treat psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, bursitis, acute gouty arthritis and epicondylitis. Also indicated for treatment of systemic lupus erythematosus, pemphigus and acute rhematic carditis. Can be used in the treatment of leukemias, lymphomas, thrombocytopenia purpura and autoimmune hemolytic anemia. Can be used to treat celiac disease, insulin resistance, ulcerative colitis and liver disorders.
DB00635PrednisoneFor the treatment of drug-induced allergic reactions, perennial or seasonal allergic rhinitis, serum sickness, giant cell arteritis acute rheumatic or nonrheumatic carditis, systemic dermatomyositis, systemic lupus erythematosus, atopic dermatitis, contact dermatitis, exfoliative dermatitis, bullous dermatitis herpetiformis, severe seborrheic dermatitis, severe (Stevens-Johnson syndrome) erythema multiforme, mycosis fungoides, pemphigus, severe psoriasis, acute adrenocortical insufficiency, Addison's disease, secondary adrenocortical insufficiency, congenital adrenal hyperplasia, hypercalcemia associated with neoplasms, nonsuppurative thyroiditis, ulceratice colitis, Crohn's disease, acquired hemolytic anemia, congenital hypoplastic anemia, erythroblastopenia, adult secondary thrombocytopenia, adult idiopathic thrombocytopenia purpura, acute or subacute bursitis, epicondylitis, acute nonspecific tenosynovitis, acute or chronic lymphocytic leukemia, Hodgkin's or non-Hodgkin's lynphomas, Waldenstrom's macroglobulinemia, primary brain tumors (adjunct), nephrotic syndrome, tuberculous meningitis, multiple sclerosis, myasthenia gravis. cerebral edema, chorioretinitis, diffuse posterior choroiditis, aleergic conjunctivitis, Herpes zoster ophthalmicus, anterior segment inflammation, iridocyclitis, iritis, keratitis, optoc neuritis, sympathetic ophthalmia, corneal marginal allergic ulcers, symptomatic sarcoidosis, Loeffler's syndrome not manageable by other means, berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy and aspiration pneumonitis.
DB02789PregnenoloneNot Available
DB00396ProgesteroneFor progesterone supplementation or replacement as part of an Assisted Reproductive Technology (ART) treatment for infertile women with progesterone deficiency and for the treatment of secondary amenorrhea. Also used for the reduction of the incidence of endometrial hyperplasia and the attendant risk of endometrial carcinoma in postmenopausal women receiving estrogen replacement therapy, as well as treatment of abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology such as fibroids or uterine cancer.
DB00896RimexoloneFor the treatment of postoperative inflammation following ocular surgery and in the treatment of anterior uveitis.
DB01108TrilostaneUsed in the treatment of Cushing's syndrome. It is normally used in short-term treatment until permanent therapy is possible.
DB01117AtovaquoneFor the treatment or prevention of Pneumocystis carinii pneumonia in patients who are intolerant to trimethoprim-sulfamethoxazole (TMP-SMX). Also indicated for the acute oral treatment of mild to moderate PCP in patients who are intolerant to TMP-SMX.
DB00980RamelteonFor the treatment of insomnia characterized by difficulty with sleep onset.
DB00425ZolpidemFor the short-term treatment of insomnia.
DB00495ZidovudineUsed in combination with other antiretroviral agents for the treatment of human immunovirus (HIV) infections.
DB00255DiethylstilbestrolUsed in the treatment of prostate cancer. Previously used in the prevention of miscarriage or premature delivery in pregnant women prone to miscarriage or premature delivery.
DB11619GestrinoneEndometriosis with or without accompanying sterility. Treatment is limited to a single course of 6 months duration per lifetime [L1699, L1700].
DB13857DemegestoneNot Available
DB00250DapsoneFor the treatment and management of leprosy and dermatitis herpetiformis.
DB00295MorphineFor the relief and treatment of severe pain.
DB14055(S)-WarfarinNot Available
DB034104-hydroxycoumarinNot Available
DB01418AcenocoumarolFor the treatment and prevention of thromboembolic diseases. More specifically, it is indicated for the for the prevention of cerebral embolism, deep vein thrombosis, pulmonary embolism, thromboembolism in infarction and transient ischemic attacks. It is used for the treatment of deep vein thrombosis and myocardial infarction.
DB08794Ethyl biscoumacetateNot Available
DB13136FluindioneNot Available
DB00682WarfarinFor the treatment of retinal vascular occlusion, pulmonary embolism, cardiomyopathy, atrial fibrillation and flutter, cerebral embolism, transient cerebral ischaemia, arterial embolism and thrombosis.
DB01355HexobarbitalFor the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli.
DB01154ThiamylalUsed for the production of complete anaesthesia of short duration, for the induction of general anaesthesia, and for inducing a hypnotic state.
DB09230AzelnidipineFor the treatment of hypertension.
DB09227BarnidipineIndicated for the treatment of mild to moderate essential hypertension and management of chronic stable angina.
DB13488BencyclaneNot Available
DB09231BenidipineBenidipine is a potent and long-lasting drug indicated for the treatment of cardiovascular diseases such as hypertension, renoparenchymal hypertension and angina pectoris.[A31950]
DB01244BepridilFor the treatment of hypertension, and chronic stable angina (classic effort-associated angina).
DB13746BioallethrinBioallethrin was used for lice and scabies infestation. Other pyrethroids are now used in place of bioallethrin.
DB08838AgmatineAgmatine is being studied experimentally for several indications such as cardioprotection, diabetes, decreased kidney function, neuroprotection (stroke, severe CNS injuries, epilepsy, glaucoma, and neuropathic pain), and psychiatric conditions (depression, anxiety, schizophrenia, and cognition). As an investigational drug, agamatine is being studied in a non-blinded prospective case study in the United States looking at patients who have been diagnosed with small fiber peripheral neuropathy.
DB11960CarboxyamidotriazoleNot Available
DB13835CaroverineNot Available
DB09232CilnidipineCilnidipine is indicated for the management of hypertension for end-organ protection.[L1436] It is reported to be useful in elderly patients and in those with diabetes and albuminuria. Cilnidipine has been increasingly used in patients with chronic kidney disease Hypertension is the term used to describe the presence of high blood pressure. The blood pressure is generated by the force of the blood pumped from the heart against the blood vessels. Thus hypertension is caused when there is too much pressure on the blood vessels and this effect can damage the blood vessel.[L1438]
DB00568CinnarizineFor the treatment of vertigo/meniere's disease, nausea and vomiting, motion sickness and also useful for vestibular symptoms of other origins.
DB04920ClevidipineFor the treatment of hypertension.
DB04838CyclandelateUsed in the treatment of various blood vessel diseases (e.g., claudication, arteriosclerosis and Raynaud's disease) and nighttime leg cramps.
DB09234DarodipineNot Available
DB14068DexniguldipineNot Available
DB14063DexverapamilNot Available
DB06446DotarizineInvestigated for use/treatment in migraine and cluster headaches.
DB09235EfonidipineFor the treatment of hypertension.
DB14064EmopamilNot Available
DB08992EperisoneNot Available
DB00593EthosuximideFor the treatment of petit mal epilepsy.
DB08980FendilineNot Available
DB13961Fish oilUnder FDA approval, fish oil pharmaceuticals are typically products consisting of a combination of the omega-3-fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and are indicated primarily as an adjunct to diet to reduce triglyceride levels in adult patients with severe (>=500 mg/dL) hypertriglyceridemia [FDA Label, F36]. Under EMA approval, such fish oil pharmaceuticals comprised of virtually the same fish and fish oil derived omega-3-fatty acids EPA and DHA are indicated specifically for (a) adjuvant treatment in secondary prevention after myocardial infarction, in addition to other standard therapy (ie. statins, antiplatelet medicinal products, beta blockers, ACE inhibitors), and (b) as a supplement to diet when dietary measures alone are insufficient to produce an adequate response, particularly with type IV hypertriglyceridemia in monotherapy or type IIb/III in combination with statins, when control of triglycerides is insufficient [L2661]. In addition, prescribing information for EMA approved fish oil pharmaceuticals are also indicated as an adjunct to diet to reduce very high (>=500 mg/dL) triglyceride levels in adult patients, much like similar FDA approved indications [F37, FDA Label].
DB04841FlunarizineUsed in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.
DB04842FluspirileneUsed for the treatment of schizophrenia.
DB00996GabapentinFor the management of postherpetic neuralgia in adults and as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients over 12 years of age with epilepsy.
DB12923GallopamilNot Available
DB00270IsradipineFor the management of mild to moderate essential hypertension. It may be used alone or concurrently with thiazide-type diuretics.
DB00555LamotrigineIndicated as adjunctive therapy for the following seizure types in patients ≥2 years of age: partial seizures/primary generalized tonic-clonic seizures/generalized seizures of Lennox-Gastaut syndrome [FDA Label]. Indicated for conversion to monotherapy in adults (≥16 years of age) with partial seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED)[FDA Label]. Indicated for the maintenance treatment of Bipolar I Disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in adults (≥18 years of age) treated for acute mood episodes with standard therapy [FDA Label].
DB00528LercanidipineFor the treatment of Hypertension, management of angina pectoris and Raynaud's syndrome
DB01202LevetiracetamUsed as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy.
DB14065LomerizineNot Available
DB00836LoperamideFor the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease or gastroenteritis. Also used for reducing the volume of discharge from ileostomies.
DB09238ManidipineFor the treatment of hypertension.
DB00825MentholUsed to treat occasional minor irritation, pain, sore mouth, and sore throat as well as cough associated with a cold or inhaled irritants.
DB01388MibefradilFor the treatment of angina and high blood pressure.
DB12092NaftopidilNot Available
DB00622NicardipineUsed for the management of patients with chronic stable angina and for the treatment of hypertension.
DB09240NiludipineNot Available
DB06712NilvadipineFor the management of vasospastic angina, chronic stable angina and hypertension.
DB04743NimesulideFor the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old.
DB00393NimodipineFor use as an adjunct to improve neurologic outcome following subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms by reducing the incidence and severity of ischemic deficits.
DB06152NylidrinNylidrin is mainly indicated in conditions like arteriosclerosis, cerebrovascular disease, peripheral vascular disease, Raynaud's disease, thrombo-angitis obliterans, and thrombophlebitis [L2285]. It may sometimes be used in the treatment of peripheral vascular disorders in addition premature labor (however, the drug is not approved for premature labor)[A32531].
DB09239NiguldipineNot Available
DB13500OtiloniumNot Available
DB01074PerhexilineFor the management of severe angina pectoris.
DB09090PinaveriumIndicated for the treatment and relief of symptoms associated with irritable bowel syndrome (IBS) associated with abdominal pain, bowel disturbances and intestinal discomfort, as well as the treatment of symptoms related to functional disorders of the biliary tract.
DB00230PregabalinPregabalin is used for the management of neuropathic pain associated with diabetic peripheral neuropathy or spinal cord injury, and postherpetic neuralgia. It is not approved for the management of fibromyalgia or as adjuntive therapy for adult partial onset seizures.[FDA label]
DB04825PrenylamineNot Available
DB12093TetrahydropalmatineNot Available
DB14066TetrandrineNot Available
DB09216Tolfenamic AcidIn the information for tolfenamic acid, it is stated that this drug, being an NSAID, is effective in treating the pain associated with the acute attack of migraines in adults.[L1293]
DB07615TranilastFor the treatment of bronchial asthma, keloid and hypertrophic scar, and allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.
DB09089TrimebutineIndicated for symptomatic treatment of irritable bowel syndrome (IBS) and treatment of postoperative paralytic ileus following abdominal surgery.
DB00347TrimethadioneUsed in the control of absence (petit mal) seizures that are refractory to treatment with other medications.
DB05885SeletracetamInvestigated for use/treatment in epilepsy.
DB12131VinpocetineNot Available
DB13950WIN 55212-2Not Available
DB06283ZiconotideNot Available
DB00909ZonisamideFor use as adjunctive treatment of partial seizures in adults with epilepsy.
DB00602IvermectinFor the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite Strongyloides stercoralis. Also for the treatment of onchocerciasis (river blindness) due to the nematode parasite Onchocerca volvulus. Can be used to treat scabies caused by Sarcoptes scabiei.
DB04845IxabepiloneInvestigated for use/treatment in breast cancer, head and neck cancer, melanoma, lung cancer, lymphoma (non-hodgkin's), prostate cancer, renal cell carcinoma, and cancer/tumors (unspecified).
DB01045RifampicinFor the treatment of Tuberculosis and Tuberculosis-related mycobacterial infections.
DB00615RifabutinFor the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection.
DB11753RifamycinNot Available
DB01201RifapentineFor the treatment of pulmonary tuberculosis.
DB01220RifaximinRifaximin has multiple indications by the FDA: for the treatment of patients (≥12 years of age) with traveller's diarrhea caused by noninvasive strains of Escherichia coli; for the reduction of overt hepatic encephalopathy recurrence in patients ≥18 years of age; and in May 2015 it was approved for irritable bowel syndrome with diarrhea (IBS-D) treatment in adult men and women.
DB08896RegorafenibRegorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.
DB01241GemfibrozilFor treatment of adult patients with very high elevations of serum triglyceride levels (types IV and V hyperlipidemia) who are at risk of developing pancreatitis (inflammation of the pancreas) and who do not respond adequately to a strict diet.
DB09083IvabradineIvabradine's indication by the FDA is to reduce the risk of hospitalization for worsening heart failure in patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤35%, who are in sinus rhythm with resting heart rate ≥70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use.
DB08881VemurafenibVemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on BRAF in the valine located in the exon 15 at codon 600, this mutation is denominated as V600E.[A31270] The V600E mutation, a substitution of glutamic acid for valine, accounts for 54% of the cases of cutaneous melanoma.[A31271] Vemurafenib approval was extended in 2017, for its use as a treatment of adult patients with Erdheim-Chester Disease whose cancer cells present BRAF V600 mutation.[L1013] Erdheim-Chester disease is an extremely rare histiocyte cell disorder that affects large bones, large vessels, central nervous system, as well as, skin and lungs. It is reported an association of Erdheim-Chester disease and V600E mutation.[A31272]
DB09068VortioxetineVortioxetine is indicated for the treatment of major depressive disorder (MDD).
DB06589PazopanibTreatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
DB08883PerampanelUsed in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures.
DB08865CrizotinibCrizotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic-lymphoma kinase (ALK)-positive as detected by a FDA-approved test.
DB08875CabozantinibFor the treatment of metastatic medullary thyroid cancer and for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.
DB08815LurasidoneTreatment of schizophrenia.
DB06636IsavuconazoniumIndicated in the treatment of invasive aspergillosis and invasive mucormycosis.
DB06626AxitinibUsed in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.
DB00318CodeineFor treatment and management of pain (systemic). It is also used as an antidiarrheal and as a cough suppressant.
DB06605ApixabanApixaban is to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It has also been used to lower the risk of developing venous thrombosis post-orthopedic surgical procedures.
DB12781BalaglitazoneNot Available
DB09201CiglitazoneNot Available
DB09198LobeglitazoneLobeglitazone was approved by the Ministry of Food and Drug Safety (South Korea) in 2013, and is being monitored by postmarketing surveillance until 2019. Lobeglitazone is not approved for use by either the Food and Drug Administration (USA), Health Canada, or by the European Medicines Agency for use in the management of diabetes.
DB09199NetoglitazoneNot Available
DB01132PioglitazonePioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [FDA Label].
DB09200RivoglitazoneNot Available
DB00412RosiglitazoneRosiglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
DB01267PaliperidoneFor the treatment of schizophrenia.
DB01259LapatinibIndicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzuma.
DB11737IcotinibIcotinib hydrochloride is a novel epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor, exhibits encouraging efficacy and tolerability in patients with advanced non-small-cell lung cancer (NSCLC) who failed previous chemotherapy.
DB00185CevimelineFor the treatment of symptoms of dry mouth in patients with Sjögren's Syndrome.
DB00188BortezomibFor treatment of multiple myeloma in patients who have not been successfully treated with at least two previous therapies.
DB00204DofetilideFor the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [AF/AFl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm
DB00208TiclopidineUsed in patients, who have had a stroke or stroke precursors and who cannot take aspirin or aspirin has not worked, to try to prevent another thrombotic stroke.
DB00216EletriptanFor the acute treatment of migraine with or without aura in adults.
DB00234ReboxetineFor the treatment of clinical depression.
DB00243RanolazineFor the treatment of chronic angina. It should be used in combination with amlodipine, beta-blockers or nitrates.
DB00246ZiprasidoneFor the treatment of schizophrenia and related psychotic disorders.
DB00286Conjugated estrogensConjugated Equine Estrogens (CEEs) are indicated for the following conditions: treatment of moderate to severe vasomotor symptoms and vulvovaginal atrophy associated with menopause; hypoestrogenism due to hypogonadism, castration or primary ovarian failure; palliation of metastatic breast cancer; palliation of advanced androgen-dependent carcinoma of the prostate; and for prevention of postmenopausal osteoporosis.
DB00297BupivacaineFor the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures.
DB00307BexaroteneUsed orally for the treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy. Also used topically for the treatment of skin lesions in early (stage IA and IB) CTCL in patients who experience refractory or persistent disease with the use of other therapies or are intolerant of other therapies.
DB00309VindesineFor the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia and acute panmyelosis
DB00317GefitinibFor the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.
DB00327HydromorphoneFor the relief of moderate to severe pain such as that due to surgery, cancer, trauma/injury, or burns.
DB00332IpratropiumFor maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
DB00342TerfenadineFor the treatment of allergic rhinitis, hay fever, and allergic skin disorders.
DB00361Vinorelbine Vinorelbine tartrate is indicated for adults in the treatment of advanced non-small cell lung cancer (NSCLC), as a single therapy or in combination with other chemotherapeutic drugs [L1998]. Used in relapsed or refractory Hodgkin lymphoma, in combination with other chemotherapy agents [L2011]. For the treatment of desmoid tumor or aggressive fibromatosis, in combination with methotrexate [L2011]. For the treatment of recurrent or metastatic squamous cell head and neck cancer [L2011]. For the treatment of recurrent ovarian cancer [L2011]. For the treatment of metastatic breast cancer, in patients previously treated with anthracyline and/or taxane therapy [L2011]. For the treatment of HER2-positive, trastuzumab-resistant, advanced breast cancer in patients previously treated with a taxane, in combination with trastuzumab and everolimus [L2011].
DB00365GrepafloxacinFor treatment of adults with mild to moderate infections caused by susceptible strains of Haemophilus influenzae, Streptococcus pneumoniae, or Moraxella catarrhalis.
DB00370MirtazapineFor the treatment of major depressive disorder.
DB00398SorafenibSorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
DB00402EszopicloneFor the treatment of insomnia
DB00433ProchlorperazineFor the symptomatic management of psychotic disorders, short term management of nonpsychotic anxiety in patients with generalized anxiety disorder, and for the control of severe nausea and vomiting of various causes.
DB00455LoratadineA self-medication that is used alone or in combination with pseudoephedrine sulfate for the symptomatic relief of seasonal allergic rhinitis. Also used for the symptomatic relief of pruritus, erythema, and urticaria associated with chronic idiopathic urticaria in patients (not for children under 6 unless directed by a clincian).
DB00470DronabinolFor the treatment of anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments
DB00471MontelukastFor the treatment of asthma
DB00496DarifenacinFor the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.
DB00518AlbendazoleFor the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium and for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.
DB00530ErlotinibFor the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Also for use, in combination with gemcitabine, as the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.
DB00533RofecoxibFor the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras.
DB00539ToremifeneFor the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or receptor-unknown tumors. Toremifene is currently under investigation as a preventative agent for prostate cancer in men with high-grade prostatic intraepithelial neoplasia and no evidence of prostate cancer.
DB00559BosentanUsed in the treatment of pulmonary arterial hypertension (PAH), to improve exercise ability and to decrease the rate of clinical worsening (in patients with WHO Class III or IV symptoms).
DB00570VinblastineFor treatment of breast cancer, testicular cancer, lymphomas, neuroblastoma, Hodgkin's and non-Hodgkin's lymphomas, mycosis fungoides, histiocytosis, and Kaposi's sarcoma.
DB00584EnalaprilFor the treatment of essential or renovascular hypertension and symptomatic congestive heart failure. It may be used alone or in combination with thiazide diuretics.
DB00624TestosteroneTo be used as hormone replacement or substitution of diminished or absent endogenous testosterone. Use in males: For management of congenital or acquired hypogonadism, hypogonadism associated with HIV infection, and male climacteric (andopause). Use in females: For palliative treatment of androgen-responsive, advanced, inoperable, metastatis (skeletal) carcinoma of the breast in women who are 1-5 years postmenopausal; testosterone esters may be used in combination with estrogens in the management of moderate to severe vasomotor symptoms associated with menopause in women who do not respond to adequately to estrogen therapy alone.
DB00625EfavirenzFor use in combination treatment of HIV infection (AIDS)
DB00636ClofibrateFor Primary Dysbetalipoproteinemia (Type III hyperlipidemia) that does not respond adequately to diet. This helps control high cholesterol and high triglyceride levels.
DB00643MebendazoleFor the treatment of Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed infections.
DB00674GalantamineFor the treatment of mild to moderate dementia of the Alzheimer's type. Has also been investigated in patients with mild cognitive impairment who did not meet the diagnostic criteria for Alzheimer's disease.
DB00678LosartanMay be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Losartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.
DB00700EplerenoneFor improvement of survival of stable patients with left ventricular systolic dysfunction (ejection fraction <40%) and clinical evidence of congestive heart failure after an acute myocardial infarction.
DB00705DelavirdineFor the treatment of HIV-1 infection in combination with appropriate antiretroviral agents when therapy is warranted
DB00731NateglinideFor the treatment of non-insulin dependent-diabetes mellitus in conjunction with diet and exercise.
DB00744ZileutonFor the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older.
DB00745ModafinilTo improve wakefulness in patients with excessive daytime sleepiness (EDS) associated with narcolepsy.
DB00757DolasetronFor the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including initial and repeat courses of chemotherapy. Also used for the prevention of postoperative nausea and vomiting. This drug can be used intravenously for the treatment of postoperative nausea and vomiting.
DB00758ClopidogrelFor the reduction of atherosclerotic events (myocardial infarction, stroke, and vascular death) in patients with atherosclerosis documented by recent stroke, recent myocardial infarction, or established peripheral arterial disease.
DB00762IrinotecanFor the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
DB00773EtoposideFor use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
DB00778RoxithromycinUsed to treat respiratory tract, urinary and soft tissue infections.
DB00813FentanylFor the treatment of cancer patients with severe pain that breaks through their regular narcotic therapy.
DB00834MifepristoneFor the medical termination of intrauterine pregnancy through 49 days' pregnancy. Also indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and are not candidates for surgery or have had unsuccessful surgery.
DB00843DonepezilFor the palliative treatment of mild to moderate dementia of the Alzheimer's type.
DB00872ConivaptanFor the treatment of euvolemic or hypervolemic hyponatremia (e.g. the syndrome of inappropriate secretion of antidiuretic hormone, or in the setting of hypothyroidism, adrenal insufficiency, pulmonary disorders, etc.) in hospitalized patients.
DB00883Isosorbide dinitrateFor the prevention of angina pectoris due to coronary artery disease.
DB00889GranisetronFor the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy (including high dose cisplatin), postoperation, and radiation (including total body irradiation and daily fractionated abdominal radiation).
DB00904OndansetronFor the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, postoperation, and radiation. Also used for the treatment of postoperative nausea and vomiting.
DB00906TiagabineFor the treatment of partial seizures
DB00907CocaineFor the introduction of local (topical) anesthesia of accessible mucous membranes of the oral, laryngeal and nasal cavities.
DB00910ParicalcitolFor treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4
DB00911TinidazoleFor the treatment of trichomoniasis caused by T. vaginalis in both female and male patients. Also for the treatment of giardiasis caused by G. duodenalis in both adults and pediatric patients older than three years of age and for the treatment of intestinal amebiasis and amebic liver abscess caused by E. histolytica in both adults and pediatric patients older than three years of age.
DB00918AlmotriptanFor the treatment of acute migraine headache in adults
DB00938SalmeterolFor the treatment of asthma and chronic obstructive pulmonary disease (COPD).
DB00956HydrocodoneFor relief of moderate to moderately severe pain. Also used for the symptomatic relief of nonproductive cough, alone or in combination with other antitussives or expectorants.
DB00962ZaleplonFor the treatment of short-term treatment of insomnia in adults.
DB00990ExemestaneFor the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
DB00997DoxorubicinDoxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.
DB01002LevobupivacaineFor the production of local or regional anesthesia for surgery and obstetrics, and for post-operative pain management
DB01006LetrozoleFor the extended adjuvant treatment of early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy. Also for first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer. Also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
DB01008BusulfanFor use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing bone marrow transplantation for acute myeloid leukemia and nonmalignant diseases.
DB01012CinacalcetFor the treatment of secondary hyperparathyroidism in patients with Chronic Kidney Disease who are on hemodialysis or peritoneal dialysis. Also for the treatment of hypercalcemia in patients with parathyroid carcinoma.
DB01020Isosorbide MononitrateFor the prevention of angina pectoris due to coronary artery disease and the treatment of acute and chronic angina pectoris, hypertension, and myocardial infarction.
DB01026KetoconazoleFor the treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis.
DB01062OxybutyninFor the treatment of overactive bladder.
DB01068ClonazepamClonazepam is used as an anticonvulsant in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic and myoclonic seizures. It can also be used for the treatment of panic disorders.
DB01105SibutramineFor the treatment of obesity.
DB01126DutasterideFor the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate gland to improve symptoms, and reduce the risk of acute urinary retention and the need for surgery.
DB01166CilostazolFor the reduction of symptoms of intermittent claudication (pain in the legs that occurs with walking and disappears with rest).
DB01167ItraconazoleFor the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.
DB01175EscitalopramLabeled indications include major depressive disorder (MDD) and generalized anxiety disorder (GAD). Unlabeled indications include treatment of mild dementia-associated agitation in nonpsychotic patients.
DB01184DomperidoneFor management of dyspepsia, heartburn, epigastric pain, nausea, and vomiting.
DB01190ClindamycinFor the treatment of serious infections caused by susceptible anaerobic bacteria, including Bacteroides spp., Peptostreptococcus, anaerobic streptococci, Clostridium spp., and microaerophilic streptococci. May be useful in polymicrobic infections such as intra-abdominal or pelvic infections, osteomyelitis, diabetic foot ulcers, aspiration pneumonia and dental infections. May also be used to treat MSSA and respiratory infections caused by S. pneumoniae and S. pyogenes in patients who are intolerant to other indicated antibiotics or who are infected with resistant organism. May be used vaginally to treat vaginosis caused by Gardnerella vaginosa. Clindamycin reduces the toxin producing effects of S. aureus and S. pyogenes and as such, may be particularly useful for treating necrotizing fasciitis. May be used topically to treat acne.
DB01215EstazolamFor the short-term management of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.
DB01216FinasterideFor the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: Improve symptoms, reduce the risk of acute urinary retention, reduce the risk of the need for surgery including transurethral resection of the prostate. Also used for the stimulation of regrowth of hair in men with mild to moderate androgenetic alopecia (male pattern alopecia, hereditary alopecia, common male baldness).
DB01218HalofantrineFor treatment of Severe malaria
DB01224QuetiapineFor the treatment of schizophrenia and related psychotic disorders.
DB01227Levomethadyl acetateFor the treatment and management of opiate dependence. It is sometimes used to treat severe pain in terminal patients.
DB01229PaclitaxelUsed in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
DB01254DasatinibFor the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.
DB01256RetapamulinFor use in adults and pediatric patients aged 9 months and older for the topical treatment of impetigo (up to 100 cm2 in total area in adults or 2% total body surface area in pediatric patients aged 9 months or older) due to Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes.
DB01261SitagliptinFor use as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. Also for use in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin or a PPARγ agonist (e.g., thiazolidinediones) when the single agent alone, with diet and exercise, does not provide adequate glycemic control.
DB01264DarunavirDarunavir, co-administered with ritonavir, and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV) infection in antiretroviral treatment-experienced adult patients, such as those with HIV-1 strains resistant to more than one protease inhibitor.
DB01268SunitinibFor the treatment of advanced renal cell carcinoma as well as the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate.
DB01263PosaconazoleFor prophylaxis of invasive Aspergillus and Candida infections in patients, 13 years of age and older, who are at high risk of developing these infections due to being severely immunocompromised as a result of procedures such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD), or due to hematologic malignancies with prolonged neutropenia from chemotherapy. Also for the treatment of oropharyngeal candidiasis, including oropharyngeal candidiasis refractory to itraconazole and/or fluconazole. Posaconazole is used as an alternative treatment for invasive aspergillosis, Fusarium infections, and zygomycosis in patients who are intolerant of, or whose disease is refractory to, other antifungals.
DB01601LopinavirIndicated in combination with other antiretroviral agents for the treatment of HIV-infection.
DB00969AlosetronOnly for the treatment of symptoms of severe diarrhea-predominant irritable bowel syndrome (IBS) in women with chronic symptoms (generally lasting greater than 6 months) who does not present with anatomic or biochemical GI abnormalities and have not responded to conventional therapy.
DB04835MaravirocFor treatment-experienced adult patients infected with only CCR5-tropic HIV-1 detectable, who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents.
DB01409TiotropiumUsed in the management of chronic obstructive pulmonary disease (COPD).
DB01591SolifenacinFor the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
DB00377PalonosetronFor the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy, as well as prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy. Also used for the prevention of postoperative nausea and vomiting for up to 24 hours post operation.
DB00580ValdecoxibFor the treatment of osteoarthritis and dysmenorrhoea
DB06144SertindoleUsed in the treatment of schizophrenia.
DB04905TesmilifeneIntended for the treatment of various forms of cancer.
DB01628EtoricoxibFor the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout.
DB06155RimonabantFor use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m2, or patients wih a BMI greater than 27 kg/m2 with associated risk factors, such as type 2 diabetes or dyslipidaemia.
DB06652VicrivirocInvestigated for use/treatment in HIV infection and viral infection.
DB06685LaquinimodInvestigated for use/treatment in multiple sclerosis.
DB01095FluvastatinTo be used as an adjunct to dietary therapy to prevent cardiovascular events. May be used as secondary prevention in patients with coronary heart disease (CHD) to reduce the risk of requiring coronary revascularization procedures, for reducing progression of coronary atherosclerosis in hypercholesterolemic patients with CHD, and for the treatment of primary hypercholesterolemia and mixed dyslidipidemia.
DB00268RopiniroleFor the treatment of the signs and symptoms of idiopathic Parkinson's disease. Also used for the treatment of restless legs syndrome.
DB05271RotigotineFor use/treatment in neurologic disorders and parkinson's disease as well as moderate-to-severe primary Restless Legs Syndrome.
DB00439CerivastatinUsed as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Types IIa and IIb) when the response to dietary restriction of saturated fat and cholesterol and other non-pharmacological measures alone has been inadequate.
DB00734RisperidoneRisperidone belongs to the class of medications known as ​second generation atypical antipsychotics [A1114, A1115, L1213]. It is widely used in the treatment of schizophrenia and mood disorders, including bipolar disorder and depression with pyschosis [A1115, A1116, L1212, L1213].
DB01037SelegilineMonotherapy for initial treatment of Parkinson's disease, as well as an adjunct therapy in patients with a decreased response to levodopa/carbadopa. Also used for the palliative treatment of mild to moderate Alzheimer's disease and at higher doses, for the treatment of depression.
DB01159HalothaneFor the induction and maintenance of general anesthesia
DB01181IfosfamideUsed as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indications include treatment of osteosarcoma, bladder cancer, ovarian cancer. small cell lung cancer, and non-Hodgkin's lymphoma.
DB01110MiconazoleFor topical application in the treatment of tinea pedis (athlete’s foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis (moniliasis), and in the treatment of tinea versicolor.
DB00814MeloxicamFor symptomatic treatment of arthritis and osteoarthritis.
DB00215CitalopramFor the treatment of depression. Off-label indications include: treatment of mild dementia-associated agitation in nonpsychotic patients, smoking cessation, ethanol abuse, obsessive-compulsive disorder (OCD) in children, and diabetic neuropathy [FDA label].
DB00472FluoxetineLabeled indication include: major depressive disorder (MDD), moderate to severe bulimia nervosa, obsessive-compulsive disorder (OCD), premenstrual dysphoric disorder (PMDD), panic disorder with or without agoraphobia, and combination treatment with olanzapine for treatment-resistant or bipolar I depression. Unlabeled indications include: selective mutism, mild dementia-associated agitation in nonpsychotic patients, post-traumatic stress disorder (PTSD), social anxiety disorder, chronic neuropathic pain, fibromyalgia, and Raynaud's phenomenon.
DB01104SertralineFor the management of major depressive disorder (MDD), posttraumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD) with or without agoraphobia, premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD) [FDA Label]. It may be used for premature ejaculation and vascular headaches as off-label indications.
DB06148MianserinFor the treatment of depression.
DB01435AntipyrineAntipyrine is an analgesic often used to test effects of other drugs on liver enzymes..
DB00531CyclophosphamideCyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
DB05109TrabectedinIndicated for treatment of advanced soft tissue sarcoma in patients refractory to or unsuitable to receive anthracycline or ifosfamide chemotherapy in Europe, Russia and South Korea. Approved for orphan drug status by the U.S. FDA for treatment of soft tissue sarcomas and ovarian cancer. Investigated for use/treatment in cancer/tumors (unspecified), gastric cancer, ovarian cancer, pediatric indications, sarcoma, and solid tumors.
DB00285VenlafaxineFor the management of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (social phobia), panic disorder with or without agoraphobia, vasomotor symptoms in women with breast cancer and in postmenopausal women, and neuropathic pain.
DB00857TerbinafineFor the treatment of dermatophyte infections of the toenail or fingernail caused by susceptible fungi. Also for the treatment of tinea capitis (scalp ringworm) and tinea corporis (body ringworm) or tinea cruris (jock itch).
DB00972AzelastineFor the symptomatic treatment of seasonal allergic rhinitis and non-allergic rhinitis, as well as symptomatic relief of ocular itching associated with allergic conjunctivitis.
DB00153ErgocalciferolFor use in the management of hypocalcemia and its clinical manifestations in patients with hypoparathyroidism, as well as for the treatment of familial hypophosphatemia (vitamin D resistant rickets). This drug has also been used in the treatment of nutritional rickets or osteomalacia, vitamin D dependent rickets, rickets or osteomalacia secondary to long-term high dose anticonvulsant therapy, early renal osteodystrophy, osteoporosis (in conjunction with calcium), and hypophosphatemia associated with Fanconi syndrome (with treatment of acidosis).
DB00201CaffeineFor management of fatigue, orthostatic hypotension, and for the short term treatment of apnea of prematurity in infants.
DB00514DextromethorphanFor treatment and relief of dry cough.
DB01248DocetaxelFor the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Also used as a single agent in the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. It is also used in combination with prednisone, in the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. Furthermore, docetaxel has uses in the treatment of gastric adenocarinoma and head and neck cancer.
DB00281LidocaineFor production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks.
DB00571PropranololFor the prophylaxis of migraine.
DB06403AmbrisentanAmbrisentan is indicated for treatment of idiopathic (‘primary’) pulmonary arterial hypertension (IPAH) and pulmonary arterial hypertension (PAH) associated with connective tissue disease in patients with WHO functional class II or III symptoms. In the United States of America, ambrisentan is also indicated in combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability.
DB00865BenzphetamineFor the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction
DB00612BisoprololFor management of heart failure, angina pectoris, and mild to moderate hypertension and for secondary prevention of myocardial infarction (MI).
DB01558BromazepamFor the short-term treatment of insomnia, short-term treatment of anxiety or panic attacks, if a benzodiazepine is required, and the alleviation of the symptoms of alcohol- and opiate-withdrawal.
DB00136CalcitriolUsed to treat vitamin D deficiency or insufficiency, refractory rickets (vitamin D resistant rickets), familial hypophosphatemia and hypoparathyroidism, and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis. Also used in conjunction with calcium in the management and prevention of primary or corticosteroid-induced osteoporosis.
DB00475ChlordiazepoxideFor the management of anxiety disorders or for the short-term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety.
DB00608ChloroquineFor the suppressive treatment and for acute attacks of malaria due to P. vivax, P.malariae, P. ovale, and susceptible strains of P. falciparum, Second-line agent in treatment of Rheumatoid Arthritis
DB00349ClobazamFor treatment and management of epilepsy and seizures associated with Lennox-Gastaut syndrome, a difficult-to-treat form of childhood epilepsy.
DB00628ClorazepateFor the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Also used as adjunctive therapy in the management of partial seizures and for the symptomatic relief of acute alcohol withdrawal.
DB01219DantroleneFor use, along with appropriate supportive measures, for the management of the fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia crises in patients of all ages. Also used preoperatively, and sometimes postoperatively, to prevent or attenuate the development of clinical and laboratory signs of malignant hyperthermia in individuals judged to be malignant hyperthermia susceptible.
DB01396DigitoxinFor the treatment and management of congestive cardiac insufficiency, arrhythmias and heart failure.
DB04855DronedaroneManagement of paroxysmal or persistent atrial fibrillation via restoration of normal sinus rhythm.
DB01590EverolimusEverolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole. Indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease. Indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. Indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. Indicated in pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.
DB00949FelbamateFor use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use.
DB06702FesoterodineFor the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).
DB00690FlurazepamFor short-term and intermittent use in patients with recurring insomnia and poor sleeping habits
DB00499FlutamideFor the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostate
DB01018GuanfacineFor use alone or in combination with other classes of antihypertensive agents in the management of hypertension. Has also been used for the treatment of attention deficit hyperactivity disorder (ADHD) in pediatric patients.
DB00358MefloquineFor the treatment of mild to moderate acute malaria caused by Mefloquineuine-susceptible strains of Plasmodium falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax. Also for the prophylaxis of Plasmodium falciparum and Plasmodium vivax malaria infections, including prophylaxis of chloroquine-resistant strains of Plasmodium falciparum.
DB04868NilotinibFor the potential treatment of various leukemias, including chronic myeloid leukemia (CML).
DB00497OxycodoneFor the treatment of diarrhoea, pulmonary oedema and for the relief of moderate to moderately severe pain.
DB01621PipotiazineFor the maintenance treatment of chronic non-agitated schizophrenic patients.
DB01058PraziquantelFor the treatment of infections due to all species of schistosoma.
DB01087PrimaquineFor the treatment of malaria.
DB00647DextropropoxypheneFor the relief of mild to moderate pain
DB00912RepaglinideAs an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
DB06228RivaroxabanRivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurrent DVT and/or PE. Due to a lack of safety studies, it is not recommended for use in those under 18 years old. Its use is also not recommended in those with severe renal impairment (<30mL/min).
DB06176RomidepsinFor the treatment of cutaneous T-cell lymphoma (CTCL) or/and peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior systemic therapy. These indications are based on response rate. Clinical benefit such as improvement in overall survival has not been demonstrated.
DB06207SilodosinTreatment for symptomatic relief of benign prostatic hyperplasia
DB06145SpiramycinMacrolide antibiotic for treatment of various infections.
DB00706TamsulosinUsed in the treatment of signs and symptoms of benign prostatic hyperplasia (reduction in urinary obstruction and relief of associated manifestations such as hesitancy, terminal dribbling of urine, interrupted or weak stream...etc.)
DB00759TetracyclineUsed to treat bacterial infections such as Rocky Mountain spotted fever, typhus fever, tick fevers, Q fever, rickettsialpox and Brill-Zinsser disease. May be used to treat infections caused by Chlamydiae spp., B. burgdorferi (Lyme disease), and upper respiratory infections caused by typical (S. pneumoniae, H. influenzae, and M. catarrhalis) and atypical organisms (C. pneumoniae, M. pneumoniae, L. pneumophila). May also be used to treat acne. Tetracycline may be an alternative drug for people who are allergic to penicillin.
DB01036TolterodineFor the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).
DB06212TolvaptanTreatment of symptomatic and resistant to fluid restriction euvolemic or hypervolemic hyponatremia associated with congestive heart failure, SIADH, and cirrhosis.
DB00193TramadolIndicated in the treatment of moderate to severe pain. Consider for those prone to constipation or respiratory depression. Tramadol is used to treat postoperative, dental, cancer, and acute musculosketetal pain and as an adjuvant to NSAID therapy in patients with osteoarthritis.
DB00440TrimethoprimFor the treatment of urinary tract infections, uncomplicated pyelonephritis (with sulfamethoxazole) and mild acute prostatitis. May be used as pericoital (with sulfamethoxazole) or continuous prophylaxis in females with recurrent cystitis. May be used as an alternative to treat asymptomatic bacteriuria during pregnancy (only before the last 6 weeks of pregnancy). Other uses include: alternative agent in respiratory tract infections (otitis, sinusitus, bronchitis and pneumonia), treatment of Pneumocystis jirovecii pneumonia (acute or prophylaxis), Nocardia infections, and traveller's diarrhea.
DB01198ZopicloneFor the short-term treatment of insomnia.
DB00252PhenytoinFor the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery.
DB01394ColchicineFor treatment and relief of pain in attacks of acute gouty arthritis.
DB01221KetamineKetamine is indicated as an anesthetic agent for recommended diagnostic and surgical procedures. If skeletal muscle relaxation is needed, it should be combined with a muscle relaxant. If the surgical procedure involves visceral pain, it should be supplemented with an agent that obtunds visceral pain. Ketamine can be used for induction of anesthesia prior other general anesthetic agents and as a supplement of low potency agents.[L1336, FDA label] Reports have indicated a potential use of ketamine as a therapeutic tool for the management of depression when administered in lower doses.[A31873] These reports have increased the interest for ketamine in this area and several clinical trials are launched for this indication.[L1337, A31874]
DB06335SaxagliptinTreatment of type 2 diabetes mellitus to improve glycemic control in combination with other agents or as monotherapy.
DB00708SufentanilUsed as an analgesic adjunct in anesthesia and as a primary anesthetic drug in procedures requiring assisted ventilation and in the relief of pain.
DB01128BicalutamideFor treatment (together with surgery or LHRH analogue) of advanced prostatic cancer.
DB01424AminophenazoneFormerly widely used as an antipyretic and analgesic in rheumatism, neuritis, and common colds. Currently used to measure total body water.
DB00363ClozapineFor use in patients with treatment-resistant schizophrenia.
DB00420PromazineUsed as an adjunct for short term treatment of moderate and severe psychomotor agitation. Also used to treat agitation or restlessness in the elderly.
DB01136CarvedilolFor the treatment of mild or moderate (NYHA class II or III) heart failure of ischemic or cardiomyopathic origin.
DB00586DiclofenacFor the acute and chronic treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis.
DB00482CelecoxibFor the relief and management of osteoarthritis (OA), rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA), ankylosing spondylitis, acute pain, primary dysmenorrhea and oral adjunct to usual care for patients with familial adenomatous polyposis [FDA label].
DB01016GlyburideIndicated as an adjunct to diet to lower the blood glucose in patients with NIDDM whose hyperglycemia cannot be satisfactorily controlled by diet alone.
DB01138SulfinpyrazoneFor the treatment of gout and gouty arthritis.
DB06739SeratrodastNot Available
DB06738KetobemidoneFor the treatment of all types of severe pain, such as postoperative, cancer, kidney stones and fractures.
DB00546AdinazolamFor the treatment of anxiety and status epilepticus.
DB00231TemazepamFor the short-term treatment of insomnia (generally 7-10 days).
DB03701VanoxerineNot Available
DB00169CholecalciferolFor the treatment of vitamin D deficiency or insufficiency, refractory rickets (vitamin D resistant rickets), familial hypophosphatemia and hypoparathyroidism, and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis. Also used in conjunction with calcium in the management and prevention of primary or corticosteroid-induced osteoporosis.
DB01192OxymorphoneFor the treatment of moderate-to-severe pain.
DB01173OrphenadrineIndicated for the treatment of Parkinson's disease.
DB06772CabazitaxelFor treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.
DB06700DesvenlafaxineDesvenlafaxine is indicated for the treatment of major depressive disorder in adults.
DB06697ArtemetherArtemether and lumefantrine combination therapy is indicated for the treatment of acute uncomplicated malaria caused by Plasmodium falciparum, including malaria acquired in chloroquine-resistant areas. May also be used to treat uncomplicated malaria when the Plasmodium species has not been identified. Indicated for use in adults and children greater than 5 kg.
DB06708LumefantrineLumefantrine and artemether combination therapy is indicated for the treatment of acute uncomplicated malaria caused by Plasmodium falciparum, including malaria acquired in chloroquine-resistant areas. May also be used to treat uncomplicated malaria when the Plasmodium species has not been identified. Indicated for use in adults and children greater than 5 kg.
DB06742AmbroxolAmbroxol is indicated as “secretolytic therapy in bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport. It promotes mucus clearance, facilitates expectoration and eases productive cough, allowing patients to breathe freely and deeply.
DB00278ArgatrobanArgatroban is indicated for prevention and treatment of thrombosis caused by heparin induced thrombocytopenia (HIT). It is also indicated for use in patients with, or at risk for, HIT who are undergoing percutaneous coronary intervention.
DB01393BezafibrateFor the treatment of primary hyperlipidaemia types IIa, IIb, III, IV and V (Fredrickson classification) corresponding to groups I, II and III of the European Atherosclerosis Society guidelines - when diet alone or improvements in lifestyle such as increased exercise or weight reduction do not lead to an adequate response. Also for the treatment of secondary hyperlipidaemias, e.g. severe hypertriglyceridemias, when sufficient improvement does not occur after correction of the underlying disorder (e.g. diabetes mellitus).
DB01194BrinzolamideFor the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
DB00835BrompheniramineFor the treatment of the symptoms of the common cold and allergic rhinitis, such as runny nose, itchy eyes, watery eyes, and sneezing.
DB01156BupropionFor the treatment of depression and as aid to smoking cessation.
DB00748CarbinoxamineFor symptomatic relief of seasonal and perennial allergic rhinitis and vasomotor rhinitis, as well as allergic conjunctivitis caused by foods and inhaled allergens. Also for the relief of allergic reactions to blood or plasma, and the symptomatic management of mild, uncomplicated allergic skin manifestations of urticaria and angioedema.
DB00567CephalexinFor the treatment of respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes; otitis media due to Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes, and Moraxella catarrhalis; skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes; bone infections caused by Staphylococcus aureus and/or Proteus mirabilis; genitourinary tract infections, including acute prostatitis, caused by Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae.
DB00477ChlorpromazineFor the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance.
DB00356ChlorzoxazoneFor the relief of discomfort associated with acute painful musculoskeletal conditions.
DB00845ClofazimineFor the treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum.
DB06470clomethiazoleInvestigated for use/treatment in strokes.
DB01559ClotiazepamFor the treatment of anxiety disorders.
DB00987CytarabineFor the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
DB00694DaunorubicinFor remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
DB00390DigoxinFor the treatment and management of congestive cardiac insufficiency, arrhythmias and heart failure.
DB01551DihydrocodeineDihydrocodeine is used for the treatment of moderate to severe pain, including post-operative and dental pain [2]. It can also be used to treat chronic pain [1], breathlessness and coughing. In heroin addicts, dihydrocodeine has been used as a substitute drug, in doses up to 2500mg/day to treat addiction. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014322/]
DB00822DisulfiramFor the treatment and management of chronic alcoholism
DB00869DorzolamideFor the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Also used prophylatically for the inhibition of perioperative IOP increase (before neodynium yttrium aluminum garnet laser posterior capsulotomy).
DB00751EpinastineFor the prevention of itching associated with allergic conjunctivitis.
DB01196EstramustineFor the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate
DB00898EthanolFor therapeutic neurolysis of nerves or ganglia for the relief of intractable chronic pain in such conditions as inoperable cancer and trigeminal neuralgia (tic douloureux), in patients for whom neurosurgical procedures are contraindicated.
DB01466EthylmorphineEthylmorphine is an analgesic used for pain relief.
DB00426FamciclovirFor the treatment of acute herpes zoster (shingles). Also for the treatment or suppression of recurrent genital herpes in immunocompetent patients and treatment of recurrent mucocutaneous herpes simplex infections in HIV infected patients.
DB01039FenofibrateFor use as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb)
DB01544FlunitrazepamFor short-term treatment of severe insomnias, that are not responsive to other hypnotics.
DB00947FulvestrantFor the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy.
DB01067GlipizideFor use as an adjunct to diet for the control of hyperglycemia and its associated symptomatology in patients with non-insulin-dependent diabetes mellitus (NIDDM; type II), formerly known as maturity-onset diabetes, after an adequate trial of dietary therapy has proved unsatisfactory.
DB05381HistamineHistamine phosphate is indicated as a diagnostic aid for evaluation of gastric acid secretory function.
DB00724ImiquimodFor the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Also indicated for the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above.
DB01103QuinacrineFor the treatment of giardiasis and cutaneous leishmaniasis and the management of malignant effusions.
DB04833MethaqualoneFor the treatment of insomnia, and as a sedative and muscle relaxant.
DB01028MethoxyfluraneFor use in the induction and maintenance of general anesthesia
DB06710MethyltestosteroneMethyltestosterone is an anabolic steroid hormone used to treat men with a testosterone deficiency. It is also used in women to treat breast cancer, breast pain, swelling due to pregnancy, and with the addition of estrogen it can treat symptoms of menopause.
DB00379MexiletineFor the treatment of ventricular tachycardia and symptomatic premature ventricular beats, and prevention of ventricular fibrillation.
DB00184NicotineFor the relief of nicotine withdrawal symptoms and as an aid to smoking cessation.
DB01595NitrazepamUsed to treat short-term sleeping problems (insomnia), such as difficulty falling asleep, frequent awakenings during the night, and early-morning awakening.
DB00768OlopatadineFor the treatment of ocular itching associated with allergic conjunctivitis.
DB00842OxazepamFor the treatment of anxiety disorders and alcohol withdrawal.
DB00316AcetaminophenFor temporary relief of fever, minor aches, and pains.
DB04930PermethrinFor the treatment of infestation with Sarcoptes scabiei (scabies).
DB00850PerphenazineFor use in the management of the manifestations of psychotic disorders and for the control of severe nausea and vomiting in adults.
DB00454MeperidineUsed to control moderate to severe pain.
DB03783PhenacetinUsed principally as an analgesic.
DB01588PrazepamFor the treatment of anxiety disorders.
DB01131ProguanilFor the causal prevention and suppression of malaria caused by susceptible strains of P. falciparum and other species of Plasmodium found in some geographical areas of the world.
DB01589QuazepamUsed to treat insomnia.
DB00296RopivacaineUsed in obstetric anesthesia and regional anesthesia for surgery.
DB01236SevofluraneUsed for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery.
DB00359SulfadiazineFor the treatment of rheumatic fever and meningococcal meningitis
DB01349TasosartanTasosartan is infrequently in the treatment of hypertension and heart failure.
DB04572ThiotepaThioTEPA is used a as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients. Also, when high dose chemotherapy with HPCT support it is appropriate for the treatment of solid tumours in adult and paediatric patients.
DB13179TroleandomycinFor the treatment of bacterial infection.
DB01392YohimbineIndicated as a sympatholytic and mydriatic. Impotence has been successfully treated with yohimbine in male patients with vascular or diabetic origins and psychogenic origins.
DB04828ZomepiracZomepirac was indicated for the management of mild to severe pain.
DB01587KetazolamKetazolam could be used for the treatment of anxiety. In approved countries, it is indicated for the treatment of anxiety, tension, irritability and similar stress related symptoms.
DB00617ParamethadioneUsed for the control of absence (petit mal) seizures that are refractory to treatment with other medications.
DB00755TretinoinFor the the induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant); For the topical treatment of acne vulgaris, flat warts and other skin conditions (psoriasis, ichthyosis congenita, icthyosis vulgaris, lamellar icthyosis, keratosis palmaris et plantaris, epidermolytic hyperkeratosis, senile comedones, senile keratosis, keratosis follicularis (Darier's disease), and basal cell carcinomas.); For palliative therapy to improve fine wrinkling, mottled hyperpigmentation, roughness associated with photodamage.
DB04946IloperidoneTreatment of acute schizophrenia.
DB06684VilazodoneVilazodone is approved for treatment of acute episodes of major depression. Labeling of vilazodone describes an increased risk of suicidal thoughts in children, adolescents and young adults. The use of vilazodone in pediatrics is not indicated. Its use with monoamine oxidase inhibitors (MAOI) is contraindicated due to increased risk of serotonin syndome. Once the MAOI is discontinued, a 14-day washout period must pass before starting vilazodone.
DB00575ClonidineMay be used as an adjunct in the treatment of hypertension, as an epidural infusion as an adjunct treatment in the management of severe cancer pain that is not relieved by opiate analgesics alone, for differential diagnosis of pheochromocytoma in hypertensive patients, prophylaxis of vascular migraine headaches, treatment of severe dysmenorrhea, management of vasomotor symptoms associated with menopause, rapid detoxification in the management of opiate withdrawal, treatment of alcohol withdrawal used in conjunction with benzodiazepines, management of nicotine dependence, topical use to reduce intraocular pressure in the treatment of open-angle and secondary glaucoma and hemorrhagic glaucoma associated with hypertension, and in the treatment of attention-deficit hyperactivity disorder (ADHD).
DB00808IndapamideFor the treatment of hypertension, alone or in combination with other antihypertensive drugs, as well as for the treatment of salt and fluid retention associated with congestive heart failure or edema from pregnancy (appropriate only in the management of edema of pathologic origin during pregnancy when clearly needed). Also used for the management of edema as a result of various causes.
DB08820IvacaftorWhen used as monotherapy as the product Kalydeco, ivacaftor is indicated for the managmenet of CF in patients age 2 years and older who have a mutation in the CFTR gene that is responsive to ivacaftor potentiation. Ivacaftor received expanded approval in May 2017 for the following 33 CFTR mutations: E56K, P67L, R74W, D110E, D110H, R117C, R117H, G178R, E193K, L206W, R347H, R352Q, A455E, S549N, S549R, G551D, G551S, D579G, S945L, S977F, F1052V, K1060T, A1067T, G1069R, R1070Q, R1070W, F1074L, D1152H, G1244E, S1251N, S1255P, D1270N, and G1349D [L768, FDA Label]. When used in combination with the drug [DB09280] as the product Orkambi, ivacaftor is indicated for the management of CF patients age 6 years and older who are homozygous for the F508del mutation in the CFTR gene.
DB04975BanoxantroneFor the treatment of various forms of cancer.
DB05039IndacaterolFor the long term, once-daily-dosing maintenance of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
DB08816TicagrelorFor the prevention of thrombotic events (for example stroke or heart attack) in patients with acute coronary syndrome or myocardial infarction with ST elevation.
DB06777Chenodeoxycholic acidChenodiol is indicated for patients with radiolucent stones in well-opacifying gallbladders, in whom selective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age. Chenodiol will not dissolve calcified (radiopaque) or radiolucent bile pigment stones.
DB06762PinacidilNot Available
DB00337PimecrolimusFor treatment of mild to moderate atopic dermatitis.
DB08827LomitapideUsed in homozygous familial hypercholesterolemia (HoFH) patients to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C).
DB08828VismodegibVismodegib is used for treating locally advanced or metastatic basal cell carcinoma in patients whose carcinoma has recurred after surgery, and in patients who are not candidates for surgery or radiation.
DB08864RilpivirineRilpivirine, in combination with other agents, is indicated for the treatment of HIV-1 infections in antiretroviral treatment-naive patients with HIV-1 RNA ≤100,000 copies/mL and CD4+ cell count >200 cells/mm3.[L1030] The FDA combination therapy approval of rilpivirine and dolutegravir is indicated for adults with HIV-1 infections whose virus is currently suppressed (< 50 copies/ml) on a stable regimen for at least six months, without history of treatment failure and no known substitutions associated to resistance to any of the two components of the therapy.[L1031]
DB06209PrasugrelIndicated in combination with acetylsalicylic acid (ASA) to prevent atherothrombotic events in patients with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI). May be used in patients with unstable angina (UA), non-ST elevation myocardial infarction (NSTEMI), ST-elevation myocardial infarction (STEMI) who are to be managed with PCI. Prasugrel is not recommended in patients 75 years of age or greater, those that weigh<60kg, and patients with a history of stroke or transient ischemic attack due to increased risk of fatal and intracranial bleeding.
DB06216AsenapineUsed for treatment in psychosis, schizophrenia and schizoaffective disorders, manic disorders, and bipolar disorders as monotherapy or in combination.
DB08870Brentuximab vedotinSeattle Genetics Announced FDA Approval of ADCETRIS® (Brentuximab Vedotin) in combination with chemotherapy for adults with previously untreated stage III or IV Classical Hodgkin Lymphoma in March 2018 [L1737, L1739]. Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates [FDA label], [L1737]. Systemic anaplastic large cell lymphoma after failure of at least one prior multi-agent chemotherapy regimen [FDA label].
DB04871LorcaserinFor the treatment of obesity, as an adjunct to a reduced-calorie diet and increased physical activity.
DB05294VandetanibVandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure.
DB08877RuxolitinibTreatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera (post-PV) myelofibrosis and post-essential thrombocythemia (post-ET) myelofibrosis. [Lexicomp] Myeolofibrosis is the proliferation of abnormal bone marrow stem cells which cause fibrosis (the excessive formation of connective tissue).
DB05812AbirateroneUsed in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer.
DB08893MirabegronMirabegron is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
DB08899EnzalutamideEnzalutamide is indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.
DB08895TofacitinibFor the treatment of moderate to severe rheumatoid arthritis which is resistant or intolerant to methotrexate therapy. It may also be used as an adjunct to methotrexate therapy, or other non-biologic disease-modifying antirheumatic drugs (DMARDS), when methotrexate alone is not sufficient. Tofacitinib has also been investigated as a preventative therapy for kidney transplant rejections, and as a treatment for psoriasis, ulcerative colitis, and ankylosing spondylitis. It is not to be initiated in patients with a history of chronic or recurrent infections, or in the presence of active infection, even if localized, due to reports of serious and sometimes fatal infections (commonly pneumonia, herpes zoster and urinary tract infections). Use of tofacitinib is also discouraged in those who have been, or are likely to be, exposed to TB. An increased likelihood of exposure may be encountered by traveling to certain areas. In addition, tofacitinib is not to be used in patients with severe hepatic impairment, or low hemoglobin (less than 9g/dL). Cautioned is advised when using tofacitinib in patients at risk of gastrointestinal perforation, and in the elderly who are more susceptible to infection.
DB06616BosutinibTreatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy in adult patients.
DB08901PonatinibPonatinib is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.
DB08903BedaquilineBedaquiline is indicated as part of combination therapy in adults (≥ 18 years) with pulmonary multi-drug resistant tuberculosis (MDR-TB).
DB08907CanagliflozinCanagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Use in type 1 diabetes mellitus patients or in treatment of diabetic ketoacidosis is not recommended.
DB06203AlogliptinIndicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
DB04938OspemifeneOspemifene is used for the treatment of moderate to dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.
DB08910PomalidomidePomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.
DB08912DabrafenibTafinlar is a kinase inhibitor that was initially indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test [FDA label]. Tafinlar in combination with [DB08911] is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. The use in combination is based on the demonstration of durable response rate. Improvement in disease-related symptoms or overall survival has not been demonstrated for Tafinlar in combination with trametinib [FDA label]. In May 2018, Tafinlar (dabrafenib) and Mekinist ([DB08911]) have been approved in combination to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene [L2712].
DB05773Trastuzumab emtansineUsed in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment.
DB00688Mycophenolate mofetilFor the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. Mycophenolate mofetil should be used concomitantly with cyclosporine and corticosteroids.
DB08918LevomilnacipranLevomilnacipran is a serotonin and norepinephrine reuptake inhibitor and is indicated for the treatment of major depressive disorder (MDD).
DB08932MacitentanMacitentan is indicated for patients with pulmonary arterial hypertension.
DB06292DapagliflozinDapagliflozin is indicated for adjunct management of glycemic control in patients with type 2 diabetes mellitus, in combination with diet and exercise.
DB09039EliglustatEliglustat is indicated for the long-term treatment of type 1 Gaucher disease in patients who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) in treatment-naive and treatment-experienced adult patients.
DB05676ApremilastInvestigated for use/treatment in psoriasis and psoriatic disorders.
DB09049NaloxegolIndicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
DB09053IbrutinibIbrutinib acquired an accelerated approval for the treatment of mantle cell lymphoma who have received at least one prior therapy.[FDA label] Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma that develops in the outer edge of a lymph node. MCL is usually diagnosed at late stages and it is easily spread into bone marrow, spleen, liver and gastrointestinal tract.[L1929] Ibrutinib is indicated for the treatment of chronic lymphocytic leukemia (CLL) who have at least one prior therapy.[FDA label] CLL is a type of cancer caused by an overproduction of lymphocytes by the bone marrow. Some of the symptoms include swollen lymph nodes and tiredness.[L1931] Ibrutinib is indicated for the treatment of chronic lymphocytic leukemia (CLL) with 17p deletion.[FDA label] CLL with 17p is a type of leukemia in which a deletion in 17p disrupts the tumor suppressor p53 by deleting one allele of the TP53 gene. The remaining allele is mainly inactivated and thus, this type of leukemia is unresponsive to p53-dependent treatments.[A32305] Ibrutinib is indicated for the treatment of patients with Waldenstrom's Macroglobulinemia (WM).[FDA label] WM, also called lymphoplasmacytic lymphoma, is a type of non-Hodgkin lymphoma in which the cancer cells make large amounts of macroglobulin. The macroglobulin is a monoclonal protein that corresponds to the type of IgM antibodies and the unrestricted formation of this protein causes typical symptoms such as excessive bleeding and effects in vision and nervous system.[L1934]
DB09074Olaparib* Indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy. * Indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. * Indicated for the treatment of patients with germline breast cancer susceptibility gene (BRCA) mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer, who have been previously treated with chemotherapy.
DB09073PalbociclibPalbociclib is indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. This indication is approved under accelerated approval based on progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
DB09082VilanterolVilanterol is approved for use in several combination products such as with fluticasone furoate under the tradename Breo Ellipta and in combination with umeclidinium bromide as Anoro Ellipta. Approved by the FDA in 2013, use of Breo Ellipta is indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema. It is also indicated for once-daily maintenance treatment of asthma in patients aged 18 or older with reversible obstructive airways disease.
DB09026AliskirenFor the treatment of hypertension, to lower blood pressure.
DB09101ElvitegravirElvitegravir in combination with an HIV protease inhibitor coadministered with ritonavir and with other antiretroviral drug(s) is indicated for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults.
DB06016CariprazineCariprazine is an atypical antipsychotic indicated for the treatment of schizophrenia and for the acute treatment of manic or mixed episodes associated with bipolar I disorder.
DB08439ParecoxibUsed for short term perioperative pain control.
DB09128BrexpiprazoleAs an adjunctive treatment of major depressive disorder (MDD) and for treatment of schizophrenia.
DB09291RolapitantRolapitant is indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
DB04908FlibanserinFor the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.
DB09102DaclatasvirIndicated for use with sofosbuvir, with or without ribavirin, for the treatment of chronic HCV genotype 1a/b or 3 infection. The dosing regimen of 60mg daclatasvir 60 mg with 400mg sofosbuvir once a day is recommended for both genontypes. Resistance: Reduced susceptibility to daclatasvir was associated with the polymorphisms at NS5A amino acid positions M28, Q30, L31, and Y93 in genotypes 1a, 1b, and 3a patients. NS5A Resistance Testing is recommended for HCV genotype 1a-infected patients with cirrhosis prior to the initiaition of the treatment, as the risk of resistance development is higher in genotype 1a patients.
DB09143SonidegibSonidegib is approved for use in the US and EU for treatment of adults with locally advanced basal cell carcinoma (BCC) that has recurred post surgery or radiation therapy. It is also approved for adult patients with BCC who are not eligible for surgery or radiation therapy. (2)
DB06603PanobinostatPanobinostat is indicated in the treatment of multiple myeloma in combination with dexamethasone and bortezomib in patients who have received 2 previous treatment regimens including bortezomib and an immunomodulatory agent. This indication is approved by accelerated approval based on progression free survival as of February 23, 2015.
DB09570IxazomibIxazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
DB11362SelexipagSelexipag is indicated for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization.
DB09183DasabuvirDasabuvir, in combination with [DB09296], [DB09297], and [DB00503] (as Viekira Pak) is indicated for the treatment of patients with HCV genotype 1a with [DB00811] or genotype 1b without [DB00811] including those with compensated cirrhosis [FDA Label].
DB09297ParitaprevirWhen used within the fixed-dose combination product with [DB09296], [DB09183], and [DB00503] as the FDA-approved product Viekira Pak, paritaprevir is indicated for the treatment of HCV genotype 1b without cirrhosis or with compensated cirrhosis, and when combined with [DB00811] for the treatment of HCV genotype 1a without cirrhosis or with compensated cirrhosis. When used within the fixed-dose combination product with [DB09296] and [DB00503] as the FDA- and Health Canada-approved product Technivie, paritaprevir is indicated in combination with [DB00811] for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis. When used within the fixed-dose combination product with [DB09296], [DB09183], and [DB00503] as the Health Canada-approved, commercially available product Holkira Pak, paritaprevir is indicated for the treatment of HCV genotype 1b with or without cirrhosis, and when combined with [DB00811] for the treatment of HCV genotype 1a with or without cirrhosis.
DB09317Synthetic Conjugated Estrogens, AFor the treatment of moderate to severe vasomotor symptoms due to menopause and for treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause.
DB09318Synthetic Conjugated Estrogens, BFor the treatment of moderate to severe vasomotor symptoms due to menopause and for the treatment of moderate to severe vaginal dryness, pain with intercourse, and symptoms of vulvar and vaginal atrophy due to menopause.
DB11581VenetoclaxFor the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy.
DB09381Estrogens, esterifiedEsterified estrogens are indicated to replace estrogen in women with ovarian failure or other conditions that cause a lack of natural estrogen in the body. It is also indicated for the treatment of symptoms of breast cancer in both men and women. In men it can be used for the treatment of advanced prostate cancer. It is also indicated for the treatment of menopausal symptoms.
DB12332RucaparibIndicated as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies. Select patients for therapy based on an FDA-approved companion diagnostic for rucaparib.
DB06654SafinamideSafinamide is indicated as an add-on treatment to levodopa with or without other medicines for Parkinson’s disease
DB12161DeutetrabenazineIndicated for the treatment of chorea associated with Huntington’s disease [FDA Label].
DB09555Dexchlorpheniramine maleateDexchlorpheniramine can be used in the treatment of perennial and seasonal allergic rhinitis, vasomotor rhiniti, allergic conjunctivitis due to inhalant allergens and foods, mild uncomplicated allergic skin manifestations of urticaria and angioedema, amelioration of allergic reactions to blood or plasma, and dermographism.
DB11613VelpatasvirVelpatasvir is used in combination therapy with other antiviral medications to treat chronic hepatitis C virus (HCV) infected patients with HCV genoptypes 1-6, and to treat HCV and HIV co-infected patients. Depending on the level of cirrhosis or decompensation, combination therapy can also include therapy with [DB00811]. When used in combination with [DB08934] as the combination product Epclusa, Velpatasvir is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis, or in combination with [DB00811] if associated with decompensated cirrhosis [FDA Label].
DB05541BrivaracetamUsed as adjunctive therapy for partial-onset seizures in patients 16 years of age or older.
DB11915ValbenazineFor the treatment of tardive dyskinesia in adults [FDA Label].
DB06670OdanacatibInvestigated for use/treatment in osteoporosis [A19388].
DB11575GrazoprevirGrazoprevir is indicated in combination with [DB11574] (as the fixed dose combination product Zepatier) with or without [DB00811] for treatment of chronic HCV genotypes 1a, 1b, or 4 infection in adults.
DB08922PerospironeFor the treatment of schizophrenia and acute cases of bipolar mania.
DB09166EtizolamIndicated for the treatment of generalized anxiety disorder with depression, panic disorder and insomnia.
DB11614RupatadineFor the symptomatic relief of nasal and non-nasal symptoms of seasonal allergic rhinitis and perennial allergic rhinitis in patients 2 years of age and older [FDA Label]. Also used for the symptomatic relief of chronic spontaneous urticaria in patients 2 years of age and older.
DB09262ImidafenacinUsed in the treatment of overactive bladder [FDA Label].
DB11828NeratinibFor use as an extended adjuvant treatment in adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy [FDA Label].
DB12026VoxilaprevirVosevi (Voxilaprevir/[DB08934]/[DB11613]) is approved for use in patients with genotypes 1-6 who have been previously treated with an NS5A inhibitor, or patients with genotypes 1a or 3 infection who have previously been treated with an HCV regimen containing [DB08934] without an NS5A inhibitor [L935].
DB13874EnasidenibIndicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation.
DB06595MidostaurinInvestigated for use/treatment in adult patients with high-risk acute myeloid leukemia (AML) who are FLT3 mutation-positive, agressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).
DB11574ElbasvirElbasvir, when used in combination with [DB11575] as the combination product Zepatier, is indicated for use with or without ribavirin for the treatment of chronic HCV genotypes 1 or 4 infection in adults [FDA Label].
DB12483CopanlisibIndicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.
DB12001Abemaciclib* Indicated in combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. * Inidicated as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.
DB12267BrigatinibThe anaplastic lymphoma kinase positive, metastatic non-small cell lung cancer (ALK+ NSCLC), represents only 3-5% of the NSCLC cancer cases, but the ALK mutation, overexpression and presence in several oncogenic fusion proteins in solid and hematologic tumors have pointed out the importance as well as its potential as a cancer therapy target.[A31311] The ALK-related cases of NSCLC are associated with the presence of the fusion gene EML4-ALK which fused the ALK protein with the echinoderm microtubule-associated protein like-4 whose original function is the correct formation of microtubules.[A31313] The presence of the aberrant fusion protein results in abnormal signaling that provokes increased cell growth, proliferation and survival.[A31316] Crizotinib is indicated for the treatment of such cases but the presence of ALK kinase domain mutations confer resistance to the treatment. Thus, brigatinib is indicated for the treatment of patients with ALK+ NSCLC with intolerance to Crizotinib.[A31314]
DB11817BaricitinibIndicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs as monotherapy or in combination with methotrexate.
DB13074MacimorelinIndicated for the diagnosis of adult growth hormone deficiency (AGHD) [FDA Label].
DB09223BlonanserinUsed for the treatment of schizophrenia [L1097].
DB09061CannabidiolWhen used in combination with delta-9-tetrahydrocannabinol as the product Sativex, cannabidiol was given a standard marketing authorization (ie. a Notice of Compliance (NOC)) by Health Canada for the following indications: 1) as adjunctive treatment for symptomatic relief of spasticity in adult patients with multiple sclerosis (MS) who have not responded adequately to other therapy and who demonstrate meaningful improvement during an initial trial of therapy [L886]; Due to the need for confirmatory studies to verify the clinical benefit coupled with the promising nature of the clinical evidence, Sativex was also given a Notice of Compliance with Conditions (NOC/c) by Health Canada for the following indications: 1) as adjunctive treatment for the symptomatic relief of neuropathic pain in adult patients with multiple sclerosis; 2) as adjunctive analgesic treatment in adult patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain [L886].
DB13943Testosterone cypionateTestosterone cypionate is used in males that present conditions derived from a deficiency or absence of endogenous testosterone. These conditions are 1) primary hypogonadism, defined as the testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome or orchidectomy; and 2) hypogonadotropic hypogonadism characterized by idiopathic gonadotropin, LHRH deficiency or pituitary-hypothalamic injury from tumors, trauma or radiation.[L1153]
DB13944Testosterone enanthateTestosterone enanthate in males is indicated as a replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone. Some of the treated conditions are 1) primary hypogonadism, defined as testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome or orchidectomy; 2) hypogonadotropic hypogonadism due to an idiopathic gonadotropin or luteinizing hormone-releasing hormone deficiency or due to a pituitary-hypothalamic injury from tumors, trauma or radiation, in this case it is important to accompany the treatment with adrenal cortical and thyroid hormone replacement therapy; 3) to stimulate puberty in patients with delayed puberty not secondary to a pathological disorder. If the conditions 1 and 2 occur prior to puberty, the androgen replacement therapy will be needed during adolescent years for the development of secondary sexual characteristics and prolonged androgen treatment might be needed it to maintain sexual characteristics after puberty.[FDA label] In females, testosterone enanthate is indicated to be used secondarily in presence of advanced inoperable metastatic mammary cancer in women who are from one to five years postmenopausal. It has also been used in premenopausal women with breast cancer who have benefited from oophorectomy and are considered to have a hormone-responsive tumor.[FDA label] Testosterone enanthate injections that are currently formulated for subcutaneous use are specifically indicated only for primary hypogonadism and hypogonadotropic hypogonadism [F1941]. The use of such formulations is limited because the safety and efficacy of these subcutaneous products in adult males with late-onset hypogonadism and males less than 18 years old have not yet been established [F1941]. Moreover, subcutaneously administered testosterone enanthate is indicated only for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies, considering the medication could cause blood pressure increases that can raise the risk of major adverse cardiovascular events like non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death [F1941].
DB13946Testosterone undecanoateTestosterone undecanoate is indicated as a testosterone replacement therapy in adult males that present conditions of deficiency or absence of endogenous testosterone. The approved conditions for the use of testosterone undecanoate are 1) primary hypogonadism, defined as a testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy or toxic damage from alcohol or heavy metals: or 2) hypogonadotropic hypogonadism caused by idiopathic gonadotropin or luteinizing hormone-releasing hormone deficiency or pituitary-hypothalamic injuries from tumors, trauma or radiation.[FDA label]
DB13952Estradiol acetateFemring is indicated for the treatment of vasomotor and urogenital symptoms associated with menopause. Use of Femring (estradiol acetate) has been shown to improve symptoms caused by atrophy of the vagina (such as dryness, burning, pruritus and dyspareunia) and/or the lower urinary tract (urinary urgency and dysuria).
DB13953Estradiol benzoateEstradiol benzoate is not currently available in any FDA or Health Canada approved products.
DB13955Estradiol dienanthateEstradiol dienanthate is not currently available in any FDA or Health Canada approved products.
DB13941PiperaquineFor the treatment of uncomplicated *Plasmodium falciparum* infection in adults, children, and infants aged 6 months and up weighing over 5 kg [FDA Label]. Used in combination with [DB11638].
DB01420Testosterone propionateTestosterone propionate is often used for muscle mass building. The original medical indication is for the treatment of androgen deficiency in male adults either in hypogonadism or andropause.[L1161] Nowadays testosterone propionate is indicated for its use in heifers in order to stimulate maximal growth.[L1160]
DB11799BictegravirBictegravir is indicated in the management of HIV-1 infection in patients not previously treated with antiretroviral therapy. Additionally, Bictegravir is indicated in the management of HIV-1 infection in patients who are virologically suppressed (HIV-1 RNA <50 c/mL) on a regular antiretroviral regimen for a minimum of three months without a history of failure in treatment and no known factors associated with the resistance to the individual components of the medication. It is used in combination with tenofovir and emtricitabine [L1219, L1220].
DB11901ApalutamideIndicated for the treatment of patients with non-metastatic, castration-resistant prostate cancer (NM-CRPC) [FDA Label].
DB09225ZotepineZotepine, like other atypical antipsychotics, is considered as the first-line treatment in newly diagnosed schizophrenia. It is usually thought to be an option of choice for managing acute schizophrenic episodes when discussion with the patient is not possible. Zotepine, as an atypical antipsychotic, is used in patients who are suffering unacceptable side effects from conventional antipsychotics or in relapse patients that were inadequately controlled.[T108] It is important to consider that the indications stated above are related to atypical antipsychotics, that zotepine is not currently FDA, Canada or EMA approved and that studies have not shown any additional benefit when compared with other approved atypical antipsychotics.[A31857] Schizophrenia is a chronic and severe mental disorder that affects how a person thinks, feels and behaves. It is usually marked for a loose reality perspective delineated by hallucinations, delusions and thought and movement disorders.[L1320]
DB11642PitolisantIndicated in adults for the treatment of narcolepsy with or without cataplexy [L1471].
DB11712TezacaftorTezacaftor, in combination with ivacaftor, is indicated for the treatment of cystic fibrosis in people aged 12 years or older who have two copies of the _F508del_ mutation or at least one mutation in the CFTR gene that is responsive to this treatment based on clinical evidence.[L1598] Cystic fibrosis is a rare, life-shortening disease caused by a defective or missing CFTR protein. This modification in the protein is caused by a mutation in the CFTR gene. The affected people carry two inherited defective copies of the CFTR gene. There are approximately 2000 known mutations in the CFTR gene. The presence of a defective or missing protein results in poor flow of salt and water into and out of the cell. This condition will cause the buildup of abnormally thick, sticky mucus in the lungs that will later potentially cause chronic lung infections and lung damage. In the patients with the _F508del_ mutation, the CFTR protein is not processed or folded normally within the cell and thus, it does not reach the cell surface.[L1599]
DB11130OpiumOpium and its derivatives are the most commonly used medications for the treatment of acute and chronic pain. Opium and its alkaloid-derivatives can also be used as tranquilizers, antitussives and in the treatment of diarrhea.[T138] The direct use of opium is not common nowadays but the use of some of its derivatives such as morphine and codeine, as well as the use of a tincture of opium for severe diarrhea can be seen in medical practice.[T139] Illegal use of opium has been registered to be for both recreational and medicinal purposes.[A32182]
DB11251TocopherolTocopherol can be used as a dietary supplement for patients with a deficit of vitamin E; this is mainly prescribed in the alpha form.[A32443] Vitamin E deficiency is rare, and it is primarily found in premature babies of very low birth weight, patients with fat malabsorption or patients with abetalipoproteinemia.[L2120] Tocopherol, due to its antioxidant properties, is studied for its use in prevention or treatment in different complex diseases such as cancer,[A32436] atherosclerosis, cardiovascular diseases,[A32442] and age-related macular degeneration.[A32444]
DB14003alpha-Tocopherol acetateThe primary health-related use for which alpha-tocopherol acetate is formally indicated is as a dietary supplement for patients who demonstrate a genuine vitamin E deficiency. At the same time, vitamin E deficiency is generally quite rare but may occur in premature babies of very low birth weight (< 1500 grams), individuals with fat-malabsorption disorders (as fat is required for the digestive tract to absorb vitamin E), or individuals with abetalipoproteinemia - a rare, inherited disorder that causes poor absorption of dietary fat - who require extremely large doses of supplemental vitamin E daily (around 100 mg/kg or 5-10 g/day) [L2120]. In all such cases, alpha-tocopherol is largely the preferred form of vitamin E to be administered. Elsewhere, vitamin E's chemical profile as a fat-soluble antioxidant that is capable of neutralizing free radicals in the body continues to generate ongoing interest and study regarding how and whether or not the vitamin can help prevent or delay various chronic diseases associated with free radicals or other potential biological effects that vitamin E possesses like cardiovascular diseases, diabetes, ocular conditions, immune illnesses, cancer, and more [T166]. None of these ongoing studies have yet to elucidate any formally significant evidence, however [T166].
DB12278PropiverineIndicated for symptomatic treatment of urinary incontinence and/or increased urinary frequency and urgency in patients with overactive bladder (OAB) [L2315]. Propiverine may also be used in patients with neurogenic bladder as a result of spinal cord injury [A32581].
DB14011NabiximolsIn Canada, Sativex has received a Notice of Compliance (NOC) for use as an as adjunctive treatment for symptomatic relief of spasticity in patients with multiple sclerosis (MS) who have not responded adequately to other therapy and who demonstrate meaningful improvement during an initial trial of therapy. Sativex has also received a Notice of Compliance with Conditions (NOC/c) for use as an adjunctive treatment for the symptomatic relief of neuropathic pain in adult patients with multiple sclerosis (MS) and as adjunctive analgesic treatment in adult patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain. Marketing authorisations with conditions reflect the promising nature of the clinical evidence and the need for confirmatory studies to verify the clinical benefit. Patients should be advised of the conditional nature of the authorizations with conditions.
DB14009Medical CannabisNot Available
DB11641VinflunineFor use as a monotherapy in adults with advanced or transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing therapy [L2381].
DB11635TocofersolanTocofersolan is indicated in vitamin E deficiency caused by digestive malabsorption in pediatric patients with congenital chronic cholestasis or hereditary chronic cholestasis from birth (full term newborns) up to 18 years of age [L2371].
DB11637DelamanidIndicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability [L1407].
DB14019FosnetupitantIndicated in combination palonosetron (as the drug Akynzeo) and dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy [FDA label]. The following are indications listed on the EMA label [F29]: Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy [F29]. Prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy [F29].
DB11274Dihydro-alpha-ergocryptineAlpha-dihydroergocryptine has been studied for the early treatment of Parkinson disease[A32980] as well as for its use in migraine prophylaxis,[A32983] treatment of low blood pressure and peripheral vascular disorder. To know more about the ergoloid mesylate mixture and its uses please visit [DB01049].
DB13293IpecacIpecac is indicated as an emetic agent for the induction of vomiting in poisoning victims who ingested systemic poison in order to prevent absorption of the chemicals through the gastrointestinal tract. In low doses, ipecac was also used as an expectorant.[L2753] Reports have suggested that ipecac was vastly used in patients with eating disorders to produce vomiting.[T49]
DB13456MidecamycinMidecamycin was used for the treatment of infections in the oral cavity, upper and lower respiratory tracts and skin and soft tissue infections. The alone use of midecamycin was mainly used in Europe or Japan.[T207]
DB14185Aripiprazole lauroxilAripiprazole lauroxil is indicated for the treatment of schizophrenia and related psychotic disorders.
DB11718EncorafenibUsed in combination with [Binimetinib] in metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test [L3335].
DB119196-O-benzylguanineNot Available
DB14583Segesterone acetateSegesterone acetate in combination with ethinyl estradiol is indicated for use by females of reproductive potential to prevent pregnancy as a combination hormonal contraceptive (CHC). It induces contraception for thirteen 28-day cycles (1 year) following vaginal administration. The vaginal system must remain in place continuously for 3 weeks (21 days) followed by a 1-week (7-day) vaginal system-free interval. The use in females with a body mass index of >29 kg/m^2 has not been adequately evaluated [FDA Label].
DB01320FosphenytoinFor the control of generalized convulsive status epilepticus and prevention and treatment of seizures occurring during neurosurgery. It can also be substituted, short-term, for oral phenytoin.
DB09065CobicistatCobicistat is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. It is not interchangeable with ritonavir to increase systemic exposure of darunavir 600 mg twice daily, fosamprenavir, saquinavir, or tipranavir due to lack of exposure data. The use of cobicistat is not recommended with darunavir 600 mg twice daily, fosamprenavir, saquinavir or tipranavir. Complex or unknown mechanisms of drug interactions preclude extrapolation of ritonavir drug interactions to certain cobicistat interactions. Cobicistat and ritonavir when administered with either atazanavir or darunavir may result in different drug interactions when used with concomitant medications.
DB00563MethotrexateMethotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. In acute lymphocytic leukemia, methotrexate is indicated in the prophylaxis of meningeal leukemia and is used in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is also indicated in the treatment of meningeal leukemia. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin’s lymphomas. Methotrexate is indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis. Methotrexate is indicated in the management of selected adults with severe, active rheumatoid arthritis (ACR criteria), or children with active polyarticular-course juvenile rheumatoid arthritis.
DB04884DapoxetineFor the treatment of premature ejaculation.
DB00476DuloxetineFor the acute and maintenance treatment of major depressive disorder (MDD), as well as acute management of generalized anxiety disorder. Also used for the management of neuropathic pain associated with diabetic peripheral neuropathy, and fibromyalgia. Has been used in the management of moderate to severe stress urinary incontinence (SUI) in women.
DB00176FluvoxamineIndicated predominantly for the management of depression and for Obsessive Compulsive Disorder (OCD) [FDA Label]. Has also been used in the management of bulimia nervosa [A250].
DB08953IndalpineNot Available
DB04896MilnacipranMilnacipran is used to treat moderate to severe clinical depression but this indication is not yet FDA-approved in the USA. Milnacipran is labelled for the treatment of fibromyalgia pain.
DB02703Fusidic AcidFor the treatment of bacterial infections.
DB09229AranidipineAranidipine has been used for many years to treat angina pectoris and hypertension.[A31895]
DB08882LinagliptinLinagliptin is used for the management of type 2 diabetes mellitus.
DB00520CaspofunginFor the treatment of esophageal candidiasis and invasive aspergillosis in patients who are refractory to or intolerant of other therapies.
DB05239CobimetinibFor the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Cobimetinib is used in combination with vemurafenib, a BRAF inhibitor.
DB09330OsimertinibOsimertinib is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA- approved test, who have progressed on or after EGFR-TKI therapy.
DB09048NetupitantNetupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy.
DB09063CeritinibCeritinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
DB11730RibociclibKisqali (ribociclib) is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably.
DB09079NintedanibNintedanib is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).
DB01656RoflumilastRoflumilast is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. Roflumilast is not a bronchodilator and is not indicated for the relief of acute bronchospasm.
DB09034SuvorexantSuvorexant is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
DB09071TasimelteonTasimelteon is indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD).
DB09030VorapaxarVorapaxar is indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or peripheral arterial disease (PAD). It is usually co-administered with acetylsalicylic acid (ASA) and/or clopidogrel, and should therefore be administered as an addition to these medications as it has not been studied alone.
DB01624ZuclopenthixolUsed in the management of acute psychoses such as mania or schizophrenia. However, the use of zuclopenthixol acetate in psychiatric emergencies as an alternative to standard treatments (haloperidol, clotiapine, etc.) should be cautioned, since well executed and documented trials of zuclopenthixol acetate for this use have yet to be conducted. Zuclopenthixol acetate is not intended for long-term use.
DB13385DihydroergocryptineNot Available
DB11273DihydroergocornineTo know more about the approved indications please visit [DB01049]
DB13345DihydroergocristineDihydroergocristine is used in some countries such as Brasil as a single agent for the treatment of cerebral and peripheric vascular events.[L2649] To know more about dihydroergocristine as part of the ergoloid mesylate mixture, please visit [DB01049].
DB09054IdelalisibIdelalisib is indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies.
DB06218LacosamideLacosamide is indicated for adjunctive therapy for partial onset seizures in patients with epilepsy over 17 years old. Injection is indicated for short term use when oral therapy is not feasible.
DB01411PranlukastUsed as an adjunct to the standard therapy of inhaled steroids with inhaled long- and/or short-acting beta-agonists.
DB00863RanitidineUsed in the treatment of peptic ulcer disease (PUD), dyspepsia, stress ulcer prophylaxis, and gastroesophageal reflux disease (GERD).
DB00989RivastigmineFor the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.
DB12329EravacyclineThis drug is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older [FDA label].
DB11742EbastineNot Available
DB06717FosaprepitantFor the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy.
DB00247MethysergideFor the treatment of vascular headache
DB12301DoravirineDoravirine is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adult patients with no prior antiretroviral treatment history [FDA Label].
DB11952DuvelisibDuvelisib is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies.[L4586] The CLL is a cancer of the blood stem cells which are the blood cells that can develop into different types of cells. In leukemia, there is an overproduction of cells that are abnormal and do not mature into blood cells and thus, they just crowd out normal cells and impair their normal function. In lymphocyte leukemia, the abnormal cell growth is observed in the lymphoid cells which are the type of blood cells that mature into lymphocytes. The CLL is the type of lymphocytic leukemia that develops slowly over months or years.[L4587] The SLL is a very similar disease to the CLL and these terms are usually referred interchangeably. The only difference between these two diseases is that in CLL the cells are found mostly in the blood and bone marrow while in SLL, the cells are mainly found in the lymph nodes.[L4588] As well, duvelisib obtained an accelerated approval for the treatment of adult patients with relapsed or refractory follicular lymphoma after at least two prior systemic therapies. This approval is still under the status of continued approval and it is restrained to confirmatory trials.[L4586] The follicular lymphoma is a B-cell lymphoma that clusters in the lymph nodes or other tissues.[L4589]
DB00339PyrazinamideFor the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents.
DB09078LenvatinibLenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.
DB09195LorpiprazoleIn 2016, lorpiprazole was classified in the "Chemical structure-related drug-like criteria of global approved drugs" as an antipsychotic and anxiolytic.[L1167] An antipsychotic is a medication used to treat a state of delusion, hallucination, paranoia or disordered thought. On the other hand, an anxiolytic is a medication used for the treatment of severe, chronic or debilitating anxiety. The anxiety state can be defined as an unpleasant state of tension, apprehension or uneasiness.[T77]
DB09288PropacetamolPropacetamol is a paracetamol prodrug of intravenous administration used to control fever and pain of perioperative period in multimodal analgesia therapy.[L1511]
DrugDrug NameTargetType
DB00224IndinavirHuman immunodeficiency virus type 1 proteasetarget
DB00224IndinavirCytochrome P450 3A4enzyme
DB00224IndinavirCytochrome P450 3A5enzyme
DB00224IndinavirCytochrome P450 3A7enzyme
DB00224IndinavirMultidrug resistance protein 1transporter
DB00224IndinavirSolute carrier family 22 member 1transporter
DB00224IndinavirMultidrug resistance-associated protein 1transporter
DB00224IndinavirSolute carrier organic anion transporter family member 1A2transporter
DB00224IndinavirSolute carrier organic anion transporter family member 1B1transporter
DB00224IndinavirCanalicular multispecific organic anion transporter 1transporter
DB00224IndinavirCytochrome P450 2D6enzyme
DB00224IndinavirUDP-glucuronosyltransferase 1-1enzyme
DB00224IndinavirSolute carrier organic anion transporter family member 2B1transporter
DB00224IndinavirBile salt export pumptransporter
DB00227Lovastatin3-hydroxy-3-methylglutaryl-coenzyme A reductasetarget
DB00227LovastatinCytochrome P450 3A4enzyme
DB00227LovastatinCytochrome P450 2C8enzyme
DB00227LovastatinIntegrin alpha-Ltarget
DB00227LovastatinHistone deacetylase 2target
DB00227LovastatinSerum paraoxonase/lactonase 3enzyme
DB00227LovastatinCytochrome P450 2C9enzyme
DB00227LovastatinCytochrome P450 3A5enzyme
DB00227LovastatinCytochrome P450 3A7enzyme
DB00227LovastatinMultidrug resistance protein 1transporter
DB00227LovastatinSolute carrier organic anion transporter family member 1A2transporter
DB00227LovastatinSolute carrier organic anion transporter family member 1B1transporter
DB00227LovastatinCytochrome P450 2D6enzyme
DB00227LovastatinUDP-glucuronosyltransferase 1-1enzyme
DB00227LovastatinUDP-glucuronosyltransferase 1-3enzyme
DB00227LovastatinUDP-glucuronosyltransferase 2B7enzyme
DB00227LovastatinCanalicular multispecific organic anion transporter 1transporter
DB00227LovastatinBile salt export pumptransporter
DB00238NevirapineCytochrome P450 3A4enzyme
DB00238NevirapineCytochrome P450 2B6enzyme
DB00238NevirapineCytochrome P450 3A5enzyme
DB00238NevirapineCytochrome P450 2C9enzyme
DB00238NevirapineCytochrome P450 2A6enzyme
DB00238NevirapineCytochrome P450 2D6enzyme
DB00238NevirapineReverse transcriptase/RNaseHtarget
DB00238NevirapineSerum albumincarrier
DB00238NevirapineCytochrome P450 1A2enzyme
DB00343DiltiazemVoltage-dependent calcium channel gamma-1 subunittarget
DB00343DiltiazemCytochrome P450 3A4enzyme
DB00343DiltiazemCytochrome P450 2C19enzyme
DB00343DiltiazemCytochrome P450 2D6enzyme
DB00343DiltiazemCytochrome P450 3A5enzyme
DB00343DiltiazemCytochrome P450 3A7enzyme
DB00343DiltiazemMultidrug resistance protein 1transporter
DB00343DiltiazemCytochrome P450 2C8enzyme
DB00381AmlodipineCarbonic anhydrase 1target
DB00381AmlodipineCytochrome P450 3A4enzyme
DB00381AmlodipineVoltage-dependent L-type calcium channel subunit alpha-1Ctarget
DB00381AmlodipineVoltage-dependent L-type calcium channel subunit beta-2target
DB00381AmlodipineCytochrome P450 1A1enzyme
DB00381AmlodipineCytochrome P450 2B6enzyme
DB00381AmlodipineVoltage-dependent N-type calcium channel subunit alpha-1Btarget
DB00381AmlodipineVoltage-dependent calcium channel subunit alpha-2/delta-1target
DB00381AmlodipineVoltage-gated calcium channel beta 1 subunit splice variant CavB1dtarget
DB00381AmlodipineVoltage-dependent calcium channel subunit alpha-2/delta-3target
DB00381AmlodipineVoltage-dependent L-type calcium channel subunit alpha-1Dtarget
DB00381AmlodipineVoltage-dependent L-type calcium channel subunit alpha-1Starget
DB00381AmlodipineCytochrome P450 3A5enzyme
DB00381AmlodipineCytochrome P450 3A7enzyme
DB00381AmlodipineMultidrug resistance protein 1transporter
DB00381AmlodipineCytochrome P450 2A6enzyme
DB00381AmlodipineCytochrome P450 2C8enzyme
DB00381AmlodipineCytochrome P450 2C9enzyme
DB00381AmlodipineCytochrome P450 2D6enzyme
DB00381AmlodipineSphingomyelin phosphodiesterasetarget
DB00401NisoldipineCytochrome P450 3A4enzyme
DB00401NisoldipineVoltage-dependent L-type calcium channel subunit alpha-1Dtarget
DB00401NisoldipineVoltage-dependent L-type calcium channel subunit alpha-1Starget
DB00401NisoldipineVoltage-dependent L-type calcium channel subunit alpha-1Ctarget
DB00401NisoldipineVoltage-dependent calcium channel subunit alpha-2/delta-1target
DB00401NisoldipineVoltage-dependent L-type calcium channel subunit beta-2target
DB00401NisoldipineCytochrome P450 3A5enzyme
DB00401NisoldipineCytochrome P450 3A7enzyme
DB00401NisoldipineMultidrug resistance protein 1transporter
DB00404AlprazolamCytochrome P450 3A4enzyme
DB00404AlprazolamCytochrome P450 2C9enzyme
DB00404AlprazolamCytochrome P450 3A5enzyme
DB00404AlprazolamCytochrome P450 3A7enzyme
DB00404AlprazolamGABA-A receptor (anion channel)target
DB00468QuininePlatelet glycoprotein IXtarget
DB00468QuinineIntermediate conductance calcium-activated potassium channel protein 4target
DB00468QuinineCytochrome P450 3A4enzyme
DB00468QuinineCytochrome P450 3A5enzyme
DB00468QuinineCytochrome P450 1A1enzyme
DB00468QuinineCytochrome P450 2D6enzyme
DB00468QuinineCytochrome P450 1A2enzyme
DB00468QuinineCytochrome P450 2C8enzyme
DB00468QuinineCytochrome P450 2C9enzyme
DB00468QuinineCytochrome P450 2C19enzyme
DB00468QuinineCytochrome P450 2E1enzyme
DB00468QuinineCytochrome P450 3A7enzyme
DB00468QuinineSolute carrier family 22 member 2transporter
DB00468QuinineSolute carrier family 22 member 1transporter
DB00468QuinineSolute carrier family 22 member 5transporter
DB00468QuinineMultidrug resistance protein 1transporter
DB00468QuinineSolute carrier organic anion transporter family member 1A2transporter
DB00468QuinineSolute carrier family 22 member 4transporter
DB00468QuinineFe(II)-protoporphyrin IXtarget
DB00468QuinineSolute carrier organic anion transporter family member 1B1transporter
DB00490Buspirone5-hydroxytryptamine receptor 1Atarget
DB00490BuspironeD(2) dopamine receptortarget
DB00490BuspironeCytochrome P450 3A4enzyme
DB00490BuspironeCytochrome P450 3A5enzyme
DB00490BuspironeCytochrome P450 3A7enzyme
DB00490BuspironeMultidrug resistance protein 1transporter
DB00490BuspironeCytochrome P450 2D6enzyme
DB00541VincristineTubulin beta chaintarget
DB00541VincristineCytochrome P450 3A4enzyme
DB00541VincristineCytochrome P450 3A5enzyme
DB00541VincristineCytochrome P450 3A7enzyme
DB00541VincristineMultidrug resistance protein 1transporter
DB00541VincristineCanalicular multispecific organic anion transporter 2transporter
DB00541VincristineSolute carrier family 22 member 3transporter
DB00541VincristineMultidrug resistance-associated protein 1transporter
DB00541VincristineMultidrug resistance-associated protein 7transporter
DB00541VincristineCanalicular multispecific organic anion transporter 1transporter
DB00541VincristineBile salt export pumptransporter
DB00541VincristineATP-binding cassette sub-family G member 2transporter
DB00541VincristineTubulin alpha-4A chaintarget
DB00541VincristineRalA-binding protein 1transporter
DB00541VincristineSolute carrier organic anion transporter family member 1B1transporter
DB00541VincristineSolute carrier organic anion transporter family member 1B3transporter
DB00604Cisapride5-hydroxytryptamine receptor 4target
DB00604Cisapride5-hydroxytryptamine receptor 3Atarget
DB00604CisapridePotassium voltage-gated channel subfamily H member 2target
DB00604Cisapride5-hydroxytryptamine receptor 2Atarget
DB00604CisaprideCytochrome P450 3A4enzyme
DB00604CisaprideCytochrome P450 3A5enzyme
DB00604CisaprideCytochrome P450 3A7enzyme
DB00604CisaprideCytochrome P450 2A6enzyme
DB00604CisaprideCytochrome P450 2B6enzyme
DB00604CisaprideCytochrome P450 2C19enzyme
DB00604CisaprideCytochrome P450 2C8enzyme
DB00604CisaprideCytochrome P450 2C9enzyme
DB00604CisaprideCytochrome P450 2D6enzyme
DB00619ImatinibPlatelet-derived growth factor receptor betatarget
DB00619ImatinibTyrosine-protein kinase ABL1target
DB00619ImatinibMast/stem cell growth factor receptor Kittarget
DB00619ImatinibRET proto-oncogenetarget
DB00619ImatinibHigh affinity nerve growth factor receptortarget
DB00619ImatinibMacrophage colony-stimulating factor 1 receptortarget
DB00619ImatinibPlatelet-derived growth factor receptor alphatarget
DB00619ImatinibEpithelial discoidin domain-containing receptor 1target
DB00619ImatinibCytochrome P450 3A4enzyme
DB00619ImatinibBCR/ABL fusion protein isoform X9target
DB00619ImatinibCytochrome P450 1A2enzyme
DB00619ImatinibCytochrome P450 2D6enzyme
DB00619ImatinibCytochrome P450 2C9enzyme
DB00619ImatinibCytochrome P450 2C19enzyme
DB00619ImatinibCytochrome P450 3A5enzyme
DB00619ImatinibCytochrome P450 3A7enzyme
DB00619ImatinibSolute carrier family 22 member 1transporter
DB00619ImatinibMultidrug resistance protein 1transporter
DB00619ImatinibSolute carrier family 22 member 2transporter
DB00619ImatinibATP-binding cassette sub-family G member 2transporter
DB00619ImatinibATP-binding cassette sub-family A member 3transporter
DB00619ImatinibProstaglandin G/H synthase 1enzyme
DB00619ImatinibSerum albumincarrier
DB00619ImatinibAlpha-1-acid glycoprotein 1carrier
DB00619ImatinibBile salt export pumptransporter
DB00637AstemizoleHistamine H1 receptortarget
DB00637AstemizolePotassium voltage-gated channel subfamily H member 2target
DB00637AstemizoleCytochrome P450 3A4enzyme
DB00637AstemizoleCytochrome P450 3A5enzyme
DB00637AstemizoleCytochrome P450 3A7enzyme
DB00637AstemizoleMultidrug resistance protein 1transporter
DB00637AstemizoleCytochrome P450 2D6enzyme
DB00637AstemizoleCytochrome P450 2J2enzyme
DB00637AstemizolePotassium voltage-gated channel subfamily H member 1target
DB00637AstemizoleMicrotubule-associated protein tautarget
DB00637AstemizoleBile salt export pumptransporter
DB00641Simvastatin3-hydroxy-3-methylglutaryl-coenzyme A reductasetarget
DB00641SimvastatinIntegrin beta-2target
DB00641SimvastatinCytochrome P450 3A4enzyme
DB00641SimvastatinCytochrome P450 2C8enzyme
DB00641SimvastatinCytochrome P450 2C9enzyme
DB00641SimvastatinCytochrome P450 2C19enzyme
DB00641SimvastatinCytochrome P450 3A5enzyme
DB00641SimvastatinCytochrome P450 3A7enzyme
DB00641SimvastatinMultidrug resistance protein 1transporter
DB00641SimvastatinSolute carrier organic anion transporter family member 1A2transporter
DB00641SimvastatinSolute carrier organic anion transporter family member 1B1transporter
DB00641SimvastatinCytochrome P450 2B6enzyme
DB00641SimvastatinCytochrome P450 2D6enzyme
DB00641SimvastatinUDP-glucuronosyltransferase 1-1enzyme
DB00641SimvastatinUDP-glucuronosyltransferase 1-3enzyme
DB00641SimvastatinUDP-glucuronosyltransferase 2B7enzyme
DB00641SimvastatinCanalicular multispecific organic anion transporter 1transporter
DB00641SimvastatinIntegrin alpha-Ltarget
DB00641SimvastatinBile salt export pumptransporter
DB00675TamoxifenEstrogen receptor alphatarget
DB00675TamoxifenEstrogen receptor betatarget
DB00675TamoxifenCytochrome P450 2C9enzyme
DB00675TamoxifenCytochrome P450 3A4enzyme
DB00675TamoxifenCytochrome P450 2D6enzyme
DB00675TamoxifenCytochrome P450 2C8enzyme
DB00675TamoxifenCytochrome P450 2B6enzyme
DB00675TamoxifenLiver carboxylesterase 1enzyme
DB00675TamoxifenCytochrome P450 3A5enzyme
DB00675TamoxifenCytochrome P450 1A1enzyme
DB00675TamoxifenCytochrome P450 1B1enzyme
DB00675TamoxifenCytochrome P450 2C19enzyme
DB00675TamoxifenDimethylaniline monooxygenase [N-oxide-forming] 1enzyme
DB00675TamoxifenDimethylaniline monooxygenase [N-oxide-forming] 3enzyme
DB00675TamoxifenCytochrome P450 3A7enzyme
DB00675TamoxifenMultidrug resistance protein 1transporter
DB00675TamoxifenATP-binding cassette sub-family G member 2transporter
DB00675TamoxifenCytochrome P450 19A1enzyme
DB00675TamoxifenCytochrome P450 2A6enzyme
DB00675TamoxifenCytochrome P450 2E1enzyme
DB00675TamoxifenUDP-glucuronosyltransferase 1-10enzyme
DB00675TamoxifenSulfotransferase 1A1enzyme
DB00675TamoxifenCanalicular multispecific organic anion transporter 1transporter
DB00675Tamoxifen3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerasetarget
DB00675TamoxifenProtein kinase Ctarget
DB00675TamoxifenAndrogen receptortarget
DB00675TamoxifenPotassium voltage-gated channel subfamily H member 2target
DB00675TamoxifenNuclear receptor subfamily 1 group I member 2target
DB00675TamoxifenEstrogen-related receptor gammatarget
DB00675TamoxifenSex hormone-binding globulintarget
DB00675TamoxifenBile salt export pumptransporter
DB00683MidazolamGamma-aminobutyric acid receptor subunit alpha-1target
DB00683MidazolamGamma-aminobutyric acid receptor subunit beta-1target
DB00683MidazolamGamma-aminobutyric acid receptor subunit beta-3target
DB00683MidazolamGamma-aminobutyric acid receptor subunit alpha-5target
DB00683MidazolamGamma-aminobutyric acid receptor subunit alpha-3target
DB00683MidazolamGamma-aminobutyric acid receptor subunit alpha-2target
DB00683MidazolamGamma-aminobutyric acid receptor subunit beta-2target
DB00683MidazolamGamma-aminobutyric acid receptor subunit alpha-4target
DB00683MidazolamGamma-aminobutyric acid receptor subunit alpha-6target
DB00683MidazolamCytochrome P450 3A4enzyme
DB00683MidazolamCytochrome P450 2B6enzyme
DB00683MidazolamCytochrome P450 3A5enzyme
DB00683MidazolamGamma-aminobutyric acid receptor subunit gamma-1target
DB00683MidazolamGamma-aminobutyric acid receptor subunit gamma-2target
DB00683MidazolamGamma-aminobutyric acid receptor subunit gamma-3target
DB00683MidazolamGamma-aminobutyric acid receptor subunit deltatarget
DB00683MidazolamGamma-aminobutyric acid receptor subunit epsilontarget
DB00683MidazolamGamma-aminobutyric acid receptor subunit pitarget
DB00683MidazolamGamma-aminobutyric acid receptor subunit rho-1target
DB00683MidazolamGamma-aminobutyric acid receptor subunit rho-2target
DB00683MidazolamGamma-aminobutyric acid receptor subunit thetatarget
DB00683MidazolamCytochrome P450 3A7enzyme
DB00683MidazolamGamma-aminobutyric acid receptor subunit rho-3target
DB00683MidazolamMultidrug resistance protein 1transporter
DB00683MidazolamSolute carrier family 22 member 1transporter
DB00683MidazolamCytochrome P450 4B1enzyme
DB00683MidazolamUDP-glucuronosyltransferase 1-4enzyme
DB00683MidazolamCytochrome P450 2E1enzyme
DB00683MidazolamBile salt export pumptransporter
DB00802AlfentanilMu-type opioid receptortarget
DB00802AlfentanilCytochrome P450 3A4enzyme
DB00802AlfentanilCytochrome P450 3A5enzyme
DB00802AlfentanilAlpha-1-acid glycoprotein 1carrier
DB00802AlfentanilSerum albumincarrier
DB00802AlfentanilCytochrome P450 3A7enzyme
DB00802AlfentanilMultidrug resistance protein 1transporter
DB00820TadalafilcGMP-specific 3',5'-cyclic phosphodiesterasetarget
DB00820TadalafilCytochrome P450 3A4enzyme
DB00820TadalafilDual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11Atarget
DB00820TadalafilCytochrome P450 3A5enzyme
DB00829DiazepamTranslocator proteintarget
DB00829DiazepamGamma-aminobutyric acid receptor subunit alpha-1target
DB00829DiazepamGamma-aminobutyric acid receptor subunit alpha-2target
DB00829DiazepamGamma-aminobutyric acid receptor subunit alpha-3target
DB00829DiazepamCytochrome P450 3A4enzyme
DB00829DiazepamSerum albumincarrier
DB00829DiazepamCytochrome P450 2C9enzyme
DB00829DiazepamCytochrome P450 2C19enzyme
DB00829DiazepamCytochrome P450 3A5enzyme
DB00829DiazepamCytochrome P450 3A7enzyme
DB00829DiazepamGamma-aminobutyric acid receptor subunit alpha-5target
DB00829DiazepamGamma-aminobutyric acid receptor subunit beta-1target
DB00829DiazepamGamma-aminobutyric acid receptor subunit beta-2target
DB00829DiazepamGamma-aminobutyric acid receptor subunit beta-3target
DB00829DiazepamGamma-aminobutyric acid receptor subunit gamma-1target
DB00829DiazepamGamma-aminobutyric acid receptor subunit gamma-2target
DB00829DiazepamGamma-aminobutyric acid receptor subunit gamma-3target
DB00829DiazepamGamma-aminobutyric acid receptor subunit deltatarget
DB00829DiazepamGamma-aminobutyric acid receptor subunit epsilontarget
DB00829DiazepamGamma-aminobutyric acid receptor subunit pitarget
DB00829DiazepamGamma-aminobutyric acid receptor subunit rho-1target
DB00829DiazepamGamma-aminobutyric acid receptor subunit rho-2target
DB00829DiazepamGamma-aminobutyric acid receptor subunit rho-3target
DB00829DiazepamGamma-aminobutyric acid receptor subunit thetatarget
DB00829DiazepamMultidrug resistance protein 1transporter
DB00829DiazepamCytochrome P450 2B6enzyme
DB00829DiazepamProstaglandin G/H synthase 1enzyme
DB00829DiazepamCytochrome P450 2C18enzyme
DB00829DiazepamCytochrome P450 2C8enzyme
DB00829DiazepamCytochrome P450 2E1enzyme
DB00829DiazepamGABA-A receptor (anion channel)target
DB00862VardenafilcGMP-specific 3',5'-cyclic phosphodiesterasetarget
DB00862VardenafilCytochrome P450 3A4enzyme
DB00862VardenafilRetinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammatarget
DB00862VardenafilRetinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammatarget
DB00862VardenafilCytochrome P450 3A5enzyme
DB00864TacrolimusPeptidyl-prolyl cis-trans isomerase FKBP1Atarget
DB00864TacrolimusCytochrome P450 3A4enzyme
DB00864TacrolimusCytochrome P450 3A5enzyme
DB00864TacrolimusCytochrome P450 3A7enzyme
DB00864TacrolimusMultidrug resistance protein 1transporter
DB00864TacrolimusATP-binding cassette sub-family A member 5transporter
DB00864TacrolimusSerum albumincarrier
DB00864TacrolimusAlpha-1-acid glycoprotein 1carrier
DB00864TacrolimusSolute carrier organic anion transporter family member 1B1transporter
DB00877SirolimusPeptidyl-prolyl cis-trans isomerase FKBP1Atarget
DB00877SirolimusCytochrome P450 3A4enzyme
DB00877SirolimusSerine/threonine-protein kinase mTORtarget
DB00877SirolimusFibroblast growth factor 2target
DB00877SirolimusCytochrome P450 3A5enzyme
DB00877SirolimusCytochrome P450 3A7enzyme
DB00877SirolimusMultidrug resistance protein 1transporter
DB00877SirolimusSolute carrier organic anion transporter family member 1B1transporter
DB00877SirolimusMultidrug and toxin extrusion protein 1transporter
DB00897TriazolamTranslocator proteintarget
DB00897TriazolamCytochrome P450 3A4enzyme
DB00897TriazolamCytochrome P450 3A5enzyme
DB00897TriazolamCytochrome P450 3A7enzyme
DB00897TriazolamGamma-aminobutyric acid receptor subunit alpha-1target
DB00897TriazolamGamma-aminobutyric acid receptor subunit alpha-2target
DB00897TriazolamGamma-aminobutyric acid receptor subunit alpha-3target
DB00897TriazolamGamma-aminobutyric acid receptor subunit alpha-4target
DB00897TriazolamGamma-aminobutyric acid receptor subunit alpha-5target
DB00897TriazolamGamma-aminobutyric acid receptor subunit alpha-6target
DB00897TriazolamGamma-aminobutyric acid receptor subunit beta-1target
DB00897TriazolamGamma-aminobutyric acid receptor subunit beta-2target
DB00897TriazolamGamma-aminobutyric acid receptor subunit beta-3target
DB00897TriazolamGamma-aminobutyric acid receptor subunit gamma-1target
DB00897TriazolamGamma-aminobutyric acid receptor subunit gamma-2target
DB00897TriazolamGamma-aminobutyric acid receptor subunit gamma-3target
DB00897TriazolamGamma-aminobutyric acid receptor subunit deltatarget
DB00897TriazolamGamma-aminobutyric acid receptor subunit epsilontarget
DB00897TriazolamGamma-aminobutyric acid receptor subunit pitarget
DB00897TriazolamGamma-aminobutyric acid receptor subunit rho-1target
DB00897TriazolamGamma-aminobutyric acid receptor subunit rho-2target
DB00897TriazolamGamma-aminobutyric acid receptor subunit rho-3target
DB00897TriazolamGamma-aminobutyric acid receptor subunit thetatarget
DB00897TriazolamCytochrome P450 2C8enzyme
DB00897TriazolamGABA-A receptor (anion channel)target
DB00976Telithromycin23S rRNAtarget
DB00976TelithromycinCytochrome P450 3A4enzyme
DB00976TelithromycinCytochrome P450 3A5enzyme
DB00976TelithromycinCytochrome P450 3A7enzyme
DB00976TelithromycinSolute carrier organic anion transporter family member 1B1transporter
DB00976TelithromycinSolute carrier organic anion transporter family member 1B3transporter
DB01023FelodipineVoltage-dependent calcium channel subunit alpha-2/delta-1target
DB01023FelodipineCalmodulintarget
DB01023FelodipineCytochrome P450 3A4enzyme
DB01023FelodipineVoltage-dependent L-type calcium channel subunit alpha-1Ctarget
DB01023FelodipineVoltage-dependent L-type calcium channel subunit beta-2target
DB01023FelodipineCytochrome P450 2C8enzyme
DB01023FelodipineCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1Btarget
DB01023FelodipineCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1Atarget
DB01023FelodipineVoltage-dependent T-type calcium channel subunit alpha-1Htarget
DB01023FelodipineVoltage-dependent calcium channel subunit alpha-2/delta-2target
DB01023FelodipineTroponin C, skeletal muscletarget
DB01023FelodipineTroponin C, slow skeletal and cardiac musclestarget
DB01023FelodipineMineralocorticoid receptortarget
DB01023FelodipineVoltage-dependent L-type calcium channel subunit alpha-1Dtarget
DB01023FelodipineVoltage-dependent L-type calcium channel subunit alpha-1Starget
DB01023FelodipineCytochrome P450 3A5enzyme
DB01023FelodipineCytochrome P450 3A7enzyme
DB01023FelodipineMultidrug resistance protein 1transporter
DB01023FelodipineCytochrome P450 2C9enzyme
DB01023FelodipineCytochrome P450 2D6enzyme
DB01023FelodipineBile salt export pumptransporter
DB01054NitrendipineVoltage-dependent calcium channel gamma-1 subunittarget
DB01054NitrendipineCytochrome P450 3A4enzyme
DB01054NitrendipineVoltage-dependent T-type calcium channel subunit alpha-1Htarget
DB01054NitrendipineVoltage-dependent calcium channel subunit alpha-2/delta-2target
DB01054NitrendipineVoltage-dependent L-type calcium channel subunit alpha-1Dtarget
DB01054NitrendipineVoltage-dependent L-type calcium channel subunit alpha-1Starget
DB01054NitrendipineVoltage-dependent L-type calcium channel subunit alpha-1Ctarget
DB01054NitrendipineVoltage-dependent calcium channel subunit alpha-2/delta-1target
DB01054NitrendipineVoltage-dependent L-type calcium channel subunit beta-2target
DB01054NitrendipineCytochrome P450 3A5enzyme
DB01054NitrendipineCytochrome P450 3A7enzyme
DB01054NitrendipineMultidrug resistance protein 1transporter
DB01054NitrendipineBile salt export pumptransporter
DB01076Atorvastatin3-hydroxy-3-methylglutaryl-coenzyme A reductasetarget
DB01076AtorvastatinCytochrome P450 3A4enzyme
DB01076AtorvastatinDipeptidyl peptidase 4target
DB01076AtorvastatinCytochrome P450 2D6enzyme
DB01076AtorvastatinCytochrome P450 2C9enzyme
DB01076AtorvastatinCytochrome P450 2C19enzyme
DB01076AtorvastatinCytochrome P450 3A5enzyme
DB01076AtorvastatinCytochrome P450 3A7enzyme
DB01076AtorvastatinMultidrug resistance protein 1transporter
DB01076AtorvastatinSolute carrier organic anion transporter family member 1A2transporter
DB01076AtorvastatinSolute carrier organic anion transporter family member 1B1transporter
DB01076AtorvastatinMultidrug resistance-associated protein 4transporter
DB01076AtorvastatinMultidrug resistance-associated protein 5transporter
DB01076AtorvastatinMultidrug resistance-associated protein 1transporter
DB01076AtorvastatinCytochrome P450 2B6enzyme
DB01076AtorvastatinCytochrome P450 2C8enzyme
DB01076AtorvastatinAryl hydrocarbon receptortarget
DB01076AtorvastatinSolute carrier organic anion transporter family member 2B1transporter
DB01076AtorvastatinSolute carrier organic anion transporter family member 1B3transporter
DB01076AtorvastatinUDP-glucuronosyltransferase 1-1enzyme
DB01076AtorvastatinUDP-glucuronosyltransferase 1-3enzyme
DB01076AtorvastatinUDP-glucuronosyltransferase 2B7enzyme
DB01076AtorvastatinCanalicular multispecific organic anion transporter 1transporter
DB01076AtorvastatinBile salt export pumptransporter
DB01100PimozideD(2) dopamine receptortarget
DB01100PimozideCalmodulintarget
DB01100PimozidePotassium voltage-gated channel subfamily H member 2target
DB01100PimozideCytochrome P450 3A4enzyme
DB01100PimozideCytochrome P450 1A2enzyme
DB01100PimozideCytochrome P450 3A5enzyme
DB01100PimozideCytochrome P450 3A7enzyme
DB01100PimozideMultidrug resistance protein 1transporter
DB01100PimozideD(3) dopamine receptortarget
DB01100PimozideCytochrome P450 2D6enzyme
DB01100PimozideCytochrome P450 2E1enzyme
DB01114ChlorphenamineHistamine H1 receptortarget
DB01114ChlorphenamineCytochrome P450 3A4enzyme
DB01114ChlorphenamineCytochrome P450 2D6enzyme
DB01114ChlorphenamineSodium-dependent serotonin transportertarget
DB01114ChlorphenamineSodium-dependent noradrenaline transportertarget
DB01114ChlorphenamineSodium-dependent dopamine transportertarget
DB01114ChlorphenamineCytochrome P450 3A5enzyme
DB01114ChlorphenamineCytochrome P450 3A7enzyme
DB01114ChlorphenamineSolute carrier family 22 member 2transporter
DB01114ChlorphenamineSolute carrier family 22 member 1transporter
DB01115NifedipineVoltage-dependent calcium channel subunit alpha-2/delta-1target
DB01115NifedipineCytochrome P450 3A4enzyme
DB01115NifedipineCytochrome P450 2E1enzyme
DB01115NifedipineCytochrome P450 2D6enzyme
DB01115NifedipineCalmodulintarget
DB01115NifedipineVoltage-dependent L-type calcium channel subunit alpha-1Dtarget
DB01115NifedipineVoltage-dependent L-type calcium channel subunit alpha-1Starget
DB01115NifedipineVoltage-dependent L-type calcium channel subunit alpha-1Ctarget
DB01115NifedipineVoltage-dependent L-type calcium channel subunit beta-2target
DB01115NifedipinePotassium voltage-gated channel subfamily A member 1target
DB01115NifedipineVoltage-dependent T-type calcium channel subunit alpha-1Htarget
DB01115NifedipineCytochrome P450 1A2enzyme
DB01115NifedipineCytochrome P450 2A6enzyme
DB01115NifedipineCytochrome P450 2C8enzyme
DB01115NifedipineCytochrome P450 3A5enzyme
DB01115NifedipineCytochrome P450 3A7enzyme
DB01115NifedipineCanalicular multispecific organic anion transporter 2transporter
DB01115NifedipineMultidrug resistance protein 1transporter
DB01115NifedipineCanalicular multispecific organic anion transporter 1transporter
DB01115NifedipineCytochrome P450 1A1enzyme
DB01115NifedipineCytochrome P450 2B6enzyme
DB01115NifedipineNuclear receptor subfamily 1 group I member 2target
DB01115NifedipineSolute carrier organic anion transporter family member 1B1transporter
DB01115NifedipineBile salt export pumptransporter
DB01211Clarithromycin50S ribosomal protein L10target
DB01211ClarithromycinCytochrome P450 3A4enzyme
DB01211ClarithromycinCytochrome P450 2C19enzyme
DB01211ClarithromycinCytochrome P450 3A5enzyme
DB01211ClarithromycinCytochrome P450 3A7enzyme
DB01211ClarithromycinMultidrug resistance protein 1transporter
DB01211ClarithromycinSolute carrier family 22 member 7transporter
DB01211ClarithromycinPotassium voltage-gated channel subfamily H member 2target
DB01211ClarithromycinSolute carrier organic anion transporter family member 1B1target
DB01211ClarithromycinSolute carrier organic anion transporter family member 1B3target
DB01211ClarithromycinBile salt export pumptransporter
DB01232SaquinavirHuman immunodeficiency virus type 1 proteasetarget
DB01232SaquinavirCytochrome P450 3A4enzyme
DB01232SaquinavirCytochrome P450 3A5enzyme
DB01232SaquinavirAlpha-1-acid glycoprotein 1carrier
DB01232SaquinavirSerum albumincarrier
DB01232SaquinavirCytochrome P450 3A7enzyme
DB01232SaquinavirMultidrug resistance protein 1transporter
DB01232SaquinavirSolute carrier family 22 member 1transporter
DB01232SaquinavirSolute carrier organic anion transporter family member 1A2transporter
DB01232SaquinavirATP-binding cassette sub-family G member 2transporter
DB01232SaquinavirSolute carrier organic anion transporter family member 1B1transporter
DB01232SaquinavirMultidrug resistance-associated protein 1transporter
DB01232SaquinavirCanalicular multispecific organic anion transporter 1transporter
DB01232SaquinavirCholesterol side-chain cleavage enzyme, mitochondrialenzyme
DB01232SaquinavirCytochrome P450 2C8enzyme
DB01232SaquinavirCytochrome P450 2D6enzyme
DB01232SaquinavirSolute carrier organic anion transporter family member 2B1transporter
DB01232SaquinavirBile salt export pumptransporter
DB01238AripiprazoleD(2) dopamine receptortarget
DB01238Aripiprazole5-hydroxytryptamine receptor 1Atarget
DB01238Aripiprazole5-hydroxytryptamine receptor 2Atarget
DB01238AripiprazoleCytochrome P450 3A4enzyme
DB01238AripiprazoleCytochrome P450 2D6enzyme
DB01238Aripiprazole5-hydroxytryptamine receptor 1Btarget
DB01238Aripiprazole5-hydroxytryptamine receptor 1Dtarget
DB01238Aripiprazole5-hydroxytryptamine receptor 1Etarget
DB01238AripiprazoleD(1A) dopamine receptortarget
DB01238AripiprazoleD(1B) dopamine receptortarget
DB01238AripiprazoleD(3) dopamine receptortarget
DB01238AripiprazoleD(4) dopamine receptortarget
DB01238Aripiprazole5-hydroxytryptamine receptor 2Ctarget
DB01238Aripiprazole5-hydroxytryptamine receptor 3Atarget
DB01238Aripiprazole5-hydroxytryptamine receptor 6target
DB01238Aripiprazole5-hydroxytryptamine receptor 7target
DB01238AripiprazoleHistamine H1 receptortarget
DB01238AripiprazoleAlpha-1A adrenergic receptortarget
DB01238AripiprazoleAlpha-1B adrenergic receptortarget
DB01238AripiprazoleAlpha-2A adrenergic receptortarget
DB01238AripiprazoleAlpha-2B adrenergic receptortarget
DB01238AripiprazoleAlpha-2C adrenergic receptortarget
DB01238AripiprazoleMuscarinic acetylcholine receptor M1target
DB01238AripiprazoleMuscarinic acetylcholine receptor M2target
DB01238AripiprazoleMuscarinic acetylcholine receptor M3target
DB01238AripiprazoleMuscarinic acetylcholine receptor M4target
DB01238AripiprazoleMuscarinic acetylcholine receptor M5target
DB01238AripiprazoleCytochrome P450 3A5enzyme
DB01238AripiprazoleCytochrome P450 3A7enzyme
DB00199Erythromycin23S rRNAtarget
DB00199ErythromycinCytochrome P450 3A4enzyme
DB00199ErythromycinCytochrome P450 3A7enzyme
DB00199ErythromycinMultidrug resistance protein 1transporter
DB00199ErythromycinSolute carrier organic anion transporter family member 1B1transporter
DB00199ErythromycinCytochrome P450 2B6enzyme
DB00199ErythromycinMotilin receptortarget
DB00199ErythromycinPotassium voltage-gated channel subfamily H member 2target
DB00199ErythromycinSerum albumintarget
DB00199ErythromycinCytochrome P450 3A5enzyme
DB00199ErythromycinSolute carrier organic anion transporter family member 1B3transporter
DB00199ErythromycinBile salt export pumptransporter
DB00564CarbamazepineSodium channel protein type 5 subunit alphatarget
DB00564CarbamazepineCytochrome P450 2C8enzyme
DB00564CarbamazepineCytochrome P450 2B6enzyme
DB00564CarbamazepineCytochrome P450 3A4enzyme
DB00564CarbamazepineCytochrome P450 1A2enzyme
DB00564CarbamazepineCytochrome P450 2C19enzyme
DB00564CarbamazepineCytochrome P450 2C9enzyme
DB00564CarbamazepineMultidrug resistance protein 1transporter
DB00564CarbamazepineCytochrome P450 3A5enzyme
DB00564CarbamazepineCytochrome P450 3A7enzyme
DB00564CarbamazepineUDP-glucuronosyltransferase 2B7enzyme
DB00564CarbamazepineRalA-binding protein 1transporter
DB00564CarbamazepineCanalicular multispecific organic anion transporter 1transporter
DB00564CarbamazepineNeuronal acetylcholine receptor subunit alpha-4target
DB00564CarbamazepineNeuronal acetylcholine receptor subunit beta-2target
DB00564CarbamazepineNuclear receptor subfamily 1 group I member 2target
DB00564CarbamazepineUDP-glucuronosyltransferase 1-1enzyme
DB00203SildenafilcGMP-specific 3',5'-cyclic phosphodiesterasetarget
DB00203SildenafilCytochrome P450 2C9enzyme
DB00203SildenafilRetinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammatarget
DB00203SildenafilRetinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammatarget
DB00203SildenafilCytochrome P450 3A4enzyme
DB00203SildenafilCytochrome P450 3A5enzyme
DB00203SildenafilCytochrome P450 3A7enzyme
DB00203SildenafilMultidrug resistance-associated protein 4transporter
DB00203SildenafilMultidrug resistance-associated protein 5transporter
DB00203SildenafilMultidrug resistance-associated protein 7transporter
DB00203SildenafilCytochrome P450 2C19enzyme
DB00203SildenafilCytochrome P450 2D6enzyme
DB00203SildenafilCytochrome P450 1A1enzyme
DB00203SildenafilCytochrome P450 2E1enzyme
DB00203SildenafilSolute carrier organic anion transporter family member 1B1transporter
DB00908QuinidineSodium channel protein type 5 subunit alphatarget
DB00908QuinidineAlpha-1-acid glycoprotein 1carrier
DB00908QuinidinePotassium voltage-gated channel subfamily H member 2target
DB00908QuinidinePotassium channel subfamily K member 1target
DB00908QuinidinePotassium channel subfamily K member 6target
DB00908QuinidineCytochrome P450 1A2enzyme
DB00908QuinidineCytochrome P450 2E1enzyme
DB00908QuinidineCytochrome P450 1A1enzyme
DB00908QuinidineCytochrome P450 2D6enzyme
DB00908QuinidineCytochrome P450 3A4enzyme
DB00908QuinidineCytochrome P450 3A7enzyme
DB00908QuinidineSolute carrier family 22 member 2transporter
DB00908QuinidineSolute carrier family 22 member 1transporter
DB00908QuinidineSolute carrier family 22 member 5transporter
DB00908QuinidineMultidrug resistance protein 1transporter
DB00908QuinidineSolute carrier organic anion transporter family member 1A2transporter
DB00908QuinidineSolute carrier family 22 member 8transporter
DB00908QuinidineCanalicular multispecific organic anion transporter 1transporter
DB00908QuinidineSolute carrier family 22 member 4transporter
DB00908QuinidineSolute carrier organic anion transporter family member 1B1transporter
DB00908QuinidineCytochrome P450 2B6enzyme
DB00908QuinidineCytochrome P450 2C9enzyme
DB00908QuinidineAlpha-1A adrenergic receptortarget
DB00908QuinidineAlpha-1B adrenergic receptortarget
DB00908QuinidineAlpha-1D adrenergic receptortarget
DB00908QuinidineBile salt export pumptransporter
DB00908QuinidineCytochrome P450 2C8enzyme
DB00656Trazodone5-hydroxytryptamine receptor 2Atarget
DB00656TrazodoneSodium-dependent serotonin transportertarget
DB00656TrazodoneAlpha-1A adrenergic receptortarget
DB00656TrazodoneAlpha-2A adrenergic receptortarget
DB00656TrazodoneHistamine H1 receptortarget
DB00656Trazodone5-hydroxytryptamine receptor 1Atarget
DB00656TrazodoneCytochrome P450 2D6enzyme
DB00656TrazodoneCytochrome P450 3A4enzyme
DB00656Trazodone5-hydroxytryptamine receptor 2Ctarget
DB00656TrazodoneAlpha-1-acid glycoprotein 1carrier
DB00656TrazodoneCytochrome P450 3A5enzyme
DB00656TrazodoneCytochrome P450 3A7enzyme
DB00656TrazodoneMultidrug resistance protein 1transporter
DB00091CyclosporineCalcium signal-modulating cyclophilin ligandtarget
DB00091CyclosporinePeptidyl-prolyl cis-trans isomerase Atarget
DB00091CyclosporineCalcineurin subunit B type 2target
DB00091CyclosporineCytochrome P450 3A5enzyme
DB00091CyclosporineCytochrome P450 3A4enzyme
DB00091CyclosporineCytochrome P450 3A7enzyme
DB00091CyclosporineMultidrug resistance protein 1transporter
DB00091CyclosporineCanalicular multispecific organic anion transporter 2transporter
DB00091CyclosporineBile salt export pumptransporter
DB00091CyclosporineMultidrug resistance-associated protein 1transporter
DB00091CyclosporineSolute carrier organic anion transporter family member 1A2transporter
DB00091CyclosporineIleal sodium/bile acid cotransportertransporter
DB00091CyclosporineSodium/bile acid cotransportertransporter
DB00091CyclosporineSolute carrier family 22 member 6transporter
DB00091CyclosporineMultidrug resistance-associated protein 7transporter
DB00091CyclosporineCanalicular multispecific organic anion transporter 1transporter
DB00091CyclosporineATP-binding cassette sub-family G member 2transporter
DB00091CyclosporineSolute carrier organic anion transporter family member 1B1transporter
DB00091CyclosporineCytochrome P450 2C19enzyme
DB00091CyclosporineCytochrome P450 2C8enzyme
DB00091CyclosporineCytochrome P450 2C9enzyme
DB00091CyclosporineCytochrome P450 2D6enzyme
DB00091CyclosporinePeptidyl-prolyl cis-trans isomerase F, mitochondrialtarget
DB00661VerapamilSodium channel protein type 5 subunit alphatarget
DB00661VerapamilATP-sensitive inward rectifier potassium channel 11target
DB00661VerapamilVoltage-dependent L-type calcium channel subunit beta-4target
DB00661VerapamilVoltage-dependent T-type calcium channel subunit alpha-1Gtarget
DB00661VerapamilVoltage-dependent L-type calcium channel subunit alpha-1Ftarget
DB00661VerapamilVoltage-dependent L-type calcium channel subunit beta-3target
DB00661VerapamilVoltage-dependent L-type calcium channel subunit alpha-1Dtarget
DB00661VerapamilVoltage-dependent L-type calcium channel subunit beta-1target
DB00661VerapamilVoltage-dependent L-type calcium channel subunit beta-2target
DB00661VerapamilPotassium voltage-gated channel subfamily H member 2target
DB00661VerapamilVoltage-dependent L-type calcium channel subunit alpha-1Starget
DB00661VerapamilVoltage-dependent L-type calcium channel subunit alpha-1Ctarget
DB00661VerapamilVoltage-dependent T-type calcium channel subunit alpha-1Itarget
DB00661VerapamilCytochrome P450 1A2enzyme
DB00661VerapamilCytochrome P450 3A5enzyme
DB00661VerapamilVoltage-dependent N-type calcium channel subunit alpha-1Btarget
DB00661VerapamilVoltage-dependent P/Q-type calcium channel subunit alpha-1Atarget
DB00661VerapamilSodium-dependent serotonin transportertarget
DB00661VerapamilCytochrome P450 3A4enzyme
DB00661VerapamilCytochrome P450 3A7enzyme
DB00661VerapamilMultidrug resistance protein 1transporter
DB00661VerapamilSolute carrier family 22 member 1transporter
DB00661VerapamilCanalicular multispecific organic anion transporter 2transporter
DB00661VerapamilMultidrug resistance-associated protein 4transporter
DB00661VerapamilSolute carrier family 22 member 5transporter
DB00661VerapamilMultidrug resistance-associated protein 1transporter
DB00661VerapamilSolute carrier organic anion transporter family member 1A2transporter
DB00661VerapamilMultidrug resistance-associated protein 7transporter
DB00661VerapamilCanalicular multispecific organic anion transporter 1transporter
DB00661VerapamilSolute carrier family 22 member 4transporter
DB00661VerapamilATP-binding cassette sub-family G member 2transporter
DB00661VerapamilSolute carrier organic anion transporter family member 1B1transporter
DB00661VerapamilCytochrome P450 2C8enzyme
DB00661VerapamilCytochrome P450 2C9enzyme
DB00661VerapamilCytochrome P450 2C18enzyme
DB00661VerapamilCytochrome P450 2B6enzyme
DB00661VerapamilCytochrome P450 2C19enzyme
DB00661VerapamilCytochrome P450 2D6enzyme
DB00661VerapamilAlpha-1A adrenergic receptortarget
DB00661VerapamilAlpha-1B adrenergic receptortarget
DB00661VerapamilAlpha-1D adrenergic receptortarget
DB00661VerapamilBile salt export pumptransporter
DB00502HaloperidolD(2) dopamine receptortarget
DB00502HaloperidolGlutamate receptor ionotropic, NMDA 2Btarget
DB00502HaloperidolD(1A) dopamine receptortarget
DB00502HaloperidolCytochrome P450 1A2enzyme
DB00502HaloperidolCytochrome P450 2D6enzyme
DB00502Haloperidol5-hydroxytryptamine receptor 2Atarget
DB00502HaloperidolD(3) dopamine receptortarget
DB00502HaloperidolCytochrome P450 3A4enzyme
DB00502HaloperidolCytochrome P450 3A5enzyme
DB00502HaloperidolCytochrome P450 3A7enzyme
DB00502HaloperidolMultidrug resistance protein 1transporter
DB00502HaloperidolCarbonyl reductase [NADPH] 1enzyme
DB00502HaloperidolUDP-glucuronosyltransferase 1-9enzyme
DB00502HaloperidolCytochrome P450 1A1enzyme
DB00502HaloperidolCytochrome P450 2C19enzyme
DB00502HaloperidolCytochrome P450 2C9enzyme
DB00502HaloperidolMelanin-concentrating hormone receptor 1target
DB00502HaloperidolSynaptic vesicular amine transportertarget
DB00207Azithromycin23S rRNAtarget
DB00207Azithromycin50S ribosomal protein L22target
DB00207Azithromycin50S ribosomal protein L4target
DB00207AzithromycinMultidrug resistance protein 1transporter
DB00207AzithromycinCytochrome P450 3A4enzyme
DB00207AzithromycinProtein-arginine deiminase type-4target
DB00207AzithromycinCytochrome P450 2A6enzyme
DB01098Rosuvastatin3-hydroxy-3-methylglutaryl-coenzyme A reductasetarget
DB01098RosuvastatinCytochrome P450 2C9enzyme
DB01098RosuvastatinMultidrug resistance-associated protein 4transporter
DB01098RosuvastatinMultidrug resistance-associated protein 1transporter
DB01098RosuvastatinCytochrome P450 2C19enzyme
DB01098RosuvastatinCytochrome P450 3A4enzyme
DB01098RosuvastatinCytochrome P450 3A5enzyme
DB01098RosuvastatinSolute carrier organic anion transporter family member 1A2transporter
DB01098RosuvastatinSolute carrier organic anion transporter family member 1B3transporter
DB01098RosuvastatinSolute carrier organic anion transporter family member 2B1transporter
DB01098RosuvastatinCystine/glutamate transportertransporter
DB01098RosuvastatinSolute carrier organic anion transporter family member 1B1transporter
DB01098RosuvastatinBile salt export pumptransporter
DB01098RosuvastatinATP-binding cassette sub-family G member 2transporter
DB01098RosuvastatinSerum albumincarrier
DB01098RosuvastatinCanalicular multispecific organic anion transporter 1transporter
DB01098RosuvastatinSolute carrier family 22 member 8transporter
DB05521TelaprevirCytochrome P450 3A4enzyme
DB05521TelaprevirNS3/4A proteintarget
DB05521TelaprevirMultidrug resistance protein 1transporter
DB05521TelaprevirSerum albumincarrier
DB05521TelaprevirAlpha-1-acid glycoprotein 1carrier
DB05521TelaprevirSolute carrier organic anion transporter family member 1B1target
DB05521TelaprevirSolute carrier organic anion transporter family member 2B1target
DB05521TelaprevirCytochrome P450 3A5enzyme
DB08873BoceprevirCytochrome P450 3A4enzyme
DB08873BoceprevirCytochrome P450 3A5enzyme
DB08873BoceprevirMultidrug resistance protein 1transporter
DB08873BoceprevirNS3/4A proteintarget
DB00503RitonavirHuman immunodeficiency virus type 1 proteasetarget
DB00503RitonavirCytochrome P450 2D6enzyme
DB00503RitonavirCytochrome P450 2C9enzyme
DB00503RitonavirCytochrome P450 2C19enzyme
DB00503RitonavirCytochrome P450 2B6enzyme
DB00503RitonavirCytochrome P450 2C8enzyme
DB00503RitonavirMultidrug resistance protein 1transporter
DB00503RitonavirMultidrug resistance-associated protein 1transporter
DB00503RitonavirCanalicular multispecific organic anion transporter 1transporter
DB00503RitonavirSolute carrier organic anion transporter family member 1A2transporter
DB00503RitonavirATP-binding cassette sub-family G member 2transporter
DB00503RitonavirSolute carrier organic anion transporter family member 1B1transporter
DB00503RitonavirCytochrome P450 1A2enzyme
DB00503RitonavirCytochrome P450 2E1enzyme
DB00503RitonavirNuclear receptor subfamily 1 group I member 2target
DB00503RitonavirSerum albumincarrier
DB00503RitonavirCytochrome P450 3A4enzyme
DB00503RitonavirCytochrome P450 3A5enzyme
DB00503RitonavirCytochrome P450 3A7enzyme
DB00503RitonavirCytochrome P450 3A43enzyme
DB00503RitonavirUDP-glucuronosyltransferase 1-1enzyme
DB00503RitonavirSolute carrier organic anion transporter family member 2B1transporter
DB00503RitonavirBile salt export pumptransporter
DB01118AmiodaroneBeta-1 adrenergic receptortarget
DB01118AmiodaronePotassium voltage-gated channel subfamily H member 2target
DB01118AmiodaroneCytochrome P450 2C8enzyme
DB01118AmiodaroneCytochrome P450 2C9enzyme
DB01118AmiodaroneCytochrome P450 2D6enzyme
DB01118AmiodaroneVoltage-dependent T-type calcium channel subunit alpha-1Htarget
DB01118AmiodaroneVoltage-dependent calcium channel subunit alpha-2/delta-2target
DB01118AmiodaroneCytochrome P450 3A4enzyme
DB01118AmiodaroneCytochrome P450 1A2enzyme
DB01118AmiodaroneCytochrome P450 3A5enzyme
DB01118AmiodaroneCytochrome P450 3A7enzyme
DB01118AmiodaroneCytochrome P450 1A1enzyme
DB01118AmiodaroneMultidrug resistance protein 1transporter
DB01118AmiodaroneCytochrome P450 2C19enzyme
DB01118AmiodaroneCytochrome P450 2A6enzyme
DB01118AmiodaroneThyroid hormone receptor alphatarget
DB01118AmiodaroneThyroid hormone receptor betatarget
DB01118AmiodaronePeroxisome proliferator-activated receptor gammatarget
DB01118AmiodaroneBile salt export pumptransporter
DB11633IsavuconazoleCytochrome P450 3A4enzyme
DB11633IsavuconazoleCytochrome P450 3A5enzyme
DB11633IsavuconazoleCytochrome P450 2C8enzyme
DB11633IsavuconazoleCytochrome P450 2C9enzyme
DB11633IsavuconazoleCytochrome P450 2C19enzyme
DB11633IsavuconazoleCytochrome P450 2D6enzyme
DB11633IsavuconazoleCytochrome P450 2B6enzyme
DB11633IsavuconazoleUDP-glucuronosyltransferase 1-9enzyme
DB11633IsavuconazoleUDP-glucuronosyltransferase 1-8enzyme
DB11633IsavuconazoleMultidrug resistance protein 1transporter
DB11633IsavuconazoleATP-binding cassette sub-family G member 2transporter
DB11633IsavuconazoleSolute carrier family 22 member 2transporter
DB11633IsavuconazoleLanosterol 14-alpha demethylasetarget
DB11633IsavuconazolePotassium voltage-gated channel subfamily H member 2target
DB11633IsavuconazoleVoltage-dependent L-type calcium channel subunit alpha-1Ctarget
DB11633IsavuconazoleG protein-activated inward rectifier potassium channel 2target
DB11633IsavuconazoleG protein-activated inward rectifier potassium channel 3target
DB11633IsavuconazoleATP-sensitive inward rectifier potassium channel 11target
DB11633IsavuconazolePotassium voltage-gated channel subfamily A member 5target
DB11633IsavuconazolePotassium voltage-gated channel subfamily D member 3target
DB11633IsavuconazolePotassium voltage-gated channel subfamily KQT member 1target
DB11633IsavuconazoleSodium channel protein type 5 subunit alphatarget
DB01072AtazanavirHuman immunodeficiency virus type 1 proteasetarget
DB01072AtazanavirCytochrome P450 3A4enzyme
DB01072AtazanavirCytochrome P450 2C9enzyme
DB01072AtazanavirMultidrug resistance protein 1transporter
DB01072AtazanavirMultidrug resistance-associated protein 1transporter
DB01072AtazanavirSerum albumincarrier
DB01072AtazanavirUDP-glucuronosyltransferase 1-1enzyme
DB01072AtazanavirSolute carrier organic anion transporter family member 1B1transporter
DB01072AtazanavirSolute carrier organic anion transporter family member 1B3transporter
DB01072AtazanavirCytochrome P450 2C8enzyme
DB01072AtazanavirBile salt export pumptransporter
DB06414EtravirineCytochrome P450 2C19enzyme
DB06414EtravirineCytochrome P450 2C9enzyme
DB06414EtravirineCytochrome P450 3A4enzyme
DB06414EtravirineGag-Pol polyproteintarget
DB06414EtravirineGag-Pol polyproteintarget
DB06414EtravirineMultidrug resistance protein 1transporter
DB06414EtravirineMultidrug resistance protein 3transporter
DB00701AmprenavirHuman immunodeficiency virus type 1 proteasetarget
DB00701AmprenavirCytochrome P450 3A4enzyme
DB00701AmprenavirMultidrug resistance protein 1transporter
DB00701AmprenavirMultidrug resistance-associated protein 1transporter
DB00701AmprenavirCytochrome P450 2B6enzyme
DB00701AmprenavirCytochrome P450 2C19enzyme
DB00701AmprenavirCytochrome P450 2C8enzyme
DB00701AmprenavirCytochrome P450 2C9enzyme
DB00701AmprenavirCytochrome P450 2D6enzyme
DB00701AmprenavirCytochrome P450 3A5enzyme
DB00701AmprenavirSolute carrier organic anion transporter family member 1B1transporter
DB00220NelfinavirHIV-1 proteasetarget
DB00220NelfinavirCytochrome P450 2C19enzyme
DB00220NelfinavirCytochrome P450 3A4enzyme
DB00220NelfinavirCytochrome P450 2B6enzyme
DB00220NelfinavirCytochrome P450 3A5enzyme
DB00220NelfinavirCytochrome P450 3A7enzyme
DB00220NelfinavirMultidrug resistance protein 1transporter
DB00220NelfinavirSolute carrier family 22 member 1transporter
DB00220NelfinavirSolute carrier organic anion transporter family member 1A2transporter
DB00220NelfinavirATP-binding cassette sub-family G member 2transporter
DB00220NelfinavirSolute carrier organic anion transporter family member 1B1transporter
DB00220NelfinavirCytochrome P450 2D6enzyme
DB00220NelfinavirSerum albumincarrier
DB00220NelfinavirUDP-glucuronosyltransferase 1-1enzyme
DB00220NelfinavirSolute carrier organic anion transporter family member 1B3transporter
DB00220NelfinavirSolute carrier organic anion transporter family member 2B1transporter
DB00220NelfinavirBile salt export pumptransporter
DB01319FosamprenavirHuman immunodeficiency virus type 1 proteasetarget
DB01319FosamprenavirCytochrome P450 3A4enzyme
DB01149Nefazodone5-hydroxytryptamine receptor 2Atarget
DB01149NefazodoneSodium-dependent serotonin transportertarget
DB01149NefazodoneSodium-dependent noradrenaline transportertarget
DB01149NefazodoneAlpha-1A adrenergic receptortarget
DB01149NefazodoneAlpha-1B adrenergic receptortarget
DB01149NefazodoneCytochrome P450 3A4enzyme
DB01149NefazodoneCytochrome P450 2D6enzyme
DB01149NefazodoneSodium-dependent dopamine transportertarget
DB01149NefazodoneAlpha-2A adrenergic receptortarget
DB01149Nefazodone5-hydroxytryptamine receptor 1Atarget
DB01149NefazodoneCYP2B proteinenzyme
DB01149NefazodoneCytochrome P450 3A5enzyme
DB01149NefazodoneMultidrug resistance protein 1transporter
DB01149Nefazodone5-hydroxytryptamine receptor 2Ctarget
DB01149NefazodonePotassium voltage-gated channel subfamily H member 2target
DB01149NefazodoneCYP3Aenzyme
DB01149NefazodoneSolute carrier organic anion transporter family member 1B3transporter
DB01149NefazodoneSolute carrier organic anion transporter family member 2B1transporter
DB01149NefazodoneBile salt export pumptransporter
DB08931RiociguatSerum albumincarrier
DB08931RiociguatAlpha-1-acid glycoprotein 1carrier
DB08931RiociguatGuanylate cyclase soluble subunit alpha-2target
DB08931RiociguatATP-binding cassette sub-family G member 2transporter
DB08931RiociguatCytochrome P450 1A1enzyme
DB08931RiociguatCytochrome P450 3A4enzyme
DB08931RiociguatCytochrome P450 2C8enzyme
DB08931RiociguatCytochrome P450 2J2enzyme
DB06290SimeprevirNS3 proteasetarget
DB06290SimeprevirSerum albumincarrier
DB06290SimeprevirCytochrome P450 1A2enzyme
DB06290SimeprevirMultidrug resistance protein 1transporter
DB06290SimeprevirSolute carrier organic anion transporter family member 1B1transporter
DB06290SimeprevirSolute carrier organic anion transporter family member 1B3transporter
DB06290SimeprevirCytochrome P450 3A4enzyme
DB06290SimeprevirCanalicular multispecific organic anion transporter 1transporter
DB06290SimeprevirATP-binding cassette sub-family G member 2transporter
DB06290SimeprevirSolute carrier organic anion transporter family member 2B1transporter
DB06290SimeprevirSodium/bile acid cotransportertransporter
DB06290SimeprevirBile salt export pumptransporter
DB06287TemsirolimusSerine/threonine-protein kinase mTORtarget
DB06287TemsirolimusCytochrome P450 3A4enzyme
DB06287TemsirolimusCytochrome P450 3A5enzyme
DB06287TemsirolimusCytochrome P450 3A7enzyme
DB06287TemsirolimusCytochrome P450 2D6enzyme
DB06287TemsirolimusMultidrug resistance protein 1transporter
DB11586AsunaprevirHepatitis C virus NS3 protease/helicasetarget
DB11586AsunaprevirMultidrug resistance protein 1carrier
DB11586AsunaprevirSolute carrier organic anion transporter family member 1B1carrier
DB11586AsunaprevirSolute carrier organic anion transporter family member 2B1carrier
DB11586AsunaprevirCYP3Aenzyme
DB11586AsunaprevirCytochrome P450 3A4enzyme
DB11586AsunaprevirCytochrome P450 3A5enzyme
DB11586AsunaprevirCytochrome P450 2A6enzyme
DB11586AsunaprevirCytochrome P450 2B6enzyme
DB11586AsunaprevirCytochrome P450 2C9enzyme
DB11586AsunaprevirCytochrome P450 2C19enzyme
DB11586AsunaprevirCytochrome P450 2D6enzyme
DB11586AsunaprevirSolute carrier organic anion transporter family member 1B1transporter
DB11586AsunaprevirSolute carrier organic anion transporter family member 1B3transporter
DB11586AsunaprevirSolute carrier organic anion transporter family member 2B1transporter
DB00321AmitriptylineSodium-dependent serotonin transportertarget
DB00321AmitriptylineSodium-dependent noradrenaline transportertarget
DB00321AmitriptylinePotassium voltage-gated channel subfamily KQT member 2target
DB00321AmitriptylineAlpha-2A adrenergic receptortarget
DB00321AmitriptylineCytochrome P450 1A2enzyme
DB00321AmitriptylineCytochrome P450 2C19enzyme
DB00321AmitriptylineCytochrome P450 2D6enzyme
DB00321AmitriptylineSerum albumincarrier
DB00321AmitriptylineAlpha-1-acid glycoprotein 1carrier
DB00321AmitriptylineMuscarinic acetylcholine receptor M1target
DB00321AmitriptylineMuscarinic acetylcholine receptor M2target
DB00321AmitriptylineMuscarinic acetylcholine receptor M3target
DB00321AmitriptylineMuscarinic acetylcholine receptor M4target
DB00321AmitriptylineMuscarinic acetylcholine receptor M5target
DB00321AmitriptylineHistamine H1 receptortarget
DB00321Amitriptyline5-hydroxytryptamine receptor 2Atarget
DB00321Amitriptyline5-hydroxytryptamine receptor 1Atarget
DB00321AmitriptylineAlpha-1A adrenergic receptortarget
DB00321AmitriptylineCytochrome P450 3A4enzyme
DB00321AmitriptylineCytochrome P450 3A5enzyme
DB00321AmitriptylinePotassium voltage-gated channel subfamily A member 1target
DB00321AmitriptylinePotassium voltage-gated channel subfamily D member 2target
DB00321AmitriptylinePotassium voltage-gated channel subfamily D member 3target
DB00321AmitriptylineAlpha-1D adrenergic receptortarget
DB00321AmitriptylineDelta-type opioid receptortarget
DB00321AmitriptylineKappa-type opioid receptortarget
DB00321AmitriptylineHigh affinity nerve growth factor receptortarget
DB00321AmitriptylineBDNF/NT-3 growth factors receptortarget
DB00321AmitriptylineCytochrome P450 2C9enzyme
DB00321AmitriptylineMultidrug resistance protein 1transporter
DB00321AmitriptylineCytochrome P450 2B6enzyme
DB00321AmitriptylineCytochrome P450 2C8enzyme
DB00321AmitriptylineCytochrome P450 2E1enzyme
DB00321AmitriptylineHistamine H2 receptortarget
DB00321AmitriptylineHistamine H4 receptortarget
DB00321AmitriptylineSigma non-opioid intracellular receptor 1target
DB00321Amitriptyline5-hydroxytryptamine receptor 2Ctarget
DB00321AmitriptylineAlpha-1B adrenergic receptortarget
DB00321Amitriptyline5-hydroxytryptamine receptor 7target
DB00321Amitriptyline5-hydroxytryptamine receptor 1Dtarget
DB00321AmitriptylineMu-type opioid receptortarget
DB00321Amitriptyline5-hydroxytryptamine receptor 1Btarget
DB00321Amitriptyline5-hydroxytryptamine receptor 6target
DB00321AmitriptylinePotassium voltage-gated channel subfamily KQT member 3target
DB00321AmitriptylineBeta adrenergic receptortarget
DB00321AmitriptylineUDP-glucuronosyltransferase 1-1enzyme
DB01242ClomipramineSodium-dependent serotonin transportertarget
DB01242ClomipramineSodium-dependent noradrenaline transportertarget
DB01242ClomipramineGlutathione S-transferase Ptarget
DB01242Clomipramine5-hydroxytryptamine receptor 2Atarget
DB01242ClomipramineCytochrome P450 1A2enzyme
DB01242ClomipramineCytochrome P450 2D6enzyme
DB01242ClomipramineCytochrome P450 2C19enzyme
DB01242ClomipramineMultidrug resistance protein 1transporter
DB01242ClomipramineCytochrome P450 3A4enzyme
DB01242Clomipramine5-hydroxytryptamine receptor 2Btarget
DB01242Clomipramine5-hydroxytryptamine receptor 2Ctarget
DB01242ClomipramineSerum albumincarrier
DB00924Cyclobenzaprine5-hydroxytryptamine receptor 2Atarget
DB00924CyclobenzaprineCytochrome P450 1A2enzyme
DB00924CyclobenzaprineCytochrome P450 3A4enzyme
DB00924CyclobenzaprineCytochrome P450 2D6enzyme
DB00924CyclobenzaprineUDP-glucuronosyltransferase 1-1enzyme
DB01142DoxepinSodium-dependent serotonin transportertarget
DB01142DoxepinSodium-dependent noradrenaline transportertarget
DB01142DoxepinHistamine H1 receptortarget
DB01142DoxepinHistamine H2 receptortarget
DB01142DoxepinCytochrome P450 2D6enzyme
DB01142DoxepinMuscarinic acetylcholine receptor M1target
DB01142DoxepinMuscarinic acetylcholine receptor M2target
DB01142DoxepinMuscarinic acetylcholine receptor M3target
DB01142DoxepinMuscarinic acetylcholine receptor M4target
DB01142DoxepinMuscarinic acetylcholine receptor M5target
DB01142DoxepinAlpha-1A adrenergic receptortarget
DB01142Doxepin5-hydroxytryptamine receptor 1Atarget
DB01142Doxepin5-hydroxytryptamine receptor 2Atarget
DB01142DoxepinD(2) dopamine receptortarget
DB01142DoxepinCytochrome P450 2C19enzyme
DB01142DoxepinCytochrome P450 2C9enzyme
DB01142DoxepinCytochrome P450 1A2enzyme
DB01142DoxepinAlpha-1-acid glycoprotein 1carrier
DB01142DoxepinMultidrug resistance protein 1transporter
DB01142Doxepin5-hydroxytryptamine receptor 2Btarget
DB01142Doxepin5-hydroxytryptamine receptor 2Ctarget
DB01142DoxepinAlpha-1B adrenergic receptortarget
DB01142DoxepinAlpha-1D adrenergic receptortarget
DB01142DoxepinAlpha-2A adrenergic receptortarget
DB01142DoxepinAlpha-2B adrenergic receptortarget
DB01142DoxepinAlpha-2C adrenergic receptortarget
DB01142DoxepinCytochrome P450 3A4enzyme
DB01142Doxepin5-hydroxytryptamine receptor 6target
DB01142DoxepinHistamine H4 receptortarget
DB01142DoxepinPotassium voltage-gated channel subfamily H member 2target
DB00458ImipramineSodium-dependent noradrenaline transportertarget
DB00458ImipramineSodium-dependent serotonin transportertarget
DB00458ImipramineCytochrome P450 1A2enzyme
DB00458ImipramineCytochrome P450 2C19enzyme
DB00458ImipramineCytochrome P450 2D6enzyme
DB00458ImipramineHistamine H1 receptortarget
DB00458ImipramineAlpha-1A adrenergic receptortarget
DB00458Imipramine5-hydroxytryptamine receptor 2Atarget
DB00458ImipramineMuscarinic acetylcholine receptor M1target
DB00458ImipramineMuscarinic acetylcholine receptor M2target
DB00458ImipramineMuscarinic acetylcholine receptor M3target
DB00458ImipramineMuscarinic acetylcholine receptor M4target
DB00458ImipramineMuscarinic acetylcholine receptor M5target
DB00458ImipraminePotassium voltage-gated channel subfamily D member 2target
DB00458ImipraminePotassium voltage-gated channel subfamily D member 3target
DB00458ImipramineAlpha-1D adrenergic receptortarget
DB00458ImipramineAlpha-1-acid glycoprotein 1carrier
DB00458ImipramineSolute carrier family 22 member 2transporter
DB00458ImipramineSolute carrier family 22 member 1transporter
DB00458ImipramineSolute carrier family 22 member 3transporter
DB00458ImipramineMultidrug resistance protein 1transporter
DB00458ImipramineSolute carrier family 22 member 4transporter
DB00458ImipramineCytochrome P450 3A4enzyme
DB00458ImipramineCytochrome P450 2B6enzyme
DB00458ImipramineCytochrome P450 2C18enzyme
DB00458ImipramineCytochrome P450 2E1enzyme
DB00458ImipramineCytochrome P450 3A7enzyme
DB00458Imipramine5-hydroxytryptamine receptor 2Ctarget
DB00458ImipramineAlpha-1B adrenergic receptortarget
DB00458Imipramine5-hydroxytryptamine receptor 7target
DB00458ImipramineD(1) dopamine receptortarget
DB00458ImipramineD(2) dopamine receptortarget
DB00458ImipraminePotassium voltage-gated channel subfamily H member 2target
DB00458ImipramineSodium-dependent dopamine transportertarget
DB00458Imipramine5-hydroxytryptamine receptor 1Atarget
DB00458Imipramine5-hydroxytryptamine receptor 6target
DB00458ImipraminePotassium voltage-gated channel subfamily H member 1target
DB00458ImipramineSerum albumincarrier
DB00458ImipramineAlpha-1-acid glycoprotein 2target
DB00540NortriptylineSodium-dependent serotonin transportertarget
DB00540NortriptylineSodium-dependent noradrenaline transportertarget
DB00540NortriptylineCytochrome P450 1A2enzyme
DB00540NortriptylineCytochrome P450 2D6enzyme
DB00540NortriptylineSerum albumincarrier
DB00540NortriptylineAlpha-1-acid glycoprotein 1carrier
DB00540NortriptylineHistamine H1 receptortarget
DB00540NortriptylineMuscarinic acetylcholine receptor M1target
DB00540NortriptylineMuscarinic acetylcholine receptor M2target
DB00540NortriptylineMuscarinic acetylcholine receptor M3target
DB00540NortriptylineMuscarinic acetylcholine receptor M4target
DB00540NortriptylineMuscarinic acetylcholine receptor M5target
DB00540Nortriptyline5-hydroxytryptamine receptor 2Atarget
DB00540NortriptylineAlpha-1A adrenergic receptortarget
DB00540Nortriptyline5-hydroxytryptamine receptor 1Atarget
DB00540NortriptylineCytochrome P450 3A4enzyme
DB00540NortriptylineCytochrome P450 3A5enzyme
DB00540NortriptylineAlpha-1D adrenergic receptortarget
DB00540NortriptylineCytochrome P450 2C19enzyme
DB00540NortriptylineProstaglandin G/H synthase 1enzyme
DB00540NortriptylineCytochrome P450 2E1enzyme
DB00540Nortriptyline5-hydroxytryptamine receptor 2Ctarget
DB00540Nortriptyline5-hydroxytryptamine receptor 6target
DB00540NortriptylineAlpha-1B adrenergic receptortarget
DB00540NortriptylineAlpha-2 adrenergic receptorstarget
DB00540NortriptylineBeta adrenergic receptortarget
DB00540NortriptylineD(2) dopamine receptortarget
DB00540NortriptylineSigma receptortarget
DB00540Nortriptyline5-hydroxytryptamine receptor 1Ctarget
DB09289TianeptineGlutamate receptor 1target
DB09289TianeptineMu-type opioid receptortarget
DB09289Tianeptine5-hydroxytryptamine receptor 1Atarget
DB09289TianeptineD(3) dopamine receptortarget
DB09289TianeptineCytochrome P450 3A4enzyme
DB00726TrimipramineSodium-dependent serotonin transportertarget
DB00726TrimipramineSodium-dependent noradrenaline transportertarget
DB00726TrimipramineCytochrome P450 2D6enzyme
DB00726TrimipramineSodium-dependent dopamine transportertarget
DB00726Trimipramine5-hydroxytryptamine receptor 2Atarget
DB00726Trimipramine5-hydroxytryptamine receptor 1Atarget
DB00726TrimipramineAlpha-1A adrenergic receptortarget
DB00726TrimipramineAlpha-1B adrenergic receptortarget
DB00726TrimipramineD(2) dopamine receptortarget
DB00726TrimipramineAlpha-2B adrenergic receptortarget
DB00726TrimipramineHistamine H1 receptortarget
DB00726TrimipramineCytochrome P450 2C19enzyme
DB00726TrimipramineCytochrome P450 3A4enzyme
DB00726TrimipramineMultidrug resistance protein 1transporter
DB00726TrimipramineCytochrome P450 2C9enzyme
DB00726Trimipramine5-hydroxytryptamine receptor 2Ctarget
DB00726Trimipramine5-hydroxytryptamine receptor 3Atarget
DB00726Trimipramine5-hydroxytryptamine receptor 1Dtarget
DB00726TrimipramineAlpha-2A adrenergic receptortarget
DB00726TrimipramineD(1) dopamine receptortarget
DB00726TrimipramineBeta adrenergic receptortarget
DB00726TrimipramineMuscarinic acetylcholine receptortarget
DB00726Trimipramine5-hydroxytryptamine receptor 1Ctarget
DB00783EstradiolEstrogen receptor alphatarget
DB00783EstradiolNuclear receptor subfamily 1 group I member 2target
DB00783EstradiolSex hormone-binding globulincarrier
DB00783EstradiolEstrogen receptor betatarget
DB00783EstradiolCytochrome P450 1A2enzyme
DB00783EstradiolUDP-glucuronosyltransferase 1-1enzyme
DB00783EstradiolSerum albumincarrier
DB00783EstradiolFatty acid-binding protein, intestinalcarrier
DB00783EstradiolCytochrome P450 3A4enzyme
DB00783EstradiolCytochrome P450 3A5enzyme
DB00783EstradiolCytochrome P450 3A7enzyme
DB00783EstradiolSolute carrier family 22 member 2transporter
DB00783EstradiolSolute carrier family 22 member 1transporter
DB00783EstradiolSolute carrier family 22 member 3transporter
DB00783EstradiolSolute carrier organic anion transporter family member 2B1transporter
DB00783EstradiolSolute carrier organic anion transporter family member 1A2transporter
DB00783EstradiolMultidrug resistance-associated protein 7transporter
DB00783EstradiolSolute carrier family 22 member 11transporter
DB00783EstradiolATP-binding cassette sub-family G member 2transporter
DB00783EstradiolSolute carrier organic anion transporter family member 1B1transporter
DB00783EstradiolMultidrug resistance protein 1transporter
DB00783EstradiolCytochrome P450 1A1enzyme
DB00783EstradiolCytochrome P450 1B1enzyme
DB00783EstradiolCytochrome P450 2C19enzyme
DB00783EstradiolCytochrome P450 2C8enzyme
DB00783EstradiolCytochrome P450 2C9enzyme
DB00783EstradiolSolute carrier family 22 member 8transporter
DB00783EstradiolSolute carrier organic anion transporter family member 1B3transporter
DB00783EstradiolSolute carrier organic anion transporter family member 1C1transporter
DB00783EstradiolSolute carrier organic anion transporter family member 4A1transporter
DB00783EstradiolNeuronal acetylcholine receptor subunit alpha-4target
DB00783EstradiolNuclear receptor coactivator 2target
DB00783EstradiolG-protein coupled estrogen receptor 1target
DB00783EstradiolATP synthase subunit atarget
DB00783EstradiolBeclin-1target
DB00783EstradiolEstradiol 17-beta-dehydrogenase 2target
DB00783EstradiolEstrogen-related receptor gammatarget
DB13954Estradiol cypionateEstrogen receptor alphatarget
DB13954Estradiol cypionateNuclear receptor subfamily 1 group I member 2target
DB13954Estradiol cypionateSex hormone-binding globulincarrier
DB13954Estradiol cypionateEstrogen receptor betatarget
DB13954Estradiol cypionateCytochrome P450 1A2enzyme
DB13954Estradiol cypionateUDP-glucuronosyltransferase 1-1enzyme
DB13954Estradiol cypionateSerum albumincarrier
DB13954Estradiol cypionateFatty acid-binding protein, intestinalcarrier
DB13954Estradiol cypionateCytochrome P450 3A4enzyme
DB13954Estradiol cypionateCytochrome P450 3A5enzyme
DB13954Estradiol cypionateCytochrome P450 3A7enzyme
DB13954Estradiol cypionateSolute carrier family 22 member 2transporter
DB13954Estradiol cypionateSolute carrier family 22 member 1transporter
DB13954Estradiol cypionateSolute carrier family 22 member 3transporter
DB13954Estradiol cypionateSolute carrier organic anion transporter family member 2B1transporter
DB13954Estradiol cypionateSolute carrier organic anion transporter family member 1A2transporter
DB13954Estradiol cypionateMultidrug resistance-associated protein 7transporter
DB13954Estradiol cypionateSolute carrier family 22 member 11transporter
DB13954Estradiol cypionateATP-binding cassette sub-family G member 2transporter
DB13954Estradiol cypionateSolute carrier organic anion transporter family member 1B1transporter
DB13954Estradiol cypionateMultidrug resistance protein 1transporter
DB13954Estradiol cypionateCytochrome P450 1A1enzyme
DB13954Estradiol cypionateCytochrome P450 1B1enzyme
DB13954Estradiol cypionateCytochrome P450 2C19enzyme
DB13954Estradiol cypionateCytochrome P450 2C8enzyme
DB13954Estradiol cypionateCytochrome P450 2C9enzyme
DB13954Estradiol cypionateSolute carrier family 22 member 8transporter
DB13954Estradiol cypionateSolute carrier organic anion transporter family member 1B3transporter
DB13954Estradiol cypionateSolute carrier organic anion transporter family member 1C1transporter
DB13954Estradiol cypionateSolute carrier organic anion transporter family member 4A1transporter
DB13954Estradiol cypionateNeuronal acetylcholine receptor subunit alpha-4target
DB13954Estradiol cypionateNuclear receptor coactivator 2target
DB13954Estradiol cypionateG-protein coupled estrogen receptor 1target
DB13954Estradiol cypionateATP synthase subunit atarget
DB13954Estradiol cypionateBeclin-1target
DB13954Estradiol cypionateEstradiol 17-beta-dehydrogenase 2target
DB13954Estradiol cypionateEstrogen-related receptor gammatarget
DB13956Estradiol valerateEstrogen receptor alphatarget
DB13956Estradiol valerateNuclear receptor subfamily 1 group I member 2target
DB13956Estradiol valerateSex hormone-binding globulincarrier
DB13956Estradiol valerateEstrogen receptor betatarget
DB13956Estradiol valerateCytochrome P450 1A2enzyme
DB13956Estradiol valerateUDP-glucuronosyltransferase 1-1enzyme
DB13956Estradiol valerateSerum albumincarrier
DB13956Estradiol valerateFatty acid-binding protein, intestinalcarrier
DB13956Estradiol valerateCytochrome P450 3A4enzyme
DB13956Estradiol valerateCytochrome P450 3A5enzyme
DB13956Estradiol valerateCytochrome P450 3A7enzyme
DB13956Estradiol valerateSolute carrier family 22 member 2transporter
DB13956Estradiol valerateSolute carrier family 22 member 1transporter
DB13956Estradiol valerateSolute carrier family 22 member 3transporter
DB13956Estradiol valerateSolute carrier organic anion transporter family member 2B1transporter
DB13956Estradiol valerateSolute carrier organic anion transporter family member 1A2transporter
DB13956Estradiol valerateMultidrug resistance-associated protein 7transporter
DB13956Estradiol valerateSolute carrier family 22 member 11transporter
DB13956Estradiol valerateATP-binding cassette sub-family G member 2transporter
DB13956Estradiol valerateSolute carrier organic anion transporter family member 1B1transporter
DB13956Estradiol valerateMultidrug resistance protein 1transporter
DB13956Estradiol valerateCytochrome P450 1A1enzyme
DB13956Estradiol valerateCytochrome P450 1B1enzyme
DB13956Estradiol valerateCytochrome P450 2C19enzyme
DB13956Estradiol valerateCytochrome P450 2C8enzyme
DB13956Estradiol valerateCytochrome P450 2C9enzyme
DB13956Estradiol valerateSolute carrier family 22 member 8transporter
DB13956Estradiol valerateSolute carrier organic anion transporter family member 1B3transporter
DB13956Estradiol valerateSolute carrier organic anion transporter family member 1C1transporter
DB13956Estradiol valerateSolute carrier organic anion transporter family member 4A1transporter
DB13956Estradiol valerateNeuronal acetylcholine receptor subunit alpha-4target
DB13956Estradiol valerateNuclear receptor coactivator 2target
DB13956Estradiol valerateG-protein coupled estrogen receptor 1target
DB13956Estradiol valerateATP synthase subunit atarget
DB13956Estradiol valerateBeclin-1target
DB13956Estradiol valerateEstradiol 17-beta-dehydrogenase 2target
DB13956Estradiol valerateEstrogen-related receptor gammatarget
DB00977EthinylestradiolEstrogen receptor alphatarget
DB00977EthinylestradiolNuclear receptor subfamily 1 group I member 2target
DB00977EthinylestradiolCytochrome P450 3A4enzyme
DB00977EthinylestradiolCytochrome P450 2C8enzyme
DB00977EthinylestradiolBile salt export pumptransporter
DB00977EthinylestradiolSodium/bile acid cotransportertransporter
DB00977EthinylestradiolCanalicular multispecific organic anion transporter 1transporter
DB00977EthinylestradiolMultidrug resistance protein 1transporter
DB00977EthinylestradiolSex hormone-binding globulintarget
DB00977EthinylestradiolUDP-glucuronosyltransferase 1-1enzyme
DB01357MestranolEstrogen receptor alphatarget
DB01357MestranolCytochrome P450 2C9enzyme
DB01357MestranolCytochrome P450 3A4enzyme
DB01357MestranolCytochrome P450 2C8enzyme
DB01223AminophyllinecGMP-inhibited 3',5'-cyclic phosphodiesterase Atarget
DB01223AminophyllineAdenosine receptor A3target
DB01223AminophyllineAdenosine receptor A1target
DB01223AminophyllineCytochrome P450 1A2enzyme
DB01223AminophyllineCytochrome P450 2E1enzyme
DB01223AminophyllineCytochrome P450 3A4enzyme
DB01223AminophyllineHistone deacetylase 2target
DB01223AminophyllineCytochrome P450 2C19enzyme
DB00277TheophyllinecGMP-inhibited 3',5'-cyclic phosphodiesterase Atarget
DB00277TheophyllinecAMP-specific 3',5'-cyclic phosphodiesterase 4Btarget
DB00277TheophyllineAdenosine receptor A2btarget
DB00277TheophyllinecAMP-specific 3',5'-cyclic phosphodiesterase 4Atarget
DB00277TheophyllinecGMP-specific 3',5'-cyclic phosphodiesterasetarget
DB00277TheophyllineAdenosine receptor A1target
DB00277TheophyllineAdenosine receptor A2atarget
DB00277TheophyllineCytochrome P450 1A2enzyme
DB00277TheophyllineAdenosine deaminaseenzyme
DB00277TheophyllineCytochrome P450 2E1enzyme
DB00277TheophyllineCytochrome P450 3A4enzyme
DB00277TheophyllineSolute carrier family 22 member 7transporter
DB00277TheophyllineCytochrome P450 1A1enzyme
DB00277TheophyllineCytochrome P450 1B1enzyme
DB00277TheophyllineCytochrome P450 2C8enzyme
DB00277TheophyllineCytochrome P450 2D6enzyme
DB00277TheophyllineHistone deacetylase 2target
DB00277TheophyllineCopine-1target
DB00277TheophyllineMinor histocompatibility antigen H13target
DB00277TheophyllineNodal modulator 1target
DB00277TheophyllinePoly [ADP-ribose] polymerase 1target
DB00277TheophyllineProtein RIC-3target
DB00277TheophyllineTubulin monoglycylase TTLL3target
DB01200BromocriptineD(2) dopamine receptortarget
DB01200BromocriptineCytochrome P450 3A4enzyme
DB01200Bromocriptine5-hydroxytryptamine receptor 1Dtarget
DB01200BromocriptineAlpha-2A adrenergic receptortarget
DB01200BromocriptineD(3) dopamine receptortarget
DB01200Bromocriptine5-hydroxytryptamine receptor 1Atarget
DB01200BromocriptineAlpha-2C adrenergic receptortarget
DB01200BromocriptineAlpha-2B adrenergic receptortarget
DB01200Bromocriptine5-hydroxytryptamine receptor 2Btarget
DB01200BromocriptineD(4) dopamine receptortarget
DB01200Bromocriptine5-hydroxytryptamine receptor 2Atarget
DB01200Bromocriptine5-hydroxytryptamine receptor 1Btarget
DB01200Bromocriptine5-hydroxytryptamine receptor 2Ctarget
DB01200BromocriptineD(1B) dopamine receptortarget
DB01200BromocriptineD(1A) dopamine receptortarget
DB01200BromocriptineAlpha-1A adrenergic receptortarget
DB01200BromocriptineAlpha-1B adrenergic receptortarget
DB01200BromocriptineAlpha-1D adrenergic receptortarget
DB01200Bromocriptine5-hydroxytryptamine receptor 7target
DB01200BromocriptineMultidrug resistance protein 1transporter
DB00248CabergolineD(2) dopamine receptortarget
DB00248Cabergoline5-hydroxytryptamine receptor 2Btarget
DB00248CabergolineD(3) dopamine receptortarget
DB00248Cabergoline5-hydroxytryptamine receptor 2Atarget
DB00248CabergolineAlpha-2B adrenergic receptortarget
DB00248Cabergoline5-hydroxytryptamine receptor 1Dtarget
DB00248CabergolineD(4) dopamine receptortarget
DB00248CabergolineAlpha-2A adrenergic receptortarget
DB00248Cabergoline5-hydroxytryptamine receptor 1Atarget
DB00248CabergolineAlpha-2C adrenergic receptortarget
DB00248CabergolineD(1B) dopamine receptortarget
DB00248CabergolineD(1A) dopamine receptortarget
DB00248Cabergoline5-hydroxytryptamine receptor 1Btarget
DB00248Cabergoline5-hydroxytryptamine receptor 2Ctarget
DB00248CabergolineCytochrome P450 3A4enzyme
DB00248Cabergoline5-hydroxytryptamine receptor 7target
DB00248CabergolineAlpha-1A adrenergic receptortarget
DB00248CabergolineAlpha-1B adrenergic receptortarget
DB00248CabergolineAlpha-1D adrenergic receptortarget
DB00248CabergolineBeta-1 adrenergic receptortarget
DB00248CabergolineBeta-2 adrenergic receptortarget
DB00248CabergolineD(1) dopamine receptortarget
DB00248CabergolineD(2S) dopamine receptortarget
DB00248CabergolineD(2L) dopamine receptortarget
DB00320Dihydroergotamine5-hydroxytryptamine receptor 1Dtarget
DB00320Dihydroergotamine5-hydroxytryptamine receptor 1Btarget
DB00320DihydroergotamineCytochrome P450 3A4enzyme
DB00320DihydroergotamineAlpha-2A adrenergic receptortarget
DB00320Dihydroergotamine5-hydroxytryptamine receptor 2Btarget
DB00320DihydroergotamineMultidrug resistance protein 1transporter
DB01049Ergoloid mesylateDopamine receptortarget
DB01049Ergoloid mesylateAlpha adrenergic receptortarget
DB01049Ergoloid mesylateBeta adrenergic receptortarget
DB01049Ergoloid mesylateSerotonin Receptorstarget
DB01049Ergoloid mesylateCytochrome P450 3A4enzyme
DB01253ErgonovineCytochrome P450 3A4enzyme
DB01253ErgonovineMultidrug resistance protein 1transporter
DB01253ErgonovineAlpha-1A adrenergic receptortarget
DB00696ErgotamineAlpha-1A adrenergic receptortarget
DB00696Ergotamine5-hydroxytryptamine receptor 1Dtarget
DB00696Ergotamine5-hydroxytryptamine receptor 1Btarget
DB00696Ergotamine5-hydroxytryptamine receptor 2Atarget
DB00696ErgotamineAlpha-2A adrenergic receptortarget
DB00696ErgotamineD(2) dopamine receptortarget
DB00696ErgotamineAlpha-2B adrenergic receptortarget
DB00696ErgotamineSodium-dependent noradrenaline transportertarget
DB00696ErgotamineCytochrome P450 3A4enzyme
DB00696ErgotamineAlpha-1B adrenergic receptortarget
DB00696ErgotamineAlpha-1D adrenergic receptortarget
DB00696ErgotamineMultidrug resistance protein 1transporter
DB00696ErgotamineD(1) dopamine receptortarget
DB00696Ergotamine5-hydroxytryptamine receptor 1Atarget
DB00696Ergotamine5-hydroxytryptamine receptor 1Ftarget
DB00696Ergotamine5-hydroxytryptamine receptor 2Ctarget
DB00696Ergotamine5-hydroxytryptamine receptor 2Btarget
DB00589LisurideD(1A) dopamine receptortarget
DB00589Lisuride5-hydroxytryptamine receptor 1Atarget
DB00589LisurideD(2) dopamine receptortarget
DB00589LisurideAlpha-2A adrenergic receptortarget
DB00589LisurideAlpha-2B adrenergic receptortarget
DB00589LisurideAlpha-2C adrenergic receptortarget
DB00589LisurideD(3) dopamine receptortarget
DB00589Lisuride5-hydroxytryptamine receptor 1Dtarget
DB00589Lisuride5-hydroxytryptamine receptor 2Btarget
DB00589Lisuride5-hydroxytryptamine receptor 2Atarget
DB00589LisurideD(4) dopamine receptortarget
DB00589Lisuride5-hydroxytryptamine receptor 2Ctarget
DB00589LisurideD(1B) dopamine receptortarget
DB00589Lisuride5-hydroxytryptamine receptor 1Btarget
DB00589LisurideCytochrome P450 2D6enzyme
DB00589LisurideCytochrome P450 3A4enzyme
DB00589Lisuride5-hydroxytryptamine receptor 7target
DB04829Lysergic Acid Diethylamide5-hydroxytryptamine receptor 1Atarget
DB04829Lysergic Acid Diethylamide5-hydroxytryptamine receptor 2Btarget
DB04829Lysergic Acid Diethylamide5-hydroxytryptamine receptor 6target
DB04829Lysergic Acid DiethylamideCytochrome P450 3A4enzyme
DB04829Lysergic Acid DiethylamideCytochrome P450 2D6enzyme
DB00353MethylergometrineD(1A) dopamine receptortarget
DB00353MethylergometrineCytochrome P450 3A4enzyme
DB00353Methylergometrine5-hydroxytryptamine receptor 2Btarget
DB01186PergolideD(2) dopamine receptortarget
DB01186PergolideD(1A) dopamine receptortarget
DB01186PergolideD(3) dopamine receptortarget
DB01186Pergolide5-hydroxytryptamine receptor 1Atarget
DB01186PergolideAlpha-1A adrenergic receptortarget
DB01186PergolideAlpha-2A adrenergic receptortarget
DB01186PergolideAlpha-2B adrenergic receptortarget
DB01186PergolideAlpha-2C adrenergic receptortarget
DB01186PergolideAlpha-1B adrenergic receptortarget
DB01186PergolideAlpha-1D adrenergic receptortarget
DB01186PergolideD(4) dopamine receptortarget
DB01186PergolideD(1B) dopamine receptortarget
DB01186Pergolide5-hydroxytryptamine receptor 1Btarget
DB01186Pergolide5-hydroxytryptamine receptor 1Dtarget
DB01186Pergolide5-hydroxytryptamine receptor 2Atarget
DB01186Pergolide5-hydroxytryptamine receptor 2Btarget
DB01186Pergolide5-hydroxytryptamine receptor 2Ctarget
DB01186PergolideCytochrome P450 2D6enzyme
DB01186PergolideCytochrome P450 3A4enzyme
DB00620TriamcinoloneCorticosteroid-binding globulincarrier
DB00620TriamcinoloneGlucocorticoid receptortarget
DB00620TriamcinoloneCytochrome P450 3A4enzyme
DB00620TriamcinoloneProstaglandin G/H synthase 2enzyme
DB00620TriamcinoloneCholinesteraseenzyme
DB00582VoriconazoleCytochrome P450 2C19enzyme
DB00582VoriconazoleCytochrome P450 3A4enzyme
DB00582VoriconazoleCytochrome P450 2C9enzyme
DB00582VoriconazoleDimethylaniline monooxygenase [N-oxide-forming] 1enzyme
DB00582VoriconazoleDimethylaniline monooxygenase [N-oxide-forming] 3enzyme
DB00582VoriconazoleCytochrome P450 3A5enzyme
DB00582VoriconazoleCytochrome P450 3A7enzyme
DB00582VoriconazoleProstaglandin G/H synthase 1enzyme
DB00582VoriconazoleLanosterol 14-alpha demethylasetarget
DB00582VoriconazoleCytochrome P450 2B6enzyme
DB00736EsomeprazolePotassium-transporting ATPase alpha chain 1target
DB00736EsomeprazoleCytochrome P450 2C19enzyme
DB00736EsomeprazoleCytochrome P450 3A4enzyme
DB00338OmeprazolePotassium-transporting ATPase alpha chain 1target
DB00338OmeprazoleCytochrome P450 2C19enzyme
DB00338OmeprazoleCytochrome P450 3A4enzyme
DB00338OmeprazoleCytochrome P450 2C9enzyme
DB00338OmeprazoleCytochrome P450 1A2enzyme
DB00338OmeprazoleCanalicular multispecific organic anion transporter 2transporter
DB00338OmeprazoleMultidrug resistance protein 1transporter
DB00338OmeprazoleATP-binding cassette sub-family G member 2transporter
DB00338OmeprazoleCholesterol side-chain cleavage enzyme, mitochondrialenzyme
DB00338OmeprazoleCytochrome P450 1A1enzyme
DB00338OmeprazoleCytochrome P450 1B1enzyme
DB00338OmeprazoleCytochrome P450 2C18enzyme
DB00338OmeprazoleCytochrome P450 2C8enzyme
DB00338OmeprazoleCytochrome P450 2D6enzyme
DB00338OmeprazoleAryl hydrocarbon receptortarget
DB01182PropafenoneSodium channel protein type 5 subunit alphatarget
DB01182PropafenonePotassium voltage-gated channel subfamily H member 2target
DB01182PropafenoneCytochrome P450 1A2enzyme
DB01182PropafenoneCytochrome P450 2D6enzyme
DB01182PropafenoneCytochrome P450 2C8enzyme
DB01182PropafenoneCytochrome P450 3A4enzyme
DB01182PropafenoneMultidrug resistance protein 1transporter
DB01182PropafenoneBeta-1 adrenergic receptortarget
DB01182PropafenoneBeta-2 adrenergic receptortarget
DB08496(R)-warfarinSerum albumincarrier
DB08496(R)-warfarinCytochrome P450 2C8enzyme
DB08496(R)-warfarinCytochrome P450 2C9enzyme
DB08496(R)-warfarinCytochrome P450 2C18enzyme
DB08496(R)-warfarinCytochrome P450 2C19enzyme
DB08496(R)-warfarinCytochrome P450 1A2enzyme
DB08496(R)-warfarinCytochrome P450 1A1enzyme
DB08496(R)-warfarinCytochrome P450 3A4enzyme
DB00946PhenprocoumonVitamin K epoxide reductase complex subunit 1target
DB00946PhenprocoumonAlpha-1-acid glycoprotein 1carrier
DB00946PhenprocoumonSerum albumincarrier
DB00946PhenprocoumonCytochrome P450 2C9enzyme
DB00946PhenprocoumonCytochrome P450 3A4enzyme
DB00946PhenprocoumonCytochrome P450 2C8enzyme
DB00444TeniposideDNA topoisomerase 2-alphatarget
DB00444TeniposideCytochrome P450 2C19enzyme
DB00444TeniposideCytochrome P450 2C9enzyme
DB00444TeniposideCytochrome P450 3A4enzyme
DB00444TeniposideMultidrug resistance-associated protein 6transporter
DB00444TeniposideATP-binding cassette sub-family G member 2transporter
DB00444TeniposideCytochrome P450 3A5enzyme
DB00932TipranavirHuman immunodeficiency virus type 1 proteasetarget
DB00932TipranavirCytochrome P450 3A4enzyme
DB00932TipranavirCytochrome P450 2D6enzyme
DB00932TipranavirCytochrome P450 2C19enzyme
DB00932TipranavirBile salt export pumptransporter
DB00932TipranavirUDP-glucuronosyltransferase 1-1enzyme
DB00932TipranavirSolute carrier organic anion transporter family member 2B1transporter
DB00932TipranavirSolute carrier organic anion transporter family member 1B1transporter
DB00932TipranavirSolute carrier organic anion transporter family member 1B3transporter
DB08867UlipristalProgesterone receptortarget
DB08867UlipristalGlucocorticoid receptortarget
DB08867UlipristalAndrogen receptortarget
DB08867UlipristalCytochrome P450 3A4enzyme
DB08867UlipristalCytochrome P450 1A2enzyme
DB08867UlipristalSerum albumincarrier
DB08867UlipristalAlpha-1-acid glycoprotein 1carrier
DB00280DisopyramideSodium channel protein type 5 subunit alphatarget
DB00280DisopyramideAlpha-1-acid glycoprotein 1carrier
DB00280DisopyramideCytochrome P450 3A4enzyme
DB00280DisopyramideMuscarinic acetylcholine receptor M1target
DB00280DisopyramideMuscarinic acetylcholine receptor M2target
DB00280DisopyramideMuscarinic acetylcholine receptor M3target
DB00280DisopyramidePotassium voltage-gated channel subfamily D member 2target
DB00280DisopyramidePotassium voltage-gated channel subfamily D member 3target
DB00280DisopyramideSolute carrier family 22 member 2transporter
DB00280DisopyramideSolute carrier family 22 member 1transporter
DB00280DisopyramidePotassium voltage-gated channel subfamily H member 2target
DB00280DisopyramideAlpha-1-acid glycoprotein 2target
DB00280DisopyramideCytochrome P450 1A2enzyme
DB00333MethadoneGlutamate receptor ionotropic, NMDA 3Atarget
DB00333MethadoneMu-type opioid receptortarget
DB00333MethadoneNeuronal acetylcholine receptor subunit alpha-10target
DB00333MethadoneCytochrome P450 2B6enzyme
DB00333MethadoneCytochrome P450 3A4enzyme
DB00333MethadoneCytochrome P450 2C19enzyme
DB00333MethadoneDelta-type opioid receptortarget
DB00333MethadoneCytochrome P450 3A5enzyme
DB00333MethadoneCytochrome P450 3A7enzyme
DB00333MethadoneCytochrome P450 2D6enzyme
DB00333MethadoneMultidrug resistance protein 1transporter
DB00333MethadoneCytochrome P450 2C8enzyme
DB00333MethadoneCytochrome P450 19A1enzyme
DB00333MethadoneCytochrome P450 1A2enzyme
DB00333MethadoneCytochrome P450 2C18enzyme
DB00333MethadoneCytochrome P450 2C9enzyme
DB00333Methadone5-hydroxytryptamine receptor 3Atarget
DB00333MethadoneLymphocyte antigen 96target
DB00333MethadoneAlpha-1-acid glycoprotein 2target
DB00346AlfuzosinAlpha-1A adrenergic receptortarget
DB00346AlfuzosinAlpha-1B adrenergic receptortarget
DB00346AlfuzosinAlpha-1D adrenergic receptortarget
DB00346AlfuzosinCytochrome P450 3A4enzyme
DB00346AlfuzosinPotassium voltage-gated channel subfamily H member 2target
DB00921BuprenorphineKappa-type opioid receptortarget
DB00921BuprenorphineMu-type opioid receptortarget
DB00921BuprenorphineCytochrome P450 3A4enzyme
DB00921BuprenorphineCytochrome P450 2D6enzyme
DB00921BuprenorphineMultidrug resistance protein 1transporter
DB00921BuprenorphineATP-binding cassette sub-family G member 2transporter
DB00921BuprenorphineCytochrome P450 2C9enzyme
DB00921BuprenorphineCytochrome P450 3A5enzyme
DB00921BuprenorphineCytochrome P450 2C8enzyme
DB00921BuprenorphineCytochrome P450 3A7enzyme
DB00921BuprenorphineUDP-glucuronosyltransferase 1-9enzyme
DB00921BuprenorphineDelta-type opioid receptortarget
DB00921BuprenorphineCytochrome P450 2A6enzyme
DB00921BuprenorphineCytochrome P450 2C18enzyme
DB00921BuprenorphineCytochrome P450 2C19enzyme
DB00921BuprenorphineNociceptin receptortarget
DB00921BuprenorphineUDP-glucuronosyltransferase 1-1enzyme
DB06237AvanafilcGMP-specific 3',5'-cyclic phosphodiesterasetarget
DB06237AvanafilCytochrome P450 3A4enzyme
DB12010FostamatinibAdenosine receptor A3target
DB12010Fostamatinibvesicular monoamine transporter 2 (VMAT2)target
DB12010FostamatinibFatty-acid amide hydrolase 1target
DB12010FostamatinibEquilibrative nucleoside transporter 1target
DB12010FostamatinibUDP-glucuronosyltransferase 1-1target
DB12010FostamatinibcGMP-specific 3',5'-cyclic phosphodiesterasetarget
DB12010FostamatinibArachidonate 5-lipoxygenasetarget
DB12010FostamatinibCathepsin Starget
DB12010FostamatinibCathepsin L1target
DB12010FostamatinibTyrosine-protein kinase ABL1target
DB12010FostamatinibCalcium-dependent protein kinase 1target
DB12010FostamatinibSerine/threonine-protein kinase PknBtarget
DB12010FostamatinibRibosomal protein S6 kinase alpha-6target
DB12010FostamatinibNon-receptor tyrosine-protein kinase TYK2target
DB12010FostamatinibAtypical kinase COQ8A, mitochondrialtarget
DB12010FostamatinibTyrosine-protein kinase JAK1target
DB12010FostamatinibHepatocyte growth factor receptortarget
DB12010FostamatinibSerine/threonine-protein kinase NIM1target
DB12010FostamatinibSerine/threonine-protein kinase MST4target
DB12010FostamatinibcAMP-dependent protein kinase catalytic subunit alphatarget
DB12010FostamatinibSerine/threonine-protein kinase 24target
DB12010FostamatinibSerine/threonine-protein kinase 3target
DB12010FostamatinibTyrosine-protein kinase Tectarget
DB12010FostamatinibTyrosine-protein kinase SYKtarget
DB12010FostamatinibSerine/threonine-protein kinase 33target
DB12010FostamatinibSerine/threonine-protein kinase 35target
DB12010FostamatinibSerine/threonine-protein kinase 36target
DB12010FostamatinibSerine/threonine-protein kinase 38target
DB12010FostamatinibSerine/threonine-protein kinase 38-liketarget
DB12010FostamatinibSTE20/SPS1-related proline-alanine-rich protein kinasetarget
DB12010FostamatinibSerine/threonine-protein kinase TAO1target
DB12010FostamatinibSerine/threonine-protein kinase TAO2target
DB12010FostamatinibSerine/threonine-protein kinase TAO3target
DB12010FostamatinibSerine/threonine-protein kinase TBK1target
DB12010FostamatinibAngiopoietin-1 receptortarget
DB12010FostamatinibDual specificity testis-specific protein kinase 1target
DB12010FostamatinibTGF-beta receptor type-1target
DB12010FostamatinibTGF-beta receptor type-2target
DB12010FostamatinibTyrosine-protein kinase receptor Tie-1target
DB12010FostamatinibSerine/threonine-protein kinase tousled-like 1target
DB12010FostamatinibSerine/threonine-protein kinase tousled-like 2target
DB12010FostamatinibTRAF2 and NCK-interacting protein kinasetarget
DB12010FostamatinibNon-receptor tyrosine-protein kinase TNK1target
DB12010FostamatinibActivated CDC42 kinase 1target
DB12010FostamatinibSerine/threonine-protein kinase TNNI3Ktarget
DB12010FostamatinibTestis-specific serine/threonine-protein kinase 1target
DB12010FostamatinibDual specificity protein kinase TTKtarget
DB12010FostamatinibTyrosine-protein kinase TXKtarget
DB12010FostamatinibTyrosine-protein kinase receptor TYRO3target
DB12010FostamatinibSerine/threonine-protein kinase ULK1target
DB12010FostamatinibSerine/threonine-protein kinase ULK2target
DB12010FostamatinibSerine/threonine-protein kinase ULK3target
DB12010FostamatinibWee1-like protein kinasetarget
DB12010FostamatinibTyrosine-protein kinase Yestarget
DB12010FostamatinibMitogen-activated protein kinase kinase kinase 19target
DB12010FostamatinibMitogen-activated protein kinase kinase kinase MLTtarget
DB12010FostamatinibTyrosine-protein kinase ZAP-70target
DB12010FostamatinibAP2-associated protein kinase 1target
DB12010FostamatinibAbelson tyrosine-protein kinase 2target
DB12010FostamatinibActivin receptor type-1target
DB12010FostamatinibActivin receptor type-1Btarget
DB12010FostamatinibAtypical kinase COQ8B, mitochondrialtarget
DB12010FostamatinibALK tyrosine kinase receptortarget
DB12010FostamatinibAnkyrin repeat and protein kinase domain-containing protein 1target
DB12010FostamatinibAurora kinase Atarget
DB12010FostamatinibAurora kinase Btarget
DB12010FostamatinibAurora kinase Ctarget
DB12010FostamatinibTyrosine-protein kinase receptor UFOtarget
DB12010FostamatinibTyrosine-protein kinase Blktarget
DB12010FostamatinibBMP-2-inducible protein kinasetarget
DB12010FostamatinibBone morphogenetic protein receptor type-1Btarget
DB12010FostamatinibBone morphogenetic protein receptor type-2target
DB12010FostamatinibCytoplasmic tyrosine-protein kinase BMXtarget
DB12010FostamatinibSerine/threonine-protein kinase B-raftarget
DB12010FostamatinibTyrosine-protein kinase BTKtarget
DB12010FostamatinibCalcium/calmodulin-dependent protein kinase type 1target
DB12010FostamatinibCalcium/calmodulin-dependent protein kinase type 1Dtarget
DB12010FostamatinibCalcium/calmodulin-dependent protein kinase type 1Gtarget
DB12010FostamatinibCalcium/calmodulin-dependent protein kinase type II subunit alphatarget
DB12010FostamatinibCalcium/calmodulin-dependent protein kinase type II subunit betatarget
DB12010FostamatinibCalcium/calmodulin-dependent protein kinase type II subunit deltatarget
DB12010FostamatinibCalcium/calmodulin-dependent protein kinase type II subunit gammatarget
DB12010FostamatinibCalcium/calmodulin-dependent protein kinase kinase 1target
DB12010FostamatinibCalcium/calmodulin-dependent protein kinase kinase 2target
DB12010FostamatinibPeripheral plasma membrane protein CASKtarget
DB12010FostamatinibKappa-caseintarget
DB12010FostamatinibCyclin-dependent kinase 1target
DB12010FostamatinibSerine/threonine-protein kinase MRCK gammatarget
DB12010FostamatinibCyclin-dependent kinase 4target
DB12010FostamatinibCyclin-dependent kinase-like 1target
DB12010FostamatinibCyclin-dependent kinase-like 2target
DB12010FostamatinibSerine/threonine-protein kinase Chk1target
DB12010FostamatinibSerine/threonine-protein kinase Chk2target
DB12010FostamatinibCitron Rho-interacting kinasetarget
DB12010FostamatinibDual specificity protein kinase CLK1target
DB12010FostamatinibDual specificity protein kinase CLK2target
DB12010FostamatinibDual specificity protein kinase CLK3target
DB12010FostamatinibDual specificity protein kinase CLK4target
DB12010FostamatinibMacrophage colony-stimulating factor 1 receptortarget
DB12010FostamatinibTyrosine-protein kinase CSKtarget
DB12010FostamatinibCasein kinase I isoform alphatarget
DB12010FostamatinibCasein kinase II subunit alphatarget
DB12010FostamatinibCasein kinase II subunit alpha'target
DB12010FostamatinibDeath-associated protein kinase 1target
DB12010FostamatinibDeath-associated protein kinase 2target
DB12010FostamatinibDeath-associated protein kinase 3target
DB12010FostamatinibSerine/threonine-protein kinase DCLK1target
DB12010FostamatinibSerine/threonine-protein kinase DCLK2target
DB12010FostamatinibSerine/threonine-protein kinase DCLK3target
DB12010FostamatinibEpithelial discoidin domain-containing receptor 1target
DB12010FostamatinibDiscoidin domain-containing receptor 2target
DB12010FostamatinibDual specificity tyrosine-phosphorylation-regulated kinase 1Atarget
DB12010FostamatinibDual specificity tyrosine-phosphorylation-regulated kinase 1Btarget
DB12010FostamatinibEpidermal growth factor receptortarget
DB12010FostamatinibEukaryotic translation initiation factor 2-alpha kinase 1target
DB12010FostamatinibInterferon-induced, double-stranded RNA-activated protein kinasetarget
DB12010FostamatinibeIF-2-alpha kinase GCN2target
DB12010FostamatinibEphrin type-A receptor 1target
DB12010FostamatinibEphrin type-A receptor 2target
DB12010FostamatinibEphrin type-A receptor 3target
DB12010FostamatinibEphrin type-A receptor 4target
DB12010FostamatinibEphrin type-A receptor 5target
DB12010FostamatinibEphrin type-A receptor 6target
DB12010FostamatinibEphrin type-A receptor 7target
DB12010FostamatinibEphrin type-A receptor 8target
DB12010FostamatinibEphrin type-B receptor 1target
DB12010FostamatinibEphrin type-B receptor 2target
DB12010FostamatinibEphrin type-B receptor 4target
DB12010FostamatinibEphrin type-B receptor 6target
DB12010FostamatinibReceptor tyrosine-protein kinase erbB-2target
DB12010FostamatinibReceptor tyrosine-protein kinase erbB-4target
DB12010FostamatinibSerine/threonine-protein kinase/endoribonuclease IRE1target
DB12010FostamatinibTyrosine-protein kinase Fertarget
DB12010FostamatinibTyrosine-protein kinase Fes/Fpstarget
DB12010FostamatinibFibroblast growth factor receptor 1target
DB12010FostamatinibFibroblast growth factor receptor 2target
DB12010FostamatinibFibroblast growth factor receptor 3target
DB12010FostamatinibTyrosine-protein kinase Fgrtarget
DB12010FostamatinibVascular endothelial growth factor receptor 1target
DB12010FostamatinibReceptor-type tyrosine-protein kinase FLT3target
DB12010FostamatinibVascular endothelial growth factor receptor 3target
DB12010FostamatinibSerine/threonine-protein kinase mTORtarget
DB12010FostamatinibTyrosine-protein kinase FRKtarget
DB12010FostamatinibTyrosine-protein kinase Fyntarget
DB12010FostamatinibCyclin-G-associated kinasetarget
DB12010FostamatinibGlycogen synthase kinase-3 alphatarget
DB12010FostamatinibGlycogen synthase kinase-3 betatarget
DB12010FostamatinibTyrosine-protein kinase HCKtarget
DB12010FostamatinibHomeodomain-interacting protein kinase 2target
DB12010FostamatinibHomeodomain-interacting protein kinase 3target
DB12010FostamatinibSerine/threonine-protein kinase ICKtarget
DB12010FostamatinibInhibitor of nuclear factor kappa-B kinase subunit betatarget
DB12010FostamatinibInhibitor of nuclear factor kappa-B kinase subunit epsilontarget
DB12010FostamatinibInsulin receptortarget
DB12010FostamatinibInsulin receptor-related proteintarget
DB12010FostamatinibInterleukin-1 receptor-associated kinase 1target
DB12010FostamatinibInterleukin-1 receptor-associated kinase 3target
DB12010FostamatinibInterleukin-1 receptor-associated kinase 4target
DB12010FostamatinibTyrosine-protein kinase ITK/TSKtarget
DB12010FostamatinibTyrosine-protein kinase JAK2target
DB12010FostamatinibTyrosine-protein kinase JAK3target
DB12010FostamatinibVascular endothelial growth factor receptor 2target
DB12010FostamatinibSerine/threonine-protein kinase SIK3target
DB12010FostamatinibMast/stem cell growth factor receptor Kittarget
DB12010FostamatinibSerine/threonine-protein kinase LATS1target
DB12010FostamatinibTyrosine-protein kinase Lcktarget
DB12010FostamatinibLIM domain kinase 1target
DB12010FostamatinibLIM domain kinase 2target
DB12010FostamatinibLeucine-rich repeat serine/threonine-protein kinase 2target
DB12010FostamatinibLeukocyte tyrosine kinase receptortarget
DB12010FostamatinibTyrosine-protein kinase Lyntarget
DB12010FostamatinibDual specificity mitogen-activated protein kinase kinase 2target
DB12010FostamatinibDual specificity mitogen-activated protein kinase kinase 3target
DB12010FostamatinibDual specificity mitogen-activated protein kinase kinase 5target
DB12010FostamatinibDual specificity mitogen-activated protein kinase kinase 6target
DB12010FostamatinibMitogen-activated protein kinase kinase kinase 1target
DB12010FostamatinibMitogen-activated protein kinase kinase kinase 10target
DB12010FostamatinibMitogen-activated protein kinase kinase kinase 11target
DB12010FostamatinibMitogen-activated protein kinase kinase kinase 12target
DB12010FostamatinibMitogen-activated protein kinase kinase kinase 13target
DB12010FostamatinibMitogen-activated protein kinase kinase kinase 15target
DB12010FostamatinibMitogen-activated protein kinase kinase kinase 2target
DB12010FostamatinibMitogen-activated protein kinase kinase kinase 3target
DB12010FostamatinibMitogen-activated protein kinase kinase kinase 4target
DB12010FostamatinibMitogen-activated protein kinase kinase kinase 6target
DB12010FostamatinibMitogen-activated protein kinase kinase kinase 9target
DB12010FostamatinibMitogen-activated protein kinase kinase kinase kinase 1target
DB12010FostamatinibMitogen-activated protein kinase kinase kinase kinase 2target
DB12010FostamatinibMitogen-activated protein kinase kinase kinase kinase 3target
DB12010FostamatinibMitogen-activated protein kinase kinase kinase kinase 4target
DB12010FostamatinibMitogen-activated protein kinase kinase kinase kinase 5target
DB12010FostamatinibMitogen-activated protein kinase 10target
DB12010FostamatinibMitogen-activated protein kinase 13target
DB12010FostamatinibMitogen-activated protein kinase 14target
DB12010FostamatinibMitogen-activated protein kinase 15target
DB12010FostamatinibMitogen-activated protein kinase 4target
DB12010FostamatinibMitogen-activated protein kinase 7target
DB12010FostamatinibMitogen-activated protein kinase 9target
DB12010FostamatinibMAP kinase-activated protein kinase 5target
DB12010FostamatinibSerine/threonine-protein kinase MARK1target
DB12010FostamatinibSerine/threonine-protein kinase MARK2target
DB12010FostamatinibMAP/microtubule affinity-regulating kinase 3target
DB12010FostamatinibMAP/microtubule affinity-regulating kinase 4target
DB12010FostamatinibCLIP-associating protein 1target
DB12010FostamatinibMicrotubule-associated serine/threonine-protein kinase 1target
DB12010FostamatinibMegakaryocyte-associated tyrosine-protein kinasetarget
DB12010FostamatinibMaternal embryonic leucine zipper kinasetarget
DB12010FostamatinibTyrosine-protein kinase Mertarget
DB12010FostamatinibMisshapen-like kinase 1target
DB12010FostamatinibMAP kinase-interacting serine/threonine-protein kinase 1target
DB12010FostamatinibMAP kinase-interacting serine/threonine-protein kinase 2target
DB12010FostamatinibMacrophage-stimulating protein receptortarget
DB12010FostamatinibMuscle, skeletal receptor tyrosine-protein kinasetarget
DB12010FostamatinibMyosin light chain kinase, smooth muscletarget
DB12010FostamatinibMyosin light chain kinase 2, skeletal/cardiac muscletarget
DB12010FostamatinibMyosin light chain kinase 3target
DB12010FostamatinibMyosin light chain kinase family member 4target
DB12010FostamatinibMyosin-IIIatarget
DB12010FostamatinibSerine/threonine-protein kinase Nek1target
DB12010FostamatinibSerine/threonine-protein kinase Nek11target
DB12010FostamatinibSerine/threonine-protein kinase Nek2target
DB12010FostamatinibSerine/threonine-protein kinase Nek3target
DB12010FostamatinibSerine/threonine-protein kinase Nek4target
DB12010FostamatinibSerine/threonine-protein kinase Nek5target
DB12010FostamatinibSerine/threonine-protein kinase Nek9target
DB12010FostamatinibHigh affinity nerve growth factor receptortarget
DB12010FostamatinibBDNF/NT-3 growth factors receptortarget
DB12010FostamatinibNT-3 growth factor receptortarget
DB12010FostamatinibNUAK family SNF1-like kinase 1target
DB12010FostamatinibNUAK family SNF1-like kinase 2target
DB12010FostamatinibSerine/threonine-protein kinase OSR1target
DB12010FostamatinibSerine/threonine-protein kinase PAK 1target
DB12010FostamatinibSerine/threonine-protein kinase PAK 2target
DB12010FostamatinibSerine/threonine-protein kinase PAK 3target
DB12010FostamatinibSerine/threonine-protein kinase PAK 4target
DB12010FostamatinibSerine/threonine-protein kinase PAK 6target
DB12010FostamatinibSerine/threonine-protein kinase PAK 5target
DB12010FostamatinibCyclin-dependent kinase 16target
DB12010FostamatinibCyclin-dependent kinase 17target
DB12010FostamatinibPlatelet-derived growth factor receptor alphatarget
DB12010FostamatinibPlatelet-derived growth factor receptor betatarget
DB12010Fostamatinib3-phosphoinositide-dependent protein kinase 1target
DB12010FostamatinibCyclin-dependent kinase 15target
DB12010FostamatinibPhosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoformtarget
DB12010FostamatinibPhosphatidylinositol 4-kinase betatarget
DB12010FostamatinibPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit betatarget
DB12010FostamatinibPhosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gammatarget
DB12010FostamatinibPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformtarget
DB12010FostamatinibPhosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoformtarget
DB12010FostamatinibSerine/threonine-protein kinase pim-1target
DB12010FostamatinibSerine/threonine-protein kinase pim-3target
DB12010FostamatinibPhosphatidylinositol 5-phosphate 4-kinase type-2 betatarget
DB12010FostamatinibPhosphatidylinositol 5-phosphate 4-kinase type-2 gammatarget
DB12010FostamatinibMembrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinasetarget
DB12010FostamatinibSerine/threonine-protein kinase N1target
DB12010FostamatinibSerine/threonine-protein kinase N2target
DB12010FostamatinibSerine/threonine-protein kinase PLK1target
DB12010FostamatinibSerine/threonine-protein kinase PLK2target
DB12010FostamatinibSerine/threonine-protein kinase PLK3target
DB12010FostamatinibSerine/threonine-protein kinase PLK4target
DB12010Fostamatinib5'-AMP-activated protein kinase catalytic subunit alpha-1target
DB12010Fostamatinib5'-AMP-activated protein kinasetarget
DB12010FostamatinibcAMP-dependent protein kinase catalytic subunit betatarget
DB12010FostamatinibProtein kinase C delta typetarget
DB12010FostamatinibProtein kinase C epsilon typetarget
DB12010FostamatinibProtein kinase C gamma typetarget
DB12010FostamatinibProtein kinase C iota typetarget
DB12010FostamatinibProtein kinase C theta typetarget
DB12010FostamatinibSerine/threonine-protein kinase D1target
DB12010FostamatinibcGMP-dependent protein kinase 2target
DB12010FostamatinibSerine/threonine-protein kinase PRP4 homologtarget
DB12010FostamatinibFocal adhesion kinase 1target
DB12010FostamatinibProtein-tyrosine kinase 2-betatarget
DB12010FostamatinibProtein-tyrosine kinase 6target
DB12010FostamatinibRAF proto-oncogene serine/threonine-protein kinasetarget
DB12010FostamatinibProto-oncogene tyrosine-protein kinase receptor Rettarget
DB12010FostamatinibSerine/threonine-protein kinase RIO1target
DB12010FostamatinibSerine/threonine-protein kinase RIO2target
DB12010FostamatinibSerine/threonine-protein kinase RIO3target
DB12010FostamatinibReceptor-interacting serine/threonine-protein kinase 1target
DB12010FostamatinibReceptor-interacting serine/threonine-protein kinase 2target
DB12010FostamatinibReceptor-interacting serine/threonine-protein kinase 4target
DB12010FostamatinibRho-associated protein kinase 2target
DB12010FostamatinibProto-oncogene tyrosine-protein kinase ROStarget
DB12010FostamatinibRibosomal protein S6 kinase alpha-1target
DB12010FostamatinibRibosomal protein S6 kinase alpha-3target
DB12010FostamatinibSerine/threonine-protein kinase SBK1target
DB12010FostamatinibUncharacterized serine/threonine-protein kinase SBK3target
DB12010FostamatinibSerine/threonine-protein kinase Sgk3target
DB12010FostamatinibSerine/threonine-protein kinase SIK1target
DB12010FostamatinibSerine/threonine-protein kinase SIK2target
DB12010FostamatinibSTE20-like serine/threonine-protein kinasetarget
DB12010FostamatinibSNF-related serine/threonine-protein kinasetarget
DB12010FostamatinibProto-oncogene tyrosine-protein kinase Srctarget
DB12010FostamatinibTyrosine-protein kinase Srmstarget
DB12010FostamatinibSerine/threonine-protein kinase 10target
DB12010FostamatinibSerine/threonine-protein kinase 16target
DB12010FostamatinibSerine/threonine-protein kinase 17Atarget
DB12010FostamatinibSerine/threonine-protein kinase 17Btarget
DB12010FostamatinibSerine/threonine-protein kinase 32Atarget
DB12010FostamatinibCytochrome P450 3A4enzyme
DB12010FostamatinibATP-binding cassette sub-family G member 2transporter
DB12010FostamatinibATP-binding cassette sub-family B member 5transporter
DB12010FostamatinibUDP-glucuronosyltransferase 1-9enzyme
DB06267UdenafilcGMP-specific 3',5'-cyclic phosphodiesterasetarget
DB06267UdenafilCytochrome P450 3A4enzyme
DB06267UdenafilCytochrome P450 3A5enzyme
DB00213PantoprazolePotassium-transporting ATPase alpha chain 1target
DB00213PantoprazoleCytochrome P450 2C19enzyme
DB00213PantoprazoleCytochrome P450 3A4enzyme
DB00213PantoprazoleMultidrug resistance protein 1transporter
DB00213PantoprazoleATP-binding cassette sub-family G member 2transporter
DB00213PantoprazoleSolute carrier organic anion transporter family member 1B1transporter
DB00448LansoprazolePotassium-transporting ATPase alpha chain 1target
DB00448LansoprazoleCytochrome P450 2C19enzyme
DB00448LansoprazoleCytochrome P450 2C9enzyme
DB00448LansoprazoleCytochrome P450 3A4enzyme
DB00448LansoprazoleMultidrug resistance protein 1transporter
DB00448LansoprazoleATP-binding cassette sub-family G member 2transporter
DB00448LansoprazoleCytochrome P450 1A1enzyme
DB00448LansoprazoleCytochrome P450 1B1enzyme
DB00448LansoprazoleCytochrome P450 2C18enzyme
DB00448LansoprazoleCytochrome P450 2C8enzyme
DB00448LansoprazoleCytochrome P450 2D6enzyme
DB00448LansoprazoleMicrotubule-associated protein tautarget
DB05351DexlansoprazolePotassium-transporting ATPase alpha chain 1target
DB05351DexlansoprazoleCytochrome P450 2C19enzyme
DB05351DexlansoprazoleCytochrome P450 3A4enzyme
DB05351DexlansoprazolePotassium-transporting ATPase subunit betatarget
DB01129RabeprazolePotassium-transporting ATPase alpha chain 1target
DB01129RabeprazoleCytochrome P450 3A4enzyme
DB01129RabeprazoleCytochrome P450 2C19enzyme
DB01129RabeprazoleATP-binding cassette sub-family G member 2transporter
DB01129RabeprazoleCytochrome P450 1A1enzyme
DB01129RabeprazoleCytochrome P450 1A2enzyme
DB01129RabeprazoleCytochrome P450 2C9enzyme
DB01129RabeprazoleCytochrome P450 2D6enzyme
DB01129RabeprazoleCytochrome P450 2C8enzyme
DB00673AprepitantSubstance-P receptortarget
DB00673AprepitantCytochrome P450 3A4enzyme
DB00673AprepitantCytochrome P450 2C9enzyme
DB00673AprepitantCytochrome P450 3A5enzyme
DB00673AprepitantCytochrome P450 3A7enzyme
DB00673AprepitantCytochrome P450 2C19enzyme
DB09236LacidipineCytochrome P450 3A4enzyme
DB09236LacidipineSerum albumincarrier
DB09236LacidipineAlpha-1-acid glycoprotein 1carrier
DB09236LacidipineVoltage dependent L type calcium channeltarget
DB14568IvosidenibIsocitrate dehydrogenase [NADP] cytoplasmictarget
DB14568IvosidenibCytochrome P450 3A4enzyme
DB14568IvosidenibCytochrome P450 2B6enzyme
DB14568IvosidenibCytochrome P450 2C9enzyme
DB14568IvosidenibCytochrome P450 2C8enzyme
DB14568IvosidenibSolute carrier family 22 member 8transporter
DB14568IvosidenibMultidrug resistance protein 1transporter
DB126293,5-diiodothyropropionic acidCytochrome P450 3A4enzyme
DB014565-androstenedioneCytochrome P450 3A4enzyme
DB00240AlclometasoneCorticosteroid-binding globulincarrier
DB00240AlclometasoneGlucocorticoid receptortarget
DB00240AlclometasoneCytochrome P450 3A4enzyme
DB04630AldosteroneMineralocorticoid receptortarget
DB04630AldosteroneMultidrug resistance protein 1transporter
DB04630AldosteroneSolute carrier family 22 member 5transporter
DB04630AldosteroneSolute carrier organic anion transporter family member 1A2transporter
DB04630AldosteroneCytochrome P450 11B1, mitochondrialenzyme
DB04630AldosteroneCytochrome P450 11B2, mitochondrialenzyme
DB04630AldosteroneSteroid 17-alpha-hydroxylase/17,20 lyaseenzyme
DB04630AldosteroneGlucocorticoid receptortarget
DB04630AldosteroneCytochrome P450 3A4enzyme
DB01431AllylestrenolCytochrome P450 3A4enzyme
DB01431AllylestrenolProgesterone receptortarget
DB01431AllylestrenolEstrogen receptor alphatarget
DB00288AmcinonideGlucocorticoid receptortarget
DB00288AmcinonideAnnexin A1target
DB00288AmcinonideCytochrome P450 3A4enzyme
DB01536AndrostenedioneAldo-keto reductase family 1 member C3target
DB01536AndrostenedioneEstradiol 17-beta-dehydrogenase 1target
DB01536Androstenedione6-deoxyerythronolide B hydroxylasetarget
DB01536Androstenedione3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1target
DB01536AndrostenedioneCytochrome P450 3A4enzyme
DB00394Beclomethasone dipropionateCorticosteroid-binding globulincarrier
DB00394Beclomethasone dipropionateGlucocorticoid receptortarget
DB00394Beclomethasone dipropionateCytochrome P450 3A5enzyme
DB00394Beclomethasone dipropionateCytochrome P450 3A4enzyme
DB00443BetamethasoneGlucocorticoid receptortarget
DB00443BetamethasoneCytochrome P450 3A4enzyme
DB00443BetamethasoneMultidrug resistance protein 1transporter
DB00443BetamethasoneCytochrome P450 19A1enzyme
DB01222BudesonideGlucocorticoid receptortarget
DB01222BudesonideCytochrome P450 3A4enzyme
DB01222BudesonideCytochrome P450 3A5enzyme
DB01222BudesonideBile salt export pumptransporter
DB01410CiclesonideCorticosteroid-binding globulincarrier
DB01410CiclesonideCytochrome P450 3A4enzyme
DB01410CiclesonideCytochrome P450 2D6enzyme
DB01410CiclesonideGlucocorticoid receptortarget
DB01410CiclesonideLiver carboxylesterase 1enzyme
DB11750ClobetasolCytochrome P450 3A4enzyme
DB01013Clobetasol propionateGlucocorticoid receptortarget
DB01013Clobetasol propionateCytochrome P450 1A1enzyme
DB01013Clobetasol propionateCytochrome P450 3A4enzyme
DB13158ClobetasoneGlucocorticoid receptortarget
DB13158ClobetasoneCytochrome P450 3A4enzyme
DB04652CorticosteroneMineralocorticoid receptortarget
DB04652CorticosteroneCorticosteroid 11-beta-dehydrogenase isozyme 1target
DB04652CorticosteroneNuclear receptor coactivator 1target
DB04652CorticosteroneCytochrome P450 3A4enzyme
DB01285CorticotropinAdrenocorticotropic hormone receptortarget
DB01285CorticotropinCorticoliberintarget
DB01285Corticotropin3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2enzyme
DB01285Corticotropin25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrialenzyme
DB01285Corticotropin1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrialenzyme
DB01285CorticotropinCytochrome P450 3A4enzyme
DB01380Cortisone acetateGlucocorticoid receptortarget
DB01380Cortisone acetateCytochrome P450 3A4enzyme
DB04839Cyproterone acetateAndrogen receptortarget
DB04839Cyproterone acetateCytochrome P450 19A1enzyme
DB04839Cyproterone acetateProstate-specific antigentarget
DB04839Cyproterone acetateCytochrome P450 3A4enzyme
DB11921DeflazacortCytochrome P450 3A4enzyme
DB11921DeflazacortCarboxylesteraseenzyme
DB09123DienogestCytochrome P450 3A4enzyme
DB09123DienogestProgesterone receptortarget
DB09123DienogestAndrogen receptortarget
DB11636NomegestrolCytochrome P450 3A4enzyme
DB13981Nomegestrol acetateCytochrome P450 3A4enzyme
DB00304DesogestrelProgesterone receptortarget
DB00304DesogestrelEstrogen receptor alphatarget
DB00304DesogestrelCytochrome P450 3A4enzyme
DB01260DesonideGlucocorticoid receptortarget
DB01260DesonideCytochrome P450 3A4enzyme
DB06780Desoxycorticosterone acetateMineralocorticoid receptortarget
DB06780Desoxycorticosterone acetateCytochrome P450 3A4enzyme
DB01134Desoxycorticosterone PivalateMineralocorticoid receptortarget
DB01134Desoxycorticosterone PivalateCytochrome P450 3A4enzyme
DB01234DexamethasoneGlucocorticoid receptortarget
DB01234DexamethasoneAnnexin A1target
DB01234DexamethasoneNitric oxide synthase, inducibletarget
DB01234DexamethasoneNuclear receptor subfamily 0 group B member 1target
DB01234DexamethasoneCytochrome P450 3A4enzyme
DB01234DexamethasoneCytochrome P450 3A5enzyme
DB01234DexamethasoneCytochrome P450 3A7enzyme
DB01234DexamethasoneBile salt export pumptransporter
DB01234DexamethasoneMultidrug resistance protein 1transporter
DB01234DexamethasoneCanalicular multispecific organic anion transporter 1transporter
DB01234DexamethasoneSolute carrier organic anion transporter family member 1A2transporter
DB01234DexamethasoneATP-binding cassette sub-family G member 2transporter
DB01234DexamethasoneCholesterol side-chain cleavage enzyme, mitochondrialenzyme
DB01234DexamethasoneSteroid 17-alpha-hydroxylase/17,20 lyaseenzyme
DB01234DexamethasoneCytochrome P450 19A1enzyme
DB01234DexamethasoneCytochrome P450 1A1enzyme
DB01234DexamethasoneCytochrome P450 1B1enzyme
DB01234DexamethasoneCytochrome P450 2A6enzyme
DB01234DexamethasoneCytochrome P450 2B6enzyme
DB01234DexamethasoneCytochrome P450 2C19enzyme
DB01234DexamethasoneCytochrome P450 2C8enzyme
DB01234DexamethasoneCytochrome P450 2D6enzyme
DB01234DexamethasoneCytochrome P450 2E1enzyme
DB01234DexamethasoneCytochrome P450 3A43enzyme
DB01234DexamethasoneCytochrome P450 4A11enzyme
DB01234DexamethasoneNuclear receptor subfamily 1 group I member 2target
DB11487Dexamethasone isonicotinateCytochrome P450 3A4enzyme
DB09095DifluocortoloneAnnexin A3target
DB09095DifluocortoloneGlucocorticoid receptortarget
DB09095DifluocortoloneCytochrome P450 3A4enzyme
DB06781DifluprednateGlucocorticoid receptortarget
DB06781DifluprednateCytochrome P450 3A4enzyme
DB01395DrospirenoneProgesterone receptortarget
DB01395DrospirenoneMineralocorticoid receptortarget
DB01395DrospirenoneAndrogen receptortarget
DB01395DrospirenoneProstaglandin G/H synthase 2enzyme
DB01395DrospirenoneCholinesteraseenzyme
DB01395DrospirenoneCytochrome P450 3A4enzyme
DB00378DydrogesteroneProgesterone receptortarget
DB00378DydrogesteroneCytochrome P450 3A4enzyme
DB03515EquileninSteroid Delta-isomerasetarget
DB03515EquileninSteroid Delta-isomerasetarget
DB03515EquileninCytochrome P450 3A4enzyme
DB02187EquilinEstradiol 17-beta-dehydrogenase 1target
DB02187EquilinEstrogen receptor alphatarget
DB02187EquilinCytochrome P450 3A4enzyme
DB00655EstroneEstrogen receptor alphatarget
DB00655EstroneCytochrome P450 1A2enzyme
DB00655EstroneCytochrome P450 1A1enzyme
DB00655EstroneSerum albumincarrier
DB00655EstroneSolute carrier organic anion transporter family member 2B1transporter
DB00655EstroneMultidrug resistance protein 1transporter
DB00655EstroneSolute carrier organic anion transporter family member 1A2transporter
DB00655EstroneATP-binding cassette sub-family G member 2transporter
DB00655EstroneSolute carrier organic anion transporter family member 1B1transporter
DB00655EstroneCytochrome P450 3A4enzyme
DB00655EstroneCytochrome P450 1B1enzyme
DB00655EstroneCytochrome P450 2B6enzyme
DB00655EstroneCytochrome P450 2C9enzyme
DB00655EstroneCytochrome P450 2E1enzyme
DB00655EstroneCytochrome P450 3A5enzyme
DB00655EstroneCytochrome P450 4A11enzyme
DB00655EstroneEstrogen receptor betatarget
DB00655EstroneAndrogen receptortarget
DB00655EstroneCytochrome P450 19A1target
DB00655EstroneSex hormone-binding globulintarget
DB00655EstroneSolute carrier family 22 member 8transporter
DB04574Estrone sulfateCytochrome P450 1A2enzyme
DB04574Estrone sulfateCytochrome P450 3A4enzyme
DB04574Estrone sulfateEstrogen receptor alphatarget
DB04574Estrone sulfateEstrogen receptor betatarget
DB04574Estrone sulfateSex hormone-binding globulincarrier
DB04574Estrone sulfateSerum albumincarrier
DB04574Estrone sulfateSolute carrier family 22 member 1transporter
DB04574Estrone sulfateCytochrome P450 2C9enzyme
DB04574Estrone sulfateMultidrug and toxin extrusion protein 1transporter
DB04574Estrone sulfateMultidrug and toxin extrusion protein 2transporter
DB13866EthynodiolCytochrome P450 3A4enzyme
DB00823Ethynodiol diacetateEstrogen receptor alphatarget
DB00823Ethynodiol diacetateProgesterone receptortarget
DB00823Ethynodiol diacetateCytochrome P450 3A4enzyme
DB00294EtonogestrelEstrogen receptor alphatarget
DB00294EtonogestrelProgesterone receptortarget
DB00294EtonogestrelCytochrome P450 3A4enzyme
DB00687FludrocortisoneMineralocorticoid receptortarget
DB00687FludrocortisoneGlucocorticoid receptortarget
DB00687FludrocortisoneAndrogen receptortarget
DB00687FludrocortisoneCytochrome P450 3A4enzyme
DB00663FlumethasoneCorticosteroid-binding globulincarrier
DB00663FlumethasoneGlucocorticoid receptortarget
DB00663FlumethasoneCytochrome P450 3A4enzyme
DB00180FlunisolideCorticosteroid-binding globulincarrier
DB00180FlunisolideGlucocorticoid receptortarget
DB00180FlunisolideCytochrome P450 3A4enzyme
DB00591Fluocinolone acetonideCorticosteroid-binding globulincarrier
DB00591Fluocinolone acetonideGlucocorticoid receptortarget
DB00591Fluocinolone acetonideCytosolic phospholipase A2enzyme
DB00591Fluocinolone acetonideCytochrome P450 3A4enzyme
DB01047FluocinonideCorticosteroid-binding globulincarrier
DB01047FluocinonideGlucocorticoid receptortarget
DB01047FluocinonideSmoothened homologtarget
DB01047FluocinonideCytochrome P450 3A4enzyme
DB08971FluocortoloneCytochrome P450 3A4enzyme
DB00324FluorometholoneCorticosteroid-binding globulincarrier
DB00324FluorometholoneCytochrome P450 3A4enzyme
DB00324FluorometholoneGlucocorticoid receptortarget
DB08970FluprednideneCytochrome P450 3A4enzyme
DB09378FluprednisoloneCytochrome P450 3A4enzyme
DB00846FlurandrenolideCorticosteroid-binding globulincarrier
DB00846FlurandrenolideGlucocorticoid receptortarget
DB00846FlurandrenolideCytochrome P450 3A4enzyme
DB13867FluticasoneCytochrome P450 3A4enzyme
DB13867FluticasoneCytochrome P450 2C8enzyme
DB13867FluticasoneMultidrug resistance protein 1carrier
DB13867FluticasoneSolute carrier organic anion transporter family member 1B1carrier
DB08906Fluticasone furoateCytochrome P450 3A4enzyme
DB08906Fluticasone furoateGlucocorticoid receptortarget
DB08906Fluticasone furoateMultidrug resistance protein 1transporter
DB08906Fluticasone furoateCytochrome P450 2C8enzyme
DB08906Fluticasone furoateSolute carrier organic anion transporter family member 1B1transporter
DB00588Fluticasone propionateCorticosteroid-binding globulincarrier
DB00588Fluticasone propionateCytosolic phospholipase A2target
DB00588Fluticasone propionateGlucocorticoid receptortarget
DB00588Fluticasone propionateCytochrome P450 3A4enzyme
DB00588Fluticasone propionateProgesterone receptortarget
DB00588Fluticasone propionateMineralocorticoid receptortarget
DB00588Fluticasone propionateCytochrome P450 3A5enzyme
DB00588Fluticasone propionateCytochrome P450 3A7enzyme
DB00588Fluticasone propionateCytochrome P450 2C8enzyme
DB00588Fluticasone propionateMultidrug resistance protein 1carrier
DB00588Fluticasone propionateSolute carrier organic anion transporter family member 1B1carrier
DB06730GestodeneCytochrome P450 3A5enzyme
DB06730GestodeneCytochrome P450 3A7enzyme
DB06730GestodeneProgesterone receptortarget
DB06730GestodeneCytochrome P450 3A4enzyme
DB06786HalcinonideSmoothened homologtarget
DB06786HalcinonideCytochrome P450 3A4enzyme
DB05212HE3286Nuclear factor NF-kappa-B p105 subunittarget
DB05212HE3286Nuclear factor NF-kappa-B p100 subunittarget
DB05212HE3286Cytochrome P450 3A4enzyme
DB00741HydrocortisoneAnnexin A1target
DB00741HydrocortisoneGlucocorticoid receptortarget
DB00741HydrocortisoneSex hormone-binding globulincarrier
DB00741HydrocortisoneCytochrome P450 3A4enzyme
DB00741HydrocortisoneCytochrome P450 3A5enzyme
DB00741HydrocortisoneCytochrome P450 3A7enzyme
DB00741HydrocortisoneMultidrug resistance protein 1transporter
DB00741HydrocortisoneSolute carrier organic anion transporter family member 1A2transporter
DB00741HydrocortisoneATP-binding cassette sub-family G member 2transporter
DB00741HydrocortisoneCytochrome P450 11B1, mitochondrialenzyme
DB00741HydrocortisoneCytochrome P450 11B2, mitochondrialenzyme
DB00741HydrocortisoneCytochrome P450 2C8enzyme
DB00741HydrocortisoneCorticosteroid-binding globulincarrier
DB00741HydrocortisoneCorticosteroid 11-beta-dehydrogenase isozyme 2target
DB00741Hydrocortisone3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1target
DB00741HydrocortisoneSolute carrier family 22 member 8transporter
DB14538Hydrocortisone aceponateAnnexin A1target
DB14538Hydrocortisone aceponateGlucocorticoid receptortarget
DB14538Hydrocortisone aceponateSex hormone-binding globulincarrier
DB14538Hydrocortisone aceponateCytochrome P450 3A4enzyme
DB14538Hydrocortisone aceponateCytochrome P450 3A5enzyme
DB14538Hydrocortisone aceponateCytochrome P450 3A7enzyme
DB14538Hydrocortisone aceponateMultidrug resistance protein 1transporter
DB14538Hydrocortisone aceponateSolute carrier organic anion transporter family member 1A2transporter
DB14538Hydrocortisone aceponateATP-binding cassette sub-family G member 2transporter
DB14538Hydrocortisone aceponateCytochrome P450 11B1, mitochondrialenzyme
DB14538Hydrocortisone aceponateCytochrome P450 11B2, mitochondrialenzyme
DB14538Hydrocortisone aceponateCytochrome P450 2C8enzyme
DB14538Hydrocortisone aceponateCorticosteroid-binding globulincarrier
DB14538Hydrocortisone aceponateCorticosteroid 11-beta-dehydrogenase isozyme 2target
DB14538Hydrocortisone aceponate3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1target
DB14538Hydrocortisone aceponateSolute carrier family 22 member 8transporter
DB14539Hydrocortisone acetateAnnexin A1target
DB14539Hydrocortisone acetateGlucocorticoid receptortarget
DB14539Hydrocortisone acetateSex hormone-binding globulincarrier
DB14539Hydrocortisone acetateCytochrome P450 3A4enzyme
DB14539Hydrocortisone acetateCytochrome P450 3A5enzyme
DB14539Hydrocortisone acetateCytochrome P450 3A7enzyme
DB14539Hydrocortisone acetateMultidrug resistance protein 1transporter
DB14539Hydrocortisone acetateSolute carrier organic anion transporter family member 1A2transporter
DB14539Hydrocortisone acetateATP-binding cassette sub-family G member 2transporter
DB14539Hydrocortisone acetateCytochrome P450 11B1, mitochondrialenzyme
DB14539Hydrocortisone acetateCytochrome P450 11B2, mitochondrialenzyme
DB14539Hydrocortisone acetateCytochrome P450 2C8enzyme
DB14539Hydrocortisone acetateCorticosteroid-binding globulincarrier
DB14539Hydrocortisone acetateCorticosteroid 11-beta-dehydrogenase isozyme 2target
DB14539Hydrocortisone acetate3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1target
DB14539Hydrocortisone acetateSolute carrier family 22 member 8transporter
DB14540Hydrocortisone butyrateAnnexin A1target
DB14540Hydrocortisone butyrateGlucocorticoid receptortarget
DB14540Hydrocortisone butyrateSex hormone-binding globulincarrier
DB14540Hydrocortisone butyrateCytochrome P450 3A4enzyme
DB14540Hydrocortisone butyrateCytochrome P450 3A5enzyme
DB14540Hydrocortisone butyrateCytochrome P450 3A7enzyme
DB14540Hydrocortisone butyrateMultidrug resistance protein 1transporter
DB14540Hydrocortisone butyrateSolute carrier organic anion transporter family member 1A2transporter
DB14540Hydrocortisone butyrateATP-binding cassette sub-family G member 2transporter
DB14540Hydrocortisone butyrateCytochrome P450 11B1, mitochondrialenzyme
DB14540Hydrocortisone butyrateCytochrome P450 11B2, mitochondrialenzyme
DB14540Hydrocortisone butyrateCytochrome P450 2C8enzyme
DB14540Hydrocortisone butyrateCorticosteroid-binding globulincarrier
DB14540Hydrocortisone butyrateCorticosteroid 11-beta-dehydrogenase isozyme 2target
DB14540Hydrocortisone butyrate3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1target
DB14540Hydrocortisone butyrateSolute carrier family 22 member 8transporter
DB14541Hydrocortisone cypionateAnnexin A1target
DB14541Hydrocortisone cypionateGlucocorticoid receptortarget
DB14541Hydrocortisone cypionateSex hormone-binding globulincarrier
DB14541Hydrocortisone cypionateCytochrome P450 3A4enzyme
DB14541Hydrocortisone cypionateCytochrome P450 3A5enzyme
DB14541Hydrocortisone cypionateCytochrome P450 3A7enzyme
DB14541Hydrocortisone cypionateMultidrug resistance protein 1transporter
DB14541Hydrocortisone cypionateSolute carrier organic anion transporter family member 1A2transporter
DB14541Hydrocortisone cypionateATP-binding cassette sub-family G member 2transporter
DB14541Hydrocortisone cypionateCytochrome P450 11B1, mitochondrialenzyme
DB14541Hydrocortisone cypionateCytochrome P450 11B2, mitochondrialenzyme
DB14541Hydrocortisone cypionateCytochrome P450 2C8enzyme
DB14541Hydrocortisone cypionateCorticosteroid-binding globulincarrier
DB14541Hydrocortisone cypionateCorticosteroid 11-beta-dehydrogenase isozyme 2target
DB14541Hydrocortisone cypionate3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1target
DB14541Hydrocortisone cypionateSolute carrier family 22 member 8transporter
DB14542Hydrocortisone phosphateAnnexin A1target
DB14542Hydrocortisone phosphateGlucocorticoid receptortarget
DB14542Hydrocortisone phosphateSex hormone-binding globulincarrier
DB14542Hydrocortisone phosphateCytochrome P450 3A4enzyme
DB14542Hydrocortisone phosphateCytochrome P450 3A5enzyme
DB14542Hydrocortisone phosphateCytochrome P450 3A7enzyme
DB14542Hydrocortisone phosphateMultidrug resistance protein 1transporter
DB14542Hydrocortisone phosphateSolute carrier organic anion transporter family member 1A2transporter
DB14542Hydrocortisone phosphateATP-binding cassette sub-family G member 2transporter
DB14542Hydrocortisone phosphateCytochrome P450 11B1, mitochondrialenzyme
DB14542Hydrocortisone phosphateCytochrome P450 11B2, mitochondrialenzyme
DB14542Hydrocortisone phosphateCytochrome P450 2C8enzyme
DB14542Hydrocortisone phosphateCorticosteroid-binding globulincarrier
DB14542Hydrocortisone phosphateCorticosteroid 11-beta-dehydrogenase isozyme 2target
DB14542Hydrocortisone phosphate3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1target
DB14542Hydrocortisone phosphateSolute carrier family 22 member 8transporter
DB14543Hydrocortisone probutateAnnexin A1target
DB14543Hydrocortisone probutateGlucocorticoid receptortarget
DB14543Hydrocortisone probutateSex hormone-binding globulincarrier
DB14543Hydrocortisone probutateCytochrome P450 3A4enzyme
DB14543Hydrocortisone probutateCytochrome P450 3A5enzyme
DB14543Hydrocortisone probutateCytochrome P450 3A7enzyme
DB14543Hydrocortisone probutateMultidrug resistance protein 1transporter
DB14543Hydrocortisone probutateSolute carrier organic anion transporter family member 1A2transporter
DB14543Hydrocortisone probutateATP-binding cassette sub-family G member 2transporter
DB14543Hydrocortisone probutateCytochrome P450 11B1, mitochondrialenzyme
DB14543Hydrocortisone probutateCytochrome P450 11B2, mitochondrialenzyme
DB14543Hydrocortisone probutateCytochrome P450 2C8enzyme
DB14543Hydrocortisone probutateCorticosteroid-binding globulincarrier
DB14543Hydrocortisone probutateCorticosteroid 11-beta-dehydrogenase isozyme 2target
DB14543Hydrocortisone probutate3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1target
DB14543Hydrocortisone probutateSolute carrier family 22 member 8transporter
DB14545Hydrocortisone succinateCytochrome P450 3A4enzyme
DB14545Hydrocortisone succinateCytochrome P450 3A5enzyme
DB14545Hydrocortisone succinateCytochrome P450 3A7enzyme
DB14545Hydrocortisone succinateCytochrome P450 2C8enzyme
DB14545Hydrocortisone succinateCytochrome P450 11B1, mitochondrialenzyme
DB14545Hydrocortisone succinateCytochrome P450 11B2, mitochondrialenzyme
DB14544Hydrocortisone valerateAnnexin A1target
DB14544Hydrocortisone valerateGlucocorticoid receptortarget
DB14544Hydrocortisone valerateSex hormone-binding globulincarrier
DB14544Hydrocortisone valerateCytochrome P450 3A4enzyme
DB14544Hydrocortisone valerateCytochrome P450 3A5enzyme
DB14544Hydrocortisone valerateCytochrome P450 3A7enzyme
DB14544Hydrocortisone valerateMultidrug resistance protein 1transporter
DB14544Hydrocortisone valerateSolute carrier organic anion transporter family member 1A2transporter
DB14544Hydrocortisone valerateATP-binding cassette sub-family G member 2transporter
DB14544Hydrocortisone valerateCytochrome P450 11B1, mitochondrialenzyme
DB14544Hydrocortisone valerateCytochrome P450 11B2, mitochondrialenzyme
DB14544Hydrocortisone valerateCytochrome P450 2C8enzyme
DB14544Hydrocortisone valerateCorticosteroid-binding globulincarrier
DB14544Hydrocortisone valerateCorticosteroid 11-beta-dehydrogenase isozyme 2target
DB14544Hydrocortisone valerate3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1target
DB14544Hydrocortisone valerateSolute carrier family 22 member 8transporter
DB14570HydroxyprogesteroneCytochrome P450 3A4enzyme
DB06789Hydroxyprogesterone caproateProgesterone receptortarget
DB06789Hydroxyprogesterone caproateCytochrome P450 3A4enzyme
DB06789Hydroxyprogesterone caproateCytochrome P450 3A5enzyme
DB06789Hydroxyprogesterone caproateCytochrome P450 2C19enzyme
DB00007LeuprolideGonadotropin-releasing hormone receptortarget
DB00007LeuprolideCytochrome P450 3A4enzyme
DB00367LevonorgestrelProgesterone receptortarget
DB00367LevonorgestrelEstrogen receptor alphatarget
DB00367Levonorgestrel3-oxo-5-alpha-steroid 4-dehydrogenase 1target
DB00367LevonorgestrelCytochrome P450 3A4enzyme
DB00367LevonorgestrelCytochrome P450 19A1enzyme
DB00367LevonorgestrelAndrogen receptortarget
DB00367LevonorgestrelSex hormone-binding globulintarget
DB00451LevothyroxineThyroid hormone receptor alphatarget
DB00451LevothyroxineThyroid hormone receptor betatarget
DB00451LevothyroxineCytochrome P450 2C8enzyme
DB00451LevothyroxineTransthyretincarrier
DB00451LevothyroxineSerum albumincarrier
DB00451LevothyroxineThyroxine-binding globulincarrier
DB00451LevothyroxineMultidrug resistance protein 1transporter
DB00451LevothyroxineMonocarboxylate transporter 8transporter
DB00451LevothyroxineSolute carrier organic anion transporter family member 1C1transporter
DB00451LevothyroxineSolute carrier organic anion transporter family member 1A2transporter
DB00451LevothyroxineSolute carrier organic anion transporter family member 1B1transporter
DB00451LevothyroxineSolute carrier organic anion transporter family member 1B3transporter
DB00451LevothyroxineSolute carrier organic anion transporter family member 4A1transporter
DB00451LevothyroxineSolute carrier organic anion transporter family member 4C1transporter
DB00451LevothyroxineLarge neutral amino acids transporter small subunit 1transporter
DB00451LevothyroxineUDP-glucuronosyltransferase 1-1enzyme
DB00451LevothyroxineSolute carrier organic anion transporter family member 2B1transporter
DB00279LiothyronineThyroid hormone receptor betatarget
DB00279LiothyronineThyroid hormone receptor alphatarget
DB00279LiothyronineThyroxine-binding globulincarrier
DB00279LiothyronineTransthyretincarrier
DB00279LiothyronineSerum albumincarrier
DB00279LiothyronineMultidrug resistance protein 1transporter
DB00279LiothyronineSolute carrier family 22 member 8transporter
DB00279LiothyronineMonocarboxylate transporter 10transporter
DB00279LiothyronineSolute carrier organic anion transporter family member 4A1transporter
DB00279LiothyronineSolute carrier organic anion transporter family member 1C1transporter
DB00279LiothyronineSolute carrier organic anion transporter family member 1A2transporter
DB00279LiothyronineSodium/bile acid cotransportertransporter
DB00279LiothyronineSolute carrier organic anion transporter family member 4C1transporter
DB00279LiothyronineSolute carrier organic anion transporter family member 1B3transporter
DB00279LiothyronineSolute carrier organic anion transporter family member 1B1transporter
DB00279LiothyronineLarge neutral amino acids transporter small subunit 1transporter
DB00279LiothyronineProliferating cell nuclear antigentarget
DB00279LiothyronineCytochrome P450 3A4enzyme
DB01583LiotrixThyroid hormone receptor alphatarget
DB01583LiotrixThyroid hormone receptor betatarget
DB01583LiotrixCytochrome P450 2C8enzyme
DB01583LiotrixSolute carrier organic anion transporter family member 1A2transporter
DB01583LiotrixSolute carrier organic anion transporter family member 1B1transporter
DB01583LiotrixSolute carrier organic anion transporter family member 1B3transporter
DB01583LiotrixSolute carrier organic anion transporter family member 4C1transporter
DB01583LiotrixSodium/bile acid cotransportertransporter
DB01583LiotrixSolute carrier organic anion transporter family member 1C1transporter
DB01583LiotrixSolute carrier organic anion transporter family member 4A1transporter
DB01583LiotrixSolute carrier family 22 member 8transporter
DB01583LiotrixMonocarboxylate transporter 8transporter
DB01583LiotrixMonocarboxylate transporter 10transporter
DB01583LiotrixMultidrug resistance protein 1transporter
DB01583LiotrixTransthyretincarrier
DB01583LiotrixThyroxine-binding globulincarrier
DB01583LiotrixSerum albumincarrier
DB01583LiotrixCytochrome P450 3A4enzyme
DB14596Loteprednol etabonateGlucocorticoid receptortarget
DB14596Loteprednol etabonateCytochrome P450 3A4enzyme
DB14596Loteprednol etabonateSerum paraoxonase/arylesterase 1enzyme
DB12474LynestrenolCytochrome P450 3A4enzyme
DB12474LynestrenolCytochrome P450 2C9enzyme
DB12474LynestrenolCytochrome P450 2C19enzyme
DB09124MedrogestoneSerum albumincarrier
DB09124MedrogestoneProgesterone receptortarget
DB09124MedrogestoneSex hormone-binding globulincarrier
DB09124MedrogestoneCorticosteroid-binding globulincarrier
DB09124MedrogestoneCytochrome P450 3A4enzyme
DB00603Medroxyprogesterone acetateProgesterone receptortarget
DB00603Medroxyprogesterone acetateEstrogen receptor alphatarget
DB00603Medroxyprogesterone acetateCytochrome P450 3A4enzyme
DB00603Medroxyprogesterone acetateCytochrome P450 2C8enzyme
DB00603Medroxyprogesterone acetate3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2enzyme
DB00603Medroxyprogesterone acetateCytochrome P450 2C9enzyme
DB00253MedrysoneCorticosteroid-binding globulincarrier
DB00253MedrysoneGlucocorticoid receptortarget
DB00253MedrysoneCytochrome P450 3A4enzyme
DB00351Megestrol acetateProgesterone receptortarget
DB00351Megestrol acetateGlucocorticoid receptortarget
DB00351Megestrol acetateMultidrug resistance protein 1transporter
DB00351Megestrol acetateCytochrome P450 3A4enzyme
DB11529MelengestrolCytochrome P450 3A4enzyme
DB09383MeprednisoneSerum albumincarrier
DB09383MeprednisoneCytochrome P450 3A4enzyme
DB00959MethylprednisoloneGlucocorticoid receptortarget
DB00959MethylprednisoloneCytochrome P450 3A4enzyme
DB00959MethylprednisoloneMultidrug resistance protein 1transporter
DB00764MometasoneGlucocorticoid receptortarget
DB00764MometasoneCytochrome P450 2C8enzyme
DB00764MometasoneProgesterone receptortarget
DB00764MometasoneCytochrome P450 3A4enzyme
DB14512Mometasone furoateGlucocorticoid receptortarget
DB14512Mometasone furoateCytochrome P450 2C8enzyme
DB14512Mometasone furoateProgesterone receptortarget
DB14512Mometasone furoateCytochrome P450 3A4enzyme
DB06713NorelgestrominSteryl-sulfataseenzyme
DB06713NorelgestrominProgesterone receptortarget
DB06713NorelgestrominSerum albumintarget
DB06713NorelgestrominAndrogen receptortarget
DB06713NorelgestrominCytochrome P450 3A4enzyme
DB00717NorethisteroneProgesterone receptortarget
DB00717NorethisteroneCytochrome P450 3A4enzyme
DB00717NorethisteroneMultidrug resistance protein 1transporter
DB00717NorethisteroneCytochrome P450 2C19enzyme
DB00717NorethisteroneCytochrome P450 3A5enzyme
DB00717NorethisteroneCytochrome P450 3A7enzyme
DB00717NorethisteroneSerum albumincarrier
DB00717NorethisteroneSex hormone-binding globulincarrier
DB09371NorethynodrelEstrogen receptor alphatarget
DB09371NorethynodrelAndrogen receptortarget
DB09371NorethynodrelSex hormone-binding globulintarget
DB09371NorethynodrelCytochrome P450 3A4enzyme
DB00957NorgestimateProgesterone receptortarget
DB00957NorgestimateEstrogen receptor alphatarget
DB00957NorgestimateCanalicular multispecific organic anion transporter 1transporter
DB00957NorgestimateCytochrome P450 3A4enzyme
DB00957NorgestimateAndrogen receptortarget
DB09389NorgestrelProgesterone receptortarget
DB09389Norgestrel3-oxo-5-alpha-steroid 4-dehydrogenase 1target
DB09389NorgestrelAndrogen receptortarget
DB09389NorgestrelCytochrome P450 3A4enzyme
DB09389NorgestrelCytochrome P450 19A1enzyme
DB01384ParamethasoneCorticosteroid-binding globulincarrier
DB01384ParamethasoneGlucocorticoid receptortarget
DB01384ParamethasoneCytochrome P450 3A4enzyme
DB01708PrasteroneSteroid Delta-isomerasetarget
DB01708PrasteroneBile salt sulfotransferasetarget
DB01708PrasteroneCholesterol oxidasetarget
DB01708PrasteroneEstradiol 17-beta-dehydrogenase 1target
DB01708PrasteroneSulfotransferase family cytosolic 2B member 1target
DB01708PrasteroneCytochrome P450 3A4enzyme
DB01708PrasteroneCytochrome P450 3A7enzyme
DB01708PrasteronePeroxisome proliferator-activated receptor alphatarget
DB01708PrasteroneEstrogen receptor alphatarget
DB01708PrasteroneSigma non-opioid intracellular receptor 1target
DB01708PrasteroneEstrogen receptor betatarget
DB01708PrasteroneNuclear receptor subfamily 1 group I member 2target
DB01708PrasteroneNuclear receptor subfamily 1 group I member 3target
DB01708PrasteroneGABA-A receptor (anion channel)target
DB01708PrasteroneNMDA receptortarget
DB01708PrasteroneAndrogen receptortarget
DB01130PrednicarbateGlucocorticoid receptortarget
DB01130PrednicarbateCytochrome P450 3A4enzyme
DB00860PrednisoloneCorticosteroid-binding globulincarrier
DB00860PrednisoloneCytochrome P450 3A4enzyme
DB00860PrednisoloneGlucocorticoid receptortarget
DB00860PrednisoloneSolute carrier organic anion transporter family member 1A2transporter
DB00860PrednisoloneMultidrug resistance protein 1transporter
DB00635PrednisoneGlucocorticoid receptortarget
DB00635PrednisoneCytochrome P450 3A4enzyme
DB00635PrednisoneMultidrug resistance protein 1transporter
DB00635PrednisoneSolute carrier organic anion transporter family member 1A2transporter
DB00635PrednisoneCytochrome P450 2C19enzyme
DB00635PrednisoneSerum albumincarrier
DB00635PrednisoneCorticosteroid 11-beta-dehydrogenase isozyme 1target
DB02789PregnenoloneSulfotransferase family cytosolic 2B member 1target
DB02789PregnenoloneSolute carrier family 10 member 6transporter
DB02789PregnenoloneNuclear receptor subfamily 1 group I member 2target
DB02789PregnenoloneCytochrome P450 3A4enzyme
DB00396ProgesteroneProgesterone receptortarget
DB00396ProgesteroneEstrogen receptor alphatarget
DB00396ProgesteroneSteroid 17-alpha-hydroxylase/17,20 lyasetarget
DB00396ProgesteroneCytochrome P450 2C19enzyme
DB00396ProgesteroneCytochrome P450 2C9enzyme
DB00396ProgesteroneCytochrome P450 3A4enzyme
DB00396ProgesteroneCytochrome P450 3A5enzyme
DB00396ProgesteroneCytochrome P450 3A7enzyme
DB00396ProgesteroneMultidrug resistance protein 1transporter
DB00396ProgesteroneSolute carrier family 22 member 2transporter
DB00396ProgesteroneSolute carrier family 22 member 1transporter
DB00396ProgesteroneSolute carrier family 22 member 3transporter
DB00396ProgesteroneBile salt export pumptransporter
DB00396ProgesteroneMultidrug resistance-associated protein 1transporter
DB00396ProgesteroneSodium/bile acid cotransportertransporter
DB00396ProgesteroneSteroid 17-alpha-hydroxylase/17,20 lyaseenzyme
DB00396ProgesteroneCytochrome P450 1A1enzyme
DB00396ProgesteroneCytochrome P450 1B1enzyme
DB00396ProgesteroneCytochrome P450 2A6enzyme
DB00396ProgesteroneCytochrome P450 2C8enzyme
DB00396ProgesteroneCytochrome P450 2D6enzyme
DB00396ProgesteroneMineralocorticoid receptortarget
DB00396ProgesteroneKappa-type opioid receptortarget
DB00396ProgesteroneNuclear receptor subfamily 1 group I member 2target
DB00396ProgesteroneAlpha-1-acid glycoprotein 1target
DB00396ProgesteroneGlucocorticoid receptortarget
DB00396ProgesteroneAndrogen receptortarget
DB00396ProgesteroneSex hormone-binding globulintarget
DB00396ProgesteroneSolute carrier organic anion transporter family member 1B1transporter
DB00396ProgesteroneATP-binding cassette sub-family G member 2transporter
DB00896RimexoloneCorticosteroid-binding globulincarrier
DB00896RimexoloneGlucocorticoid receptortarget
DB00896RimexoloneCytochrome P450 3A4enzyme
DB01108Trilostane3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1target
DB01108Trilostane3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2target
DB01108TrilostaneEstrogen receptor betatarget
DB01108TrilostaneEstrogen receptor alphatarget
DB01108TrilostaneCytochrome P450 3A4enzyme
DB01117AtovaquoneDihydroorotate dehydrogenase (quinone), mitochondrialtarget
DB01117AtovaquoneDihydroorotate dehydrogenase (quinone), mitochondrialtarget
DB01117AtovaquoneCytochrome btarget
DB01117AtovaquoneCytochrome P450 2C9enzyme
DB01117AtovaquoneCytochrome P450 3A4enzyme
DB00980RamelteonMelatonin receptor type 1Btarget
DB00980RamelteonMelatonin receptor type 1Atarget
DB00980RamelteonCytochrome P450 1A2enzyme
DB00980RamelteonCytochrome P450 2C19enzyme
DB00980RamelteonCytochrome P450 3A4enzyme
DB00980RamelteonCytochrome P450 2C9enzyme
DB00425ZolpidemGamma-aminobutyric acid receptor subunit alpha-1target
DB00425ZolpidemCytochrome P450 3A4enzyme
DB00425ZolpidemCytochrome P450 1A2enzyme
DB00425ZolpidemGamma-aminobutyric acid receptor subunit alpha-2target
DB00425ZolpidemGamma-aminobutyric acid receptor subunit alpha-3target
DB00425ZolpidemCytochrome P450 3A5enzyme
DB00425ZolpidemCytochrome P450 3A7enzyme
DB00425ZolpidemCytochrome P450 2C9enzyme
DB00425ZolpidemCytochrome P450 2C19enzyme
DB00425ZolpidemCytochrome P450 2D6enzyme
DB00425ZolpidemProstaglandin G/H synthase 1enzyme
DB00425ZolpidemGamma-aminobutyric acid receptor subunit beta-3target
DB00425ZolpidemGamma-aminobutyric acid receptor subunit gamma-2target
DB00495ZidovudineSerum albumincarrier
DB00495ZidovudineCytochrome P450 2A6enzyme
DB00495ZidovudineCytochrome P450 2C8enzyme
DB00495ZidovudineCytochrome P450 2C9enzyme
DB00495ZidovudineCytochrome P450 3A4enzyme
DB00495ZidovudineReverse transcriptase/RNaseHtarget
DB00495ZidovudineSolute carrier family 22 member 2transporter
DB00495ZidovudineSolute carrier family 22 member 6transporter
DB00495ZidovudineSolute carrier family 22 member 7transporter
DB00495ZidovudineSolute carrier family 22 member 8transporter
DB00495ZidovudineSolute carrier family 22 member 11transporter
DB00495ZidovudineSodium/nucleoside cotransporter 1transporter
DB00495ZidovudineEquilibrative nucleoside transporter 2transporter
DB00495ZidovudineMultidrug resistance protein 1transporter
DB00495ZidovudineMultidrug resistance-associated protein 4transporter
DB00495ZidovudineMultidrug resistance-associated protein 5transporter
DB00495ZidovudineATP-binding cassette sub-family G member 2transporter
DB00495ZidovudineTelomerase reverse transcriptasetarget
DB00495ZidovudineThymidine kinase, cytosolicenzyme
DB00495ZidovudineUDP-glucuronosyltransferase 2B7enzyme
DB00495ZidovudineUDP-glucuronosyltransferase 1-1enzyme
DB00255DiethylstilbestrolEstrogen receptor alphatarget
DB00255DiethylstilbestrolEstrogen-related receptor gammatarget
DB00255DiethylstilbestrolTransthyretincarrier
DB00255DiethylstilbestrolCatechol O-methyltransferaseenzyme
DB00255DiethylstilbestrolCytochrome P450 19A1enzyme
DB00255DiethylstilbestrolATP-binding cassette sub-family G member 2transporter
DB00255DiethylstilbestrolMultidrug resistance protein 1transporter
DB00255DiethylstilbestrolEstrogen receptor betatarget
DB00255DiethylstilbestrolCytochrome P450 3A4enzyme
DB00255DiethylstilbestrolCytochrome P450 2C8enzyme
DB00255DiethylstilbestrolCytochrome P450 2C9enzyme
DB00255DiethylstilbestrolCytochrome P450 2E1enzyme
DB00255DiethylstilbestrolSteroid hormone receptor ERR1target
DB00255DiethylstilbestrolSteroid hormone receptor ERR2target
DB00255DiethylstilbestrolNuclear receptor coactivator 2target
DB00255DiethylstilbestrolNuclear receptor subfamily 1 group I member 2target
DB00255DiethylstilbestrolAndrogen receptortarget
DB00255DiethylstilbestrolSex hormone-binding globulintarget
DB00255DiethylstilbestrolSolute carrier organic anion transporter family member 1B1transporter
DB00255DiethylstilbestrolSolute carrier organic anion transporter family member 2B1transporter
DB00255DiethylstilbestrolBile salt export pumptransporter
DB11619GestrinoneSex hormone-binding globulintarget
DB11619GestrinoneProgesterone receptortarget
DB11619GestrinoneGlucocorticoid receptortarget
DB11619GestrinoneAndrogen receptortarget
DB11619GestrinoneGonadotropin-releasing hormone receptortarget
DB11619GestrinoneEstrogen receptor alphatarget
DB11619GestrinoneCytochrome P450 3A4enzyme
DB13857DemegestoneProgesterone receptortarget
DB13857DemegestoneCytochrome P450 3A4enzyme
DB00250DapsoneInactive dihydropteroate synthase 2target
DB00250DapsoneDihydropteroate synthase 1target
DB00250DapsoneCytochrome P450 2C9enzyme
DB00250DapsoneCytochrome P450 2E1enzyme
DB00250DapsoneCytochrome P450 3A4enzyme
DB00250DapsoneDimethylaniline monooxygenase [N-oxide-forming] 3enzyme
DB00250DapsoneProstaglandin G/H synthase 1enzyme
DB00250DapsoneProstaglandin G/H synthase 2enzyme
DB00250DapsoneCytochrome P450 2C8enzyme
DB00250DapsoneCytochrome P450 2C19enzyme
DB00250DapsoneArylamine N-acetyltransferase 2enzyme
DB00250DapsoneCytochrome P450 3A5enzyme
DB00250DapsoneCytochrome P450 3A7enzyme
DB00250DapsoneMyeloperoxidaseenzyme
DB00250DapsoneCytochrome P450 2C18enzyme
DB00295MorphineMu-type opioid receptortarget
DB00295MorphineDelta-type opioid receptortarget
DB00295MorphineKappa-type opioid receptortarget
DB00295MorphineCytochrome P450 2D6enzyme
DB00295MorphineMultidrug resistance protein 1transporter
DB00295MorphineCytochrome P450 2C8enzyme
DB00295MorphineCytochrome P450 3A4enzyme
DB00295MorphineUDP-glucuronosyltransferase 2B7enzyme
DB00295MorphineUDP-glucuronosyltransferase 1-1enzyme
DB00295MorphineUDP-glucuronosyltransferase 1-8enzyme
DB00295MorphineUDP-glucuronosyltransferase 2B15enzyme
DB00295MorphineUDP-glucuronosyltransferase 2B4enzyme
DB00295MorphineUDP-glucuronosyltransferase 1-3enzyme
DB00295MorphineLymphocyte antigen 96target
DB14055(S)-WarfarinCytochrome P450 3A4enzyme
DB14055(S)-WarfarinCytochrome P450 2C8enzyme
DB14055(S)-WarfarinCytochrome P450 2C9enzyme
DB14055(S)-WarfarinCytochrome P450 2C18enzyme
DB14055(S)-WarfarinCytochrome P450 2C19enzyme
DB034104-hydroxycoumarin